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ABSTRACT OF THESIS (Regulation 7.9)
Adaption to a chemically challenging environment is a critical aspect
of the evolutionary process. As a result a wide variety of systems
involved in xenobiotic metabolism have evolved. Two such systems are
the phase I (drug toxification) Cytochrome P-450 monooxygenases and
the phase II (drug detoxification) glutathione S-transferases. In
order to evaluate the role of specific gene products in chemical
toxicity and mutagenicity members of each of these groups have been
expressed in the lower eukaryote S.cerevisiae and the mutation
frequency and sensitivity to a wide variety of cytotoxic agents
examined.
A cDNA encoding the rat P-450IIB1 protein has been expressed to a
level of between 0.1-0.2% of total yeast protein. The protein was
localised to the microsomal fraction and found to be functional as
determined by activity towards the model substrate,
benzyloxyresorufin. An attempt was made to develop this P450IIB1
expressing strain as a viable short term test (STT) for the screening
of potential mutagens. To this end the strain was exposed to a series
of known mutagens all requiring metabolic activation by cytochrome P-
450 to exert their effects. An increase in mutation frequency, as
determined by resistance to L-canavanine, was obtained when exposed to
the anticancer drug, cyclophosphamide and the mycotoxin,
sterigmatocystin. The PB-inducible cytochrome P-450's have been
implicated in the metabolism of these chemicals. The specificity and
potential of this P450IIB1 expressing strain and the possibilities for
the expression of cytochrome P-450's in S. cerevisiae as an STT is
discussed.
The overexpression of the glutathione S-transferases (GST) has been
associated with drug resistance. In order to directly evaluate this
possibility the human alpha (BqB^) and pi class GST have been
expressed in S, cerevisiae either singly or in tandem. These strains
were then exposed to a variety of alkylating agents, anticancer drugs
and organic hydroperoxides to determine if GST overexpression
modulates sensitivity to cytotoxic insult. In all cases GST
expression resulted in a significant reduction in the cytotoxic
effects of these agents. These data provide evidence that the
overexpression of GST observed in cells resistant to anticancer drugs
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The following sections are meant to represent a
broad overview of the cytochrome P-450 and glutathione S-
transferase enzyme systems. A more comprehensive look at
the aspects of these enzyme systems of direct relevance
to this thesis are to be found at the beginning of
Chapters 3 and 4.
1.1 Discovery of Cytochrome P-450
Living organisms are constantly exposed to chemical
substances, some necessary for life, some with medicinal
value and others of no functional value. The latter two
groups are referred to as xenobiotics (Astrom & De
Pierre, 1986). Xenobiotics have always been present in
the environment, either being formed by natural processes
or, more frequently in an industrial society, as by¬
products of modern industrial concerns. The toxic effects
of xenobiotic exposure can be combatted in two ways,
either the compound is prevented from entering the body
(or cell), and/or is excreted rapidly (Astrom & De
Pierre, 1986). Problems arise when the xenobiotic is
lipophilic. In these cases the lipid based cell membrane
provides no permeability barrier towards xenobiotics and
also excretion cannot be carried out via the aqueous
solutions of bile or urine.
Thus in the absence of systems to render lipophilic
xenobiotics more water-soluble cellular accumulation
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would occur until toxic concentrations are reached.
Fortunately, systems designed to facilitate the excretion
of hydrophobic compounds have evolved. These systems
involve oxidation reactions that are predominantly
catalysed by the cytochrome P-450 dependent
monooxygenases (P-450) (Wolf, 1986).
P-450 was first identified as a reduced carbon
monoxide complex with an absorption band at 450nm
(Garfinkel, 1958; Klingenberg, 1958). This pigment was
further characterised and named cytochrome P-450 (Omura &
Sato, 1964). The original function of P-450 remains
obscure, however the ancestral protein evolved at a very
early time and P-450 can be detected in virtually all
organisms including bacteria, yeast, plants, insects and
vertebrates. P-450's have probably existed for more than
1.5 billion years (Nebert & Gonzalez, 1987) . Various
theories have been proposed for the function of the
earliest P-450 suggesting that it may have provided a way
to utilise otherwise inert molecules in the environment
by the incorporation of molecular oxygen (Nebert &
Gonzalez, 1985). The oxidation of straight chain alkanes
produces alcohols which may have represented an initial
step in the formation of fatty acids. These could then
have been used either as an energy source or as a
component of biological membranes (Nebert & Gonzalez,
1985). P-450 may also have been involved in the
3
deactivation of reactive oxygen species due to its innate
peroxidase activity (Nebert & Gonzalez, 1985).
Alternatively it has been proposed that P-450 may have
initially evolved as an oxygen 'sensor' or as an enzyme
involved in the synthesis of steroids (Nebert & Gonzalez,
1985).
The P-450 monooxygenase system is located in the
endoplasmic reticulum (ER). This system comprises two
proteins; the flavoprotein NADPH-dependent cytochrome P-
450 reductase (P-450 reductase) which reduces P-450 by a
two electron transfer mechanism (White & Coon, 1980).
The second electron may also be transferred from
cytochrome b5 (Guengerich, 1979). More than 75% of the
P-450 reductase is found to be located free of the lipid
bilayer of the ER whereas the P-450 protein itself is
found to be embedded in the membrane by the insertion-
halt-transfer sequence located at the amino terminal of
the protein. The stoichiometry of P-450 reductase: P-450
protein in mammalian liver ranges between 1:10 and 1:100
(Nebert & Gonzalez, 1987).
In general P-450 mediated metabolism results from
the insertion of one atom derived from molecular oxygen
into C-H bonds. However, dependent on the substrate and
the nature of the intermediates, many different reactions
are possible as shown in Figure 1.1. Thus various
reactions catalysed by P-450 include aliphatic and
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aromatic oxidation, N-,0- and S- dealkylations, oxidative
deaminations, sulphoxide formation, N-oxidation, N-
hydroxylation and oxidative and reductive dehalogenation.
Dependent on the rate and stability of reactive
intermediates formed by P-450 mediated reactions as well
as the presence of Phase II enzymes (epoxide hydrolases,
glutathione S-transferases, etc) two pathways exist.
There can be further metabolism (e.g. conjugation to
glutathione) and the excretion of highly polar species in
the bile or urine. Alternatively the reactive
intermediates can covalently bind to proteins and nucleic
acids within the cell. The second pathway has been shown
to be associated with chemical carcinogenesis , mutagenesis ,
drug toxicity and teratogenesis (Wolf, 1986; Nebert &
Gonzalez, 1987; Gonzalez, 1988). It should, however, be
noted that not all P-450's are involved in catabolic
reactions. P-450's located in the adrenal gland are
involved in the formation of steroids. These include two
microsomal (steroid 17a-hydroxylase and steroid 21-
hydroxyla^e) and two mitochondrial (cholesterol side
change cleavage and steroid lip-hydroxylase) enzymes
(Nebert, 1988) .
1.2 Cytochrome P-450 Evolution
The P-450 system has diverged and duplicated
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Fig.1.1 Cytochrome P-450 Catalysed Reactions.
Shown are the varied types of reactions catalysed by the cytochrome P-450 monooxygenase
enzymes. This figure is reproduced from Nebert & Gonzalez (1987).
regarded as a gene superfamily probably comprising at
least 50 genes in mammals (Wolf, 1986). Evolutionary
relationships between P-4507s can be estimated by
comparing amino acid sequences (67 at the end of January,
1987) (Nebert & Gonzalez, 1987). These comparisons can
be used to construct phylogenetic trees as shown in
Figure 1.2. At present the P-450 supergene family
consists of 13 families including two bacterial, two
yeast, one insect and eight vertebrate families (Nebert &
Gonzalez, 1987). Families I to IV code for microsomal
enzymes involved in the formation of complex metabolites
while families XVII, XIX, XXI and XXII encode P-450's
involved in steroid biogenesis. The mitochondrial P-
4507s are found in family XI. The P-450 identified in
the house-fly is in family VI. In micro-organisms the
two yeast P-4507s are found in families LI and LII while
the bacterial P-450 of Pseudomonas is found in family
P450CI and that from Bacillus megaterium represents the
CII gene family (Gonzalez, 1988).
A number of conclusions can be drawn from the
phylogenetic tree in Figure 1.2. The unit evolutionary
period (UEP) can be calculated, i.e. the time in millions
of years for a 1% change in amino acid sequence. For P-
4507s this is found to vary between two and four. Since
the UEP is thought to be predictive: of the structural
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Fig.1.2 Cytochrome P-450 Phylogenetic Tree.
The divergence times given in this phylogenetic tree are calculated according to Nelson &
Strobel (1987) using 69 P-450 sequences. A description of the reactions catalysed by the
different P-450 families shown are described in the text. This figure is reproduced from
Gonzalez (1988).
diversity UEP's can be particularly informative. For
example, histones, which are amongst the most stable of
all proteins have a UEP of 400 since they require a
highly conserved tertiary structure in order to function
(Gonzalez, 1988). At the other end of the scale are the
immunoglobulins which have a UEP of only 0.7 to allow for
a diverse antigen binding capacity (Gonzalez, 1988).
Thus since P-450 must evolve to metabolise a wide variety
of structurally diverse compounds and, therefore, are
required to be very adaptable this explains a very high
rate of divergence.
The evolution of the various P-450 enzymes is also
illustrated in Figure 1.2. Phylogenetic trees suggest
that the early P-450's may have evolved to metabolise
cholesterol and its derivatives. Amongst the oldest P-
450's are the mitochondrial enzymes in the P450XI family
involved in cholesterol metabolism (Nelson & Strobel,
1987) . P-450 enzymes involved in cholesterol
biosynthesis evolved before the divergence of prokaryotes
from eukaryotes since three types of bacteria are known
to contain - and presumably synthesise - cholesterol or
partially demethylated lanosterol derivatives (Bloch,
1983) . Related to these P-450's are those involved in
fatty acid metabolism which along with the cholesterol
metabolising enzymes may have been involved in the
maintenance of membrane integrity in the early eukaryotes
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(Nebert & Gonzalez, 1985). A later evolutionary event
was probably the endogenous steroid synthesising enzymes
and the catabolic enzymes, around 900 million years ago.
The latter group have diverged rapidly over the last 400
million years into the major drug and carcinogen
metabolising enzymes of the P450I and P450II gene
families (Nelson & Strobel, 1987). It has been suggested
that the rapid increase in the number of P-450's within
certain gene families in the last 400 million years may
have coincided with the emergence of aquatic vertebrates
on to land and the resultant dietary changes associated
with consumption of land vegetation (Nelson & Strobel,
1987) .
1.3 Regulation of Cytochrome P-450
It is now becoming apparent that P-450 genes are
under complex control, during development, in response to
endogenous signals, and following the exposure of the
organism to xenobiotics. That P-450 regulation can
involve age, sex, diet and endogenous compounds was
initially shown by Conney (1967). This is now known to
involve sex specific expression, and developmental,
transcriptional as well as post-transcriptional
regulation. The following paragraphs give examples of
the factors known to be involved in the control of P-450
expression during an organisms life-cycle.
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1.3.1 Sex Specific P-450 Gene Expression
A variety of mechanisms involving both induction
and suppression are involved in the sexual
differentiation of P-450's. It has been suggested that
the control of P-450 between the sexes is via suppression
rather than induction (Gonzalez, 1988). An example of
this is seen in P450IIIA mRNA expression where formation
is suppressed in female rats at the onset of puberty
(Gonzalez, 1988). This decrease in P450IIIA mRNA may be
controlled via a corresponding decrease in circulating
corticosteroid levels (Waxman et al. 1988). As well as
steroid hormone levels growth hormone is known to play a
role in sex-specific repression (Gonzalez, 1988).
Hypophysectomy reduces circulating growth hormone in male
rats which leads to an increase in testosterone 60-
hydroxylase activity.
However, the pulsatile infusion of growth hormone
decreases the level of this enzyme (Yamazo et al. 1986).
How steroid and pituitary hormones control the
suppression of certain P-450's in a sex-specific manner
is as yet unknown.
1.3.2 Developmental Regulation of P-450 Expression
In general most P-450's are not expressed or
inducible prior to birth. However, exceptions are the
P450IIB and P450IIEI genes of the rat and the P450IA1
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gene of the mouse. Rat P450IA1 was found not to be
inducible by 3-methylocholanthrene (MC) (Giachelli et al.
1987). Why there should be species differences in
developmental regulation as well as the factors
controlling prenatally inducible P450/s remain as yet
undiscovered.
1.3.3 Transcriptional regulation of Cytochrome P-450
Expression
The most studied P-450 with respect to
transcriptional regulation is the MC/TCDD induction
response. Exposure to MC causes an increase in aryl
hydrocarbon hydroxylase activity in rats. The use of
metabolic inhibitors has shown that this response was due
to transcriptional activation (Gelboin & Blackburn,
1963). The analysis of this system has delineated the
types of transcriptional regulation occurring in P-450
expression. Mostly this work has been carried out using
P450IA1 promoter - CAT constructs. Among the elements
found were an inducible enhancer, found in multiple
copies and named the xenobiotic regulatory element (XRE)
(Fujuiswa-Sehara et al. 1987). This has been shown to be
15 nucleotides in length and to bind nuclear proteins
(Fujuisawa-Sehara et al. 1987) . Within the same region
of the P450IA1 promoter there is also a drug-regulatory
element (DRE) separate from the XRE (Gonzalez, 1988).
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Closer to the transcriptional start site, an element that
was found to suppress constitutive expression from the
P450IA1 promoter has been discovered (Hines et al. 1988) .
Thus P-450 regulation at the level of transcription can
involve both induction and suppression.
1.3.4 Post-Transcriptional Regulation of Cytochrome P-
450 Expression
Post-transcriptional regulation can occur at the
level of mRNA or protein and both are used to control P-
450 expression. For example, P450IA2 mRNA is stabilised
in the liver and extrahepatic tissues by exposure to TCDD
(Gonzalez, 1988). P450p mRNA is also stabilised by the
antibiotic TAO (Watkins et al. 1986). TAO has also been
shown to decrease P450p protein degradation (Watkins et
al, 1986). Perhaps the best example of post-
transcriptional regulation is seen with the P450IE1
enzyme. The administration of small organic compounds
such as acetone, pyrazole and ethanol cause a rapid
induction in P450IE1 protein while leaving mRNA levels
unaffected. Studies using in vivo pulse labelling with
amino acids ruled out the possibility of an increase in
translation but suggested that the protein itself was
being stabilised (Gonzalez, 1988).
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1.4 Cytochrome P-450 Expression and Carcinogenesis
The response of an organism to a drug is dependent
on its rate of metabolism. This metabolism can lead to
drug deactivation, or in some cases lead to activation,
cyclophosphamide for example. Thus the polymorphic
expression of P-450 in humans leads to altered drug
metabolism which is of considerable pharmacological and
toxicological relevance (Wolf, 1986). The polymorphic
expression of P-450 has been shown to alter
susceptibility to environmental toxins and carcinogens.
For example, the difference in P450IA1 levels in
mice is associated with an increase in carcinogen-induced
sarcomas, skin and lung carcinomas, lymphomas and
leukaemias, such that a higher expression of P450IA1
protein increases susceptibility (Nebert & Jensen, 1979) .
It has been postulated that the expression of P450IA1 may
be important in a variety of human cancers, such as those
of the lung, larynx, kidney and cancers of the urinary
tract (Nebert & Jensen, 1979). However, studies to date
have been contradictory and the role of P450IA1
expression is still unclear (Wolf, 1986).
In man there also appears to be polymorphisms
associated with the P450IIC and P450IID gene families.
There have been suggestions that the level of steroid
hormone catabolism within an organism can be related to
cancer susceptibility. These reactions are of importance
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where circulating hormone levels have been shown to play
a role in tumour development, for example endometrial and
breast cancers (Wolf, 1986). In the human population the
16a- hydroxylation of estradiol (an activity associated
with the P450IIC family) has been linked with the
incidence of mammary tumours (Bradlow et al. 1985). It
should, however, be noted that P-450's other than the
P450IIC protein can catalyse the 16 a-hydroxylation
reaction and thus may also be implicated in the
susceptibility of the organism to cancers of this type.
The polymorphism associated with P450IID1 expression
relating to debrisoquine metabolism has been extensively
studied (Gonzalez et al. 1988). The homozygous poor
metabolizers, as well as the hetrazygotes appear to have
a considerably reduced risk of lung and liver cancer
(Ayesh et al. 1984). It should be noted, however, that
the studies which suggest that polymorphic P-450
expression alters cancer susceptibility are few and
produce questionable data. For example, the P450IID1
locus was linked to drug-induced Parkinsons disease
(Borbeau et al. 1984). However little emphasis is now
placed on this study due to the lack of proper controls.
Xenobiotic exposure without doubt plays an important role
in cancer development. Thus the polymorphic expression
of P-450 may play an important role in those cancers in
which xenobiotic exposure plays a part. However, the
studies to date are far from conclusive.
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1.5 Cytochrome P-450 Expression in S.cerevisiae
Cytochrome P-450 was initially detected in mammalian
liver microsomes. Its presence in other organelles,
tissues and species was unclear. However, it was
established that P-450 were expressed in many tissues and
also in various vertebrates, invertebrates, plants and
also micro-organisms. This included the discovery of the
P-450 system in S.cerevisiae and in 40 other microbial
systems (Kapelli, 1986). Lindenmayer & Smith (1964)
initially demonstrated that cellular extracts of
S.cerevisiae contained P-450. The formation of P-450 in
the yeast S.cerevisiae has since been characterised as a
protein associated with growth in glucose (Wiseman et al.
1978; Blatiak et al. 1985). S.cerevisiae P-450 levels
are, therefore, limited by the physiological state of
fermentation (Kapelli, 1986). Wiseman & King (1982) have
suggested that any one of four factors is required for
optimal P-450 synthesis in S.cerevisiae
1) A concentration of glucose between 4 and 20%.
2) Anaerobic growth conditions (decreases mitochondrial
cytochrome synthesis).
3) Inhibition of mitochondrial protein synthesis
(which may increase the heme pool).
4) Use of respiratory deficient mutants.
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These factors suggest an inverse correlation between
mitochondrial cytochrome and cytochrome P-450 content.
This has been shown to be the case (Kapelli, 1986).
1.5.1 Physiological Role of Cytochrome P-450 in
S.cerevisiae
It has been shown that P-450 in S.cerevisiae is
involved in the late stages of ergosterol biosynthesis
(the major yeast membrane sterol). Ohan et al (1978)
have shown an oxygen and NADPH-dependent conversion of
lanosterol to 4,4 dimethyl zymosterol in S.cerevisiae.
This can be inhibited by antibodies raised against P-450.
Aoyama and Yoshida (1978) then demonstrated that, in a
reconstituted system, yeast P-450 could oxidatively
remove the 14a-methyl group of lanosterol.
A second P-450 in S.cerevisiae has been
demonstrated by Hata and co-workers (1983) who have shown
the presence of a - desaturation reaction of ergosta-
5,7-dien-3(3 -ol. This reaction is still observed in the
14 a- demethylase deficient strain, SGI. The
desaturation reaction had reduced activity in the mutant
strain N22. However, the 14a-demethylation activity was
normal (Hata et al. 1983).
Aoyama et al (1978) have also purified the NADPH
dependent cytochrome P-450 reductase (yeast reductase)
from yeast microsomes. This protein was shown to give a
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functional monooxygenase system in a reconstituted assay.
However, more importantly, the purified yeast reductase
was shown to couple with rabbit liver P-450 to catalyse
benzphetamine N-demethylation. This provided direct
evidence for the coupling of a mammalian P-450 to yeast
reductase to produce a functional monooxygenase system.
An essential requirement if a mammalian P-450 expressed
in yeast is to be active.
1.5.2 S.cerevisiae in Mutagenicity Testing
Many studies have shown that mutation assays using
yeasts can be used to predict carcinogenic potential and
that these assays compare favourably with other
eukaryotic test systems in identifying chemical mutagens
(Moustacchi et al. 1986). Yeast can also detect a number
of mutagens that are negative in prokaryotic mutation
tests, for example paraffins, olefins and actinomycin D.
They are also inexpensive to perform (Moustacchi et al.
1986). To date, 492 chemicals have been evaluated in
S.cerevisiae (Zimmerman et al. 1984) together with 41
other industrial compounds (Dean et al. 1985) and 20
compounds identified in pulp mill effluents (Nestmann &
Lee, 1985).
The bioactivation of promutagens has been shown to
occur in S.cerevisiae (Callen & Philpot, 1977; Callen et
al, 1978; Callen et al. 1980; Kelly & Parry, 1983; Kelly
et al. 1985) with a correlation between high cellular P-
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450 levels and activation. The main question in the use
of S.cerevisiae is whether the P-450 system produces the
same metabolites as a hepatic S9 fraction. It is also
possible that the activation observed in yeast does not
only occur via a P-450 mediated reaction (Kapelli, 1986).
Other problems are that yeast are often less sensitive
than bacteria in terms of the minimal chemical
concentrations required to elicit a response. This is
probably due to very powerful cellular detoxification
processes as well as the tough outer cell wall
(Moustacchi et al. 1986) . However the cloning and
expression of different mammalian P-450 cDNAS offers the
possibility of constructed yeast strains with a specific
and well characterised activation system. Were this to
occur it would make S.cerevisiae a very useful organism
for short-term mutagenicity tests.
1.6 Glutathione S-transferases
As mentioned previously (Section 1.1) certain
compounds present in the environment play a central role
in the development of cancer. These include drugs, food
additives, industrial effluents, pesticides and cigarette
smoke (Ames, 1979; Chasseaud, 1979). When humans are
exposed to xenobiotics they can be converted by a variety
of cellular reactions into products that are more, less or
equally toxic as the parent compound. For example, the
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oxidation reactions carried out by P-450 can produce
carcinogenic species from chemicals that are otherwise
chemically inert (Nebert & Gonzalez, 1985; Wolf, 1986;
Gonzalez, 1988). P-450 is an example of a phase I
(toxification) enzyme but present within the cell are a
variety of phase II (detoxification) enzymes which
include the glutathione S-transferases (GST). The action
of GST in a conjugation reaction with the thiol compound
glutathione (GSH) generally produces products that are
less toxic to the cell than the parent compound.
GST were first identified by Booth, Boyland & Sims
(1961) where a partially purified liver enzyme was shown
to catalyse the formation of GSH derivatives from various
compounds. It was later suggested that the role of GST
and GSH was in the protection of cellular constituents
from the damage caused by electrophilic agents (Boyland &
Chasseaud, 1969). In the reactions catalysed by GST, the
sulphur atom of GSH donates electrons for the
nucleophilic attack on, or reduction of, an electrophilic
substrate. The GSH conjugate can either be excreted
directly or further metabolised (Mannervik, 1985).
Further metabolism, via hydrolysis, results in an S-
(chemical)-cysteine derivative which is subsequently N-
acetylated to yield a mercapturic acid, the normal
excretion product of GSH conjugates in the urine
(Mannervik, 1985).
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There are multiple forms of GST which have been
shown to be present in all organisms so far examined.
Chromatographic and electrophoretic measurements along
with activity measurements using the 'general7 substrate
l-chloro-2,4-dinitobenzene (CDNB) has led to the
discovery of GST in man, rat, mouse, hamster, guinea pig,
chicken, cow, monkey, sheep, trout, shark, little skate,
grass grub, house-fly, american cockroach, six species of
earthworm, pea seedlings and corn (Mannervik, 1985).
However, it has been reported that GST is not present in
yeast (Jakoby, 1978). The existence of multiple GST
isoenzymes within an organism and its conservation
through evolution suggests an important biological
function (Mannervik, 1985). If, as suggested,
detoxification is the major role of GST then the presence
of several forms may allow for a broader range of
substrate specificity than would otherwise be possible,
and therefore, GST can be found as both cytosolic and
microsomal forms. The cytosolic forms will be dealt
with in detail here. The cytosolic and microsomal forms
of GST act either as dimeric or trimeric proteins
respectively with each subunit possessing its own
distinct active site. The ability of the cytosolic
enzymes to form dimers does not appear to influence
catalytic activity (Mannervik, 1988). There is little
information on the active site structure within the GST
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enzyme. However, each site has a binding site for GSH
and an adjacent, partly hydrophobic, binding site for the
electrophilic substrate. These subsites within the
active site cavity have been referred to as the G- and H-
sites respectively (Mannervik et al. 1978). It has been
demonstrated that GST have high specificity for GSH as
the active thiol suggesting very strict steric
requirements for binding to the G-site (Habig et al.
1974). It is likely that the three charged groups of the
GSH molecule are bound to amino acid side chains of
opposite charge in the GST protein (Mannervik, 1985).
The H-subsite seems to display a great deal of
flexibility to accommodate a wide variety of chemical
groups as the electrophilic substrate. For example, rat
GST 3-3 (mu class enzyme) acts on both 1,2-dichloro-4-
nitrobenzene and bromosulfophthalein, the first is
uncharged while the second is both negatively charged and
a much larger molecule (Habig et al. 1974).
1.7 GST Nomenclature
Since their initial discovery (Booth et al. 1961)
a variety of nomenclatures have been used:
glutathione S-alkyltransferase, glutathione S-
aryltransferase, glutathione S-aralkyltransferase,
glutathione S-alkenetransferase, glutathione S-
epoxidetransferase, nitrate ester reductase, steroid
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isomerase, A -3-ketosteroid isomerase and ligandin
(Jakoby, 1978). These titles were based on the erroneous
assumption that unique enzymes are responsible for each
activity (Mannervik, 1985).
However, comparison of the specific activities of
purified GST with a variety of substrates demonstrated
that all GST isoenzymes have broad and overlapping
substrate specificities. This nomenclature was thus
inadequate to designate GST isoenzymes.
A new nomenclature has been proposed using numbers
to indicate subunit composition (Jakoby et al. 1984).
Thus each GST dimer is identified on the basis of the
numbers given to its two constituents (Jakoby et al.
1984) . Subsequently each of the proteins have been
classified, on the basis of sequence homology, into three
gene families termed alpha, mu and pi (Mannervik &
Danielson, 1988). Most work has been carried out in the
rat with the nomenclature shown in Table 1.1.
At present human GST have been denoted by Greek
letters. At present two enzymes with basic isoelectric
points have been referred to as GST and B2 (Stockman
et al. 1987). An enzyme with near neutral isoelectric
point point was named GST and acidic proteins from
erythrocytes or placenta GST A or pi respectively
(although these may in fact be the same protein)
(Mannervik, 1985). Thus in humans at least three
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NOMENCLATURE FOR RAT CYTOSOLTC GLUTATHIONE S-TRANSFERASES
New nomenclature Previous nomenclature




Glutathione transferase 2-2 aa Yc
Glutathione transferase 3-3 a V
Glutathione transferase 3-4 C V' Yb2
Glutathione transferase 3-6 p
Glutathione transferase 4-4 d Yb2
Glutathione transferase 4-6 s
Glutathione transferase 5-5 e
Glutathione transferase 6-6 mt Yn
Glutathione transferase 7-7 p yp
Glutathione transferase 8-8 k Yk or Yf
Table 1.1 Rat Glutathione S-transferase Nomenclature.
The new nomenclature proposed for the rat cytosolic glutathione S-transferases is shown.
Also included are the nomenclatures previously used for these enzymes. This table is
reproduced from Mannervik & Danielson (1988).
distinct groups exist termed: alpha (B-^B^, bib2' B2B2^
mu (p) and pi (A/pi)• This nomenclature is shown in
Table 1.2.
1.8 Characterisation of Human GST
Since the studies presented in chapters 4 and 5
involve human alpha and pi class GST, the following gives
a brief outline of the diagnostic substrates for each of
the three classes (alpha, mu and pi). All classes also
exhibit high activity towards the 'general' substrate
CDNB.
1.8.1 Human Alpha Class GST
This class of GST isoenzyme has characteristically I
high selenium-independent glutathione peroxidase activity
with organic hydroperoxides, such as curaene
hydroperoxide. Also this class of human enzyme
has high isomerase activity with /f-androstene-3,17-dione
as substrate (Mannervik, 1985). The dimeric protein has
an Mr of approximately 51,000. Alpha class GST appear to
be abundant in all human livers.
1.8.2 Human Mu Class GST
A diagnostic substrate for this class of GST is
trans-4-phenyl-3-butene-2-one while other high activity
substrates are trans stilbene oxide, styrene-7,8-oxide
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CHARACTERISTICS OF THE HUMAN CYTOSOLIC GLUTATHIONE S-TRANSFERASES
Isoenzyme Class Subunit Mr(KD1 Isoelectric point
Alpha 25 8.9
B1B2 Alpha 25 8.75
B2B2 Alpha 25 8.4
(1 Mu 2 6.5 6.6
V Mu 26.5 5.5
7t Pi 23 4.8
Skin"9-9" Alpha 27.5 9.9
Table 1.2 Human Glutathione S-transferase Nomenclature.
The class and subunit composition of the human cytosolic enzymes is given Also included
are the molecular weights (kD) of each subunit and their isoelectric points. This table is
reproduced from Mannervik & Danielson (1988).
and benzo(a)pyrene-4,5-oxide (Mannervik, 1985). The
dimeric protein has an Mr of approximately 53,000.
Genetic studies using liver samples from Chinese, Indian
and Caucasian subjects has demonstrated that a gene
within the mu locus in humans is polymorphic and the
protein is expressed in only 60% of subjects (Ketterer,
1988).
1.8.3 Human Pi Class GST
GST pi can be characteristically diagnosed using the
substrate ethacrynic acid (Mannervik, 1985). The Mr of
the dimeric GST is approximately 47,000. Although
possessing no selenium independent glutathione peroxidase
activity towards cumene hydroperoxide GST pi does have
considerable such activity with linoleate hydroperoxide
as substrate (Ketterer, 1988). Linoleate hydroperoxide
is thought to be a breakdown product formed by damage to
biological membranes.
1.9 Glutathione (GSH)
The tripeptide Y-glutamyl cysteinyl glycine,
glutathione is one of the most abundant small organic
molecules in nature (Meister & Anderson, 1983) . GSH is
synthesised intracellularly by the consecutive actions ofy
-glutamyl cysteine synthetase (reaction 1) and GSH
synthetase (reaction 2). Reaction 1 is negatively
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feedback regulated by GSH itself. GSH can also be
degraded (reaction 3) by Y-glutamyl transpeptidase. The
turnover of GSH is controlled by the activity of T-
glutamyl transpeptidase the location of which is
restricted and specific (Hanigan & Pitot, 1985).
Most tissues contain GSH with intracellular levels
being as high as 15mM in the lens and 5-10mM in the
liver (Ketterer, 1988). It should be noted that GSH need
not necessarily be found in every cell in a tissue in
which it is present. For example, although the overall
concentration of GSH in the brain is 1.5 - 2 mM
histochemical studies show no GSH present in the neuronal
stroma (Ketterer, 1988).
1.10 Influence of GSH on Antineoplastic Therapy
GSH metabolism can exert an influence on
antineoplastic therapy in four ways as detailed below:-
1.10.1 GSH and Detoxification of Anticancer Drugs
GSH is involved in the detoxification of two
classes of anticancer drug, electrophilic agents and
those drugs which generate reactive oxygen species (Wolf
et al. 1987b). The first type represent the alkylating
type of anticancer agent including cyclophosphamide,
chlorambucil and melphalan. The second are those which
yield hydrogen peroxide and free radicals such as the
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superoxide anion (Hayes & Wolf, 1988) . Many of the
latter group are the quinone-containing anticancer drugs
such as adriamycin, daunorubicin and mitomycin C. Thus
the intracellular concentration of GSH within normal and
tumour cells will be an important factor in determining
therapeutic efficacy (Wolf et al. 1987b).
1.10.2 GSH and Toxification of Anticancer Drugs
GSH is known to cause toxification of anticancer
drugs in a limited number of cases, these being
azathiopurine and bleomycin. The formation of the GSH-
imidazole adduct is believed to be the major route of
azathiopurine toxification (Arrick & Nathan, 1984).
Bleomycin forms a complex with ferrous iron that can
react with molecular oxygen in such a way that an
oxidised ferric iron-bleomycin complex is formed which
also results in the formation of superoxide anion
(Caspary et al. 1981). It has been proposed (Caspary et
al, 1981) that the binding of GSH to the ferric iron-
bleomycin complex results in the reduction back to the
active ferrous iron state. Thus a catalytic oxidation-
reduction cycle is produced in which reducing equivalents
from GSH are ultimately transferred to molecular oxygen
to form superoxide anion (Caspary et al. 1981).
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1.10.3 Role of GSH in Anticancer Drug Delivery
The sole example of GSH modifying the delivery of
a drug is with methotrexate. The uptake of methotrexate
by cultured rat hepatocytes is accelerated by the
addition of GSH to the medium (Leszczynska & Pfaff,
1982). Obviously GSH dependent metabolism and excretion
of anticancer drugs ultimately affects delivery to the
target cell but the influence of GSH on drug uptake, as
suggested by methotrexate, may represent another
fundamental role for GSH in antineoplastic therapy.
1.10.4 Alteration of GSH Levels by Anticancer Drug Treat¬
ment
It is known that the exposure of an animal to a
low dose of a cytotoxic compound has the potential to
protect against a normally lethal dose of the same
compound (Millar et al. 1975). Studies in which
cyclophosphamide has been used to 'prime' the bone marrow
cells of mice has shown that maximum protection against a
lethal dose of cyclophosphamide coincides with peak GSH
levels (Adams et al. 1985) such that GSH levels in the
primed bone marrow cells were between 1.8-and 3-fold
higher than controls. Cancer chemotherapy depends on a
narrow therapeutic index thus the over-production of GSH
could lead to clinical drug resistance within a tumour.
This could lead to a tumour that is refractory to further
therapy (Carmichael et al. 1986).
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1.11 Physiological Roles of GST
1.11.1 Catalytic Role
On the basis of their catalytic capabilities and
high concentration (up to 10% of the cytosolic protein in
rat liver) GST appear to be closely involved in the
detoxification of ingested compounds.
As previously stated the substrates of GST, both
xenobiotics and normal dietary constituents, can be
converted to less toxic species when conjugated to GSH.
These conjugates whether excreted directly into the bile
or, after further metabolism by the kidney, removes
potentially harmful compounds from the host. Thus an
important question is whether the function of GST is to
detoxify the xenobiotics to which the organism is exposed
or whether there are also endogenous substrates for GST?
The formation both in vivo and in vitro of GSH conjugates
of steroids suggests the latter is indeed the case. GSH
conjugates of the reactive metabolites of estradiol 17 p
and 2-hydroxyestradiol-17p have been shown to form in
vivo (Mannervik, 1985). Some prostaglandins can also
serve as substrates for purified GST (Chaud hari et al.
1978). The epoxide derivative of arachidonic acid,
leukotriene A4 methylester, is also conjugated to GSH by
purified GST (Mannervik et al. 1984) . Leukotrienes
constitute the 'slow reacting substance of anaphylaxis' a
presumed mediator of allergic and anaphylatic reactions.
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Mannervik et al (1984) found that the three human classes
of GST differed significantly in their catalytic
activity. The pi class GST showed limited ability to
convert leukotriene A4 methylester while the alpha and mu
classes catalysed almost complete conversion of the
substrate into leuktriene C4 mono methylester. Thus GST
seem to play an important role in the metabolism of
steroids and leukotrienes suggestive of a fundamental
role in cellular processes.
Cholesterol oc-oxide, a product of lipid
peroxidation, has also been identified as a substrate for
GST (Meyer & Ketterer, 1982). This and the peroxidase
activity of GST suggests that GST may play an important
role in the protection of biological membranes from lipid
peroxidation. This may be of relevance in the protection
of cells from the effects of anticancer drugs such as
adriamycin whose peroxidative potential is known to
damage biological membranes (Tritton & Lee, 1982).
1.11.2 Role as Liaandin
In 1969 Arias and coworkers isolated a protein
from rat liver which could bind bilirubin (Levi et al.
1969). They named this the Y protein. Marey & Litwack
(1969) independently isolated a protein with an affinity
to bind a metabolite of Cortisol while Ketterer et al
(1967) had previously isolated a protein that could
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covalently link the dye butter yellow (4-dimethyl
aminobenzene) which he named azo-dye carcinogen binding
protein. The use of antibodies against the Y protein
established that all three groups had isolated the same
protein which was renamed ligandin (Litwack et al. 1971).
Ligandin was identified as a 45kD, basic protein composed
of two subunits. Habig et al (1974) subsequently showed
it to be identical to rat GST B (an alpha class protein).
The term 'ligandin' was used to describe its affinity for
a wide range of ligands of a hydrophobic character
(Jakoby, 1978). These include polycyclic aromatic
hydrocarbons, steroids, heme and its derivatives, a
variety of drugs including lipophilic antibiotics and
thyroid hormones. In fact the number of ligands bound
suggests that Ligandin, and to a lesser extent other GST,
may serve as an intracellular binding protein on as broad
a scale as albumin performs that function extracellularly
(Jakoby, 1978).
1.11.3 Covalent Binding
Since many of the substrates for GST are vigorous
alkylating agents it is not surprising that some react
directly with GST to form stable covalent linkages, for
example CDNB. Thus any compound with a strong
electrophilic centre will be able to react with the
proteins with which it comes into contact (Jakoby, 1978).
29
If the reagent becomes bound to GST then an interaction
with a nucleophilic group on the protein, rather than
with DNA, is greatly increased. It should be remembered
that ligandin was initially isolated as an azodye
carcinogen binding protein capable of forming a covalent
linkage to the azodye butter yellow (Ketterer et al.
1967). A large number of procarcinogens are oxidised by
cytochrome P-450 to produce highly reactive electrophilic
reagents which are potent carcinogens (Wolf, 1986) . All
are capable of being deactivated by covalent linkage to
GST (Jakoby, 1978).
1.12 GST and Drug Resistance
In carcinogenesis , GST are of interest for several
reasons. They may confer an advantage of preneoplastic
cells over their normal counterparts. They may confer
resistance to chemotherapeutic drugs and may also have
diagnostic value as tumour markers. The role of GST in
drug resistance will be dealt with in detail in Chapter
4, however, all three classes of GST have been
implicated in this phenomenon.
GST pi (Cowan et al. 1986; Batist et al. 1986), GST
alpha (Robson et al. 1987); Lewis et al. 1988) and GST mu
(Smith et al. 1989) have all been shown to be over-
expressed in cell lines made resistant to cytotoxic
drugs. A microsomal GST has also been implicated in
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resistance to nitrogen mustards (Clapper & Tew, 1989).
In vivo studies have shown a change in GST and GST
related enzymes before and after the onset of clinical
drug resistance (Wolf et al. 1987). Also GST have been
implicated in rat hepatocarcinogenesis (Farber, 1984a).
1.13 Aims of Thesis
The aim of this thesis was to examine the mutagenic
and cytotoxic consequences when mammalian drug
metabolising enzymes in the form of cytochrome P-450 or
glutathione S-transferases were expressed within the
lower eukaryote S♦cerevisiae. As an example of the P-450
system a cDNA coding for the rat P450IIB1 (PB3a) protein
was expressed. The resultant recombinant strain was then
to be evaluated for its potential in short-term
mutagenicity testing. Secondly cDNAs coding for members
of the human alpha (B^B^) or pi class GST were expressed
in S.cerevisiae to determine if GST play a role in







E.coli DH1 (F-recAl. qvrA96. thi-1. hsdR17, supE44)
This strain was used as a recipient for pBR322 based
vectors since it is a good host for large scale growth
and purification of plasmids (Bolivar et al. 1977).
E.coli K"12 JM101 (lhi, SUBE, (prQAB-Iac ) F'(traD36 proAB Iar.7 MlfjlQ))
This strain was used as a host for the pUC based
vectors which contain the p-galactosidase gene. In the
presence of IPTG, X-gal, and ampicillin a JM101 colony
carrying such a vector appears blue. However, the f}-
galactosidase gene can be disrupted by the insertion of
DNA into the multiple cloning sites of these vectors.
The resultant bacterial colonies though still
resistant to ampicillin appear white when exposed to IPTG
and X-gal.
2.1.2 Yeast Strains
1. S.cerevisiae RH971 (a. Ieu2. his4, troll
2. S.cerevisiae 1.103-5D (p.Ieu2- 3/112, ura3-52. trpl.
suc5. malO)
3. S.cerevisiae 1.1-6B (a,leu2- 3/112, ura3-52. trpl,
malO sucO)
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4. S.cerevisiae ENYWA-1A fa. Ieu2-.3/112; ura3-52,
trpl. his2-Al. SUC3, MAL3 . MAL2-80)
5. S. cerevisiae YS18 fa.his3-ll. his3-15. Ieu2~3/ll2,
CanR. ura3-5. trpl)
6. S.cerevisiae UTL7A fa. leu2-3/112. ura3-52.trpl)
The above strains were a gift from Dr A. Hinnen,
Ciba-Geigy Biocentre, Basle, Switzerland. They all have
trpl genotype required for the pMA56 expression vector.
7. S.cerevisiae KY118 fa. his3- 200, lvs2-801am. ade2-
101oc, trolAl. ura3-52)
This strain was used as a recipient for the
expression vectors used in this study. This was
principally because the strain was found to have
extremely low (almost undetectable) endogenous cytochrome
P-450 levels. This strain was a gift from Dr J.D. Beggs,
Dept. Molecular Biology, University of Edinburgh.
2.2 Microbial Culture
2.2.1 E.coli Culture Media
L-broth/litre: lOg tryptone (DIFCO) , 5g Yeast
Extract (DIFCO), 5g Sodium chloride (Sigma).
2g/l glucose (BDH chemicals) was added as a supplement
for plasmid growth. (L-Agar contains in addition 15g/l
agar (DIFCO). 2xYT/litre 16g tryptone, lOg Yeast extract,
5g Sodium chloride, pH7.0
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Terrific Broth/litre: 12g tryptone, 24g Yeast
extract, 4.0 ml Glycerol (Sigma), 100 ml 0.17M Potassium
dihydrogen orthophosphate; 0.72M di-Potassium hydrogen
orthophosphate.
Antibiotics
A stock solution (50mg/ml) of ampicillin (Sigma)
was prepared on sterile dlW and stored at -20"C. For
cultures containing both pUC and pBR322 plasmids
ampicillin was used at a final concentration of 50ug/ml
for L-broth and 2xYT and 25ug/ml for Terrific Broth.
2.2.2 Yeast Culture Media
YPDA/litre: lOg Yeast extract (DIFCO), lOg Peptone
(DIFCO), 20g Glucose (BDH), 20mg Adenine Sulphate (Sigma)
(Adenine sulphate although only required for ade strains
was always included). (YPDA agar contains in addition
20g/l agar). Yeast minimal medium/litre 6.7g Yeast
Nitrogen base without amino acids (DIFCO), 20g Glucose,
20mg amino acids and vitamins as required to give
supplemented synthetic SD medium.
Supplemented synthetic SD medium plus casamino
acids/litre 6.7g Yeast nitrogen base without amino acids,
20g glucose, lOg casamino acids, 20mg vitamins as




The plasmids used in this study were the general
cloning vector pUC-9 and the yeast expression vectors
pMA56 and pVTlOOU (Figure 2.01).
2.4 DNA Analysis
2.4.1 Small Scale Preparation of pUC DNA
The lithium chloride (LiCl) method was used
(Willimzig, 1985). L-broth (3ml) or 2xYT broth (3ml)
containing 50pg/ml ampicillin was inoculated from a
single bacterial colony and grown at 37°C overnight
in an orbital shaker (200 rpm). The culture was pelleted
sequentially in a 1.5ml eppendorf tube and the
supernatant discarded. The pellet was resuspended in
400jll of TELT (50mM Tris-HCl(pH7.5), 62.5mM EDTA, 2.5M
LiCl, 0.4% W/V Triton xlOO). To this was added 40pl of
lOOmg/xnl fresh lysozyme in TELT. The sample was then
boiled for 90 sec and cooled for 10 min on ice to
precipitate rRNA and protein. The precipitate was
pelleted by an 8 min centrifugation in a microfuge and
the supernatant removed to a tube containing 0.6 volumes
of isopropanol. This was immediately placed at 4°C for
10 min. After a further centrifugation the pellet was
washed with 70% ethanol, dried, and resuspended in 40pl
of TE (10mm Tris-HCl pH7.5, ImM EDTA). The plasmid DNA




Fig.2.01 Restriction Maps of the Vectors Used in This Study.
The yeast expression vectors pMA56 and pVTlOO-U contain the 2 micron origin of
replication and the constitutive alcohol dehydrogenase promoter, ADC1. In addition pMA56
contains TRP1 as a selectable marker in S.cerevisiae and pVTlOO-U URA3. The pUC-9





2.4.2 Large Scale Preparation of Plasmid DNA
Single bacterial colonies were picked and
transferred to L-Broth (10ml) supplemented with
ampicillin (50pg/ml) and the resulting overnight cultures
used to inoculate 500ml of Terrific Broth again
containing ampicillin (25>ig/ml) . This culture was
incubated at 37°C overnight in an orbital shaker.
Cells were harvested by centrifugation at 5,000
rpm for 10 min and the cell pellets resuspended in 2ml of
GTE (50mM glucose, 2mM Tris-HCl pH8.0, lOmM EDTA). To
this was added 8ml of a fresh solution of lysozyme
(lOmg/ml) in GTE and the solution incubated on ice for 30
min. 20ml of fresh alkaline SDS (0.2M NaOH, 1% SDS) was
added and after a further 10 min incubation on ice 15 ml
of high salt solution (3M potassium acetate, 2M acetic
acid) was added. The white precipitate formed was
removed after 30 min on ice by centrifugation at 8,000
rpm for 10 min. The supernatant was then filtered
through muslin and the DNA precipitated by a 20 min
incubation at -20°C after the addition of 2 volumes of
100% ethanol. The precipitate was collected by
centrifugation at 10,000 rpm for 10 min at 4°C and
resuspended in 6ml of acetate MOPS (0.1M sodium acetate,
0.05M MOPS pH8.0). DNA was again precipitated by the
addition of 2 volumes of 100% ethanol followed by a 20
min incubation at -20°C. A centrifugation at 10,000 rpm
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for 10 min was used to collect the DNA precipitate. The
DNA was resuspended in 10ml of TE and the E.coli genomic
DNA and rRNA differentially precipitated by the addition
of 1/3 volume 7.5M ammonium acetate and a 20 min
incubation on ice. This was then centrifuged at 12,000
rpm for 20 min and the pellet discarded. 2 volumes of
100% ethanol was then added to the supernatant and
incubated at -70°C for 60 min. The precipitate
(consisting of plasmid DNA, RNA and lipopolysaccaride)
was collected by centrifugation and resuspended in 2ml
of TE containing 50mM NaCl and 0.1% SDS. RNAase A
(DNAase free) (BDH) was added (100pg/ml) and the solution
incubated at 37'C for 15 min. The SDS concentration was
increased to 1% and proteinase K (BDH) added (lOOpg/ml)
after a one hour incubation at 37 *C. The DNA was
precipitated by the addition of 1/10 volume 3M sodium
acetate (pH4.8) and 2.5 volumes of 100% ethanol (60 min
incubation at -70°C). DNA was collected by
centrifugation and then resuspended in 3.21ml TE, 3.55g
CsCl and 340ul ethidium bromide (lOmg/ml). The solution
was then loaded into a 5ml polyallomer tube (Sorvall) and
placed in a TV865 vertical rotor and centrifuged at
40,000 rpm for 18 hr at 20°C. The plasmid band was
visualised using U.V. light (300nm) and collected using a
lml hand held pipettman (Gilsen). The ethidium bromide
was removed by extraction with butan-2-ol saturated with
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diw. The DNA was precipitated with 2 volumes of 70%
ethanol (-70°C for 30 min) and collected by a
centrifugation for 15 min at 10,000 rpm. The DNA was
resuspended in 1ml TE and then reprecipitated with 1/10
volume 3M sodium acetate (pH4.8) and 2.5 volumes of 100%
ethanol. After further centrifugation the DNA was dried
and resuspended in 500ul TE and the DNA concentration
checked by agarose gel electrophoresis.
2.5 Restriction Endonuclease Digestion
Restriction enzymes were purchased from Boehringer-
Mannheim, New England Biolabs, BRL or Amersham
International. Digestions (usually containing l-10ug
plasmid DNA) were carried out in either low (lOmM MgCl2,
lOmM Tris-HCL, pH7.5), medium (50mM NaCl, lOmM MgCl2,
lOmM Tris-HCl, pH7.5) or high salt (lOOmM NaCl, lOmM
MgCl2, 500mM Tris-HCl, pH7.5) buffers according to the
manufacturers recommendations. Incubations times ranged
between 2 and 12 hr at enzyme volumes up to 1/10 the
total digestion volume. Reactions were stopped using
1/10 volume of STOP (20% Ficoll, lOmM EDTA).
2.6 Gel Electrophoresis of DNA
DNA samples were analysed using horizontal agarose
gel kits (Sigma type II). Agarose was used at a
concentration of 1% and the gels electrophoresed at a
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voltage of 60V/gel in 1 x TBE buffer [89mM Tris-Borate
(BDH), 89mM Boric acid (BDH), 2mM EDTA (BDH)]. Gels were
then stained by the addition of 40pl of ethidium bromide
(lOmg/ml) to 1 x TBE buffer for 10 min. After de-
staining the gels (10 min in 1 x TBE) DNA was visualised
by UV illumination. Gels were photographed using Kodak
film. The DNA size markers used during agarose gel
electrophoresis were Hind III digested CI857 sam7 lambda
phage DNA and Haelll cut0x174 coliphage DNA. Usually ljag
of marker DNA was loaded per track.















DNA separated on agarose gels was transferred to
nitro-cellulose or Hybond-N-nylon sheets (Amersham)
according to Southern (1975). Gels were soaked for 45
min in denaturing solution (1.5M NaCl, 0.5M NaOH) under
shaking conditions then transferred to neutralising
solution (3M NaCl, 0.5M Tris-HCl, pH7.5) for a further 45
min. DNA was then transferred overnight from gel to
Nitro-cellulose or Hybond in 20xSSC (3M NaCl, 0.3M
sodium citrate) through a wick of 3mm filter paper.
Transferred DNA was immobilised on the nitro-cellulose by
baking at 80'C in vacuo for 1 - 2 hr or on Hybond by
exposure to U.V. for 5 min.
2.8 Isolation of cDNA
cDNA inserts were isolated from the parental vector
DNA by preparative gel electrophoresis and subsequent
centrifugation through a 20^im spin-X columns (Costar) .
Plasmid DNA (10 - 20jag) was digested to completion with
the appropriate restriction enzyme and DNA fragments
separated by electrophoresis in a 1% agarose gel.
Agarose containing the DNA band of interest was
visualised using ethidium bromide staining, and excised
using a scalpel. The agarose was finely chopped and
placed in a spin-X column which was centrifuged at 13,500
rpm in a microfuge pre-chilled to 4°C. The DNA in the
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resulting supernatant was precipitated by the addition of
1/10 volume 3M sodium acetate (pH4.8) and 2.5 volumes
100% ethanol. After incubation at -20'C overnight the
DNA was collected by centrifugation, dried and
resuspended in 10 - 20}il TE for further use.
2.9 Ligation of DNA Fragments
Ligations were carried out using 100 - 200pg of
linearised vector DNA and a 5-fold molar excess of insert
DNA in ligation buffer (50mM Tris-HCl pH7.5, lOmM MgCl2)
supplemented with ImM DTT, ImM rATP and 10 units of T4
DNA ligase in a total volume of 10 - 2 0/il. Incubations
were carried out overnight at room temperature for
cohesive end ligations or at 4#C for blunt end ligations.
2.9.1 Dephosphorvlation of DNA Using Bacterial Alkaline
Phosphatase (BAP)
EcoRI digested DNA (5jig) was dissolved in lxCIP
buffer (50mM Tris-HCl, pH9.0, ImM MgCl2, O.lmM ZnCl2, ImM
spermidine), to this was added 1 unit of BAP (Amersham)
and the solution incubated at 37"C for 30 min. Another 1
unit of BAP was then added and the incubation continued
for a further 30 min. To this was then added 1/10 volume
of EDTA (0.2M) and SDS to a final concentration of 0.5%.
The solution was then placed at 70°C for 10 min, then the
volume made up to 50jil with TE buffer. The DNA was then
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extracted with phenol, phenol/chloroform, chloroform and
ether. Sodium acetate (3M) pH5.5 was added to 1/10 of
the volume along with 2.5 volumes of 100% ethanol. The
solution was incubated at -70°C for 60 min and the DNA
recovered by centrifugation, desiccated then resuspended
in TE buffer at a concentration of 0.2pg/ml.
2.10 Radiolabelling of DNA
2.10.1 Random Priming
The random priming of isolated cDNAs with







Where OLB is a mixture of the following solutions (A,B
and C) in a ratio of 2:5:3:
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5jil dATP in 3mM Tris-HCl, pH8.0, 0.2mM
EDTA pH7.0
5pl dTTP in 3mM Tris-HCl, pH5.0. 0.2mM
EDTA pH7.0
5^il dGTP in 3mM Tris-HCl, pH8.0, 0.2mM
EDTA pH7.0
Solution B: 2M Hepes titrated to pH6.6 with 5M NaOH.
Solution C: Hexadeoxyribonucleotides (Pharmacia) in
3mM Tris-HCl, pH8.0, 0.2mM EDTA, pH7.0,
to a concentration of 90 OD units/ml.
The random prime mix was incubated at 37"C for 2 hr. The
400pl of TE was added before boiling for 10 min to
separate the DNA strands. The mix was then incubated for
15 min on ice prior to use.
2.10.2 Radiolabellinq of Synthetic Linkers
Linkers were labelled using the polynucleotide
kinase reaction as described by Manniatis et al (1982).
DNA (2jig) was suspended in 6pl of TE to which was added
ljil of lOx Linker-kinase buffer [0.7M Tris-HCl, pH7.6,
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0.1M MgCl2, 50mM DTT (Sigma)], 20jiCi 32P dATP (Amersham)
and 10 units of polynucleotide kinase (Amersham). This
was then incubated at 37°C for 15 min whereafter a
further lpl of lOx Linker-kinase buffer was added
together with 10 units of polynucleotide kinase and ljil
ATP (lOmM) and the volume made up to 20pl with diw.
This solution was incubated for a further 30 min at 37°C.
The linkers were then stored at -20°C until used.
Prior to use, linkers were tested for their
ability to ligate as follows:- kinased linkers (100;ag) ,
ligation buffer (50mM Tris-HCl, pH7.5, lOmM MgCl2) T4 DNA
Ligase (10 units) were incubated together for 4 hr at
4°C. The ligase was then heat inactivated at 65°C for
15 min. This solution was then analysed by
electrophoresis through an 8% polyacrylamide gel run in
0.5xTBE. Also tested were kinased linkers which had not
been ligated. After electrophoresis the gel was dried
down, wrapped in Saran wrap and subjected to
autoradiography at -70°C.
2.10.3 Klenow Reaction to Fill In the Cohesive Ends of
DNA
The method used to remove cohesive was essentially
that of Maniatis et al (1982). DNA (lOjig) was incubated
in lxnick-translation buffer (50mM Tris-HCl, pH7.2,
0.01M MgS04, O.lmM DTT, 50jjg/ml BSA) containing 2nmols of
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unlabelled dCTP, dGTP and dTTP. 32P dATP (ljaCi) and
Klenow enzyme (2 units) (Amersham) was then added. The
solution was incubated at room temperature for 10 min,
then 2 nmols of unlabelled dATP was added and the
reaction continued for a further 20 min. The Klenow
enzyme was then heat inactivated at 70°C for 5 min. 1/10
volume of the solution was loaded onto a 1% agarose gel
then after electrophoresis the gel was dried down and
subjected to autoradiography to check the incorporation
of J^P dATP as a measure of the success of the reaction.
2.11 Hybridisation of Radiolabelled cDNA To Nucleic Acids
Bound To Membranes







150-200ug/ml denatured salmon sperm DNA
2x Denhardts
where 2 x Denhardts:
0.02% BSA (Sigma)
0.02% PVP 360 (Sigma)
0.02% Ficoll 400 (Sigma)
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Radiolabelled cDNA probe was then added to the bag and
hybridised overnight at 68"C. Filters were washed for 4
x 30 min in hybridisation wash (2x SSC, 0.1% SDS and 0.1%
pyrophosphate) at 68°C.
2.12 Autoradiography
Radioactive 32P-labelled nucleic acid probes
hybridised to nitro-cellulose or Hybond filters were
visualised by exposure of Kodak X-ARS film. Filters were
placed at -70°C (for 1-7 days) in X-ray cassettes with
intensifying screens with the film placed on top. Films
were developed using a Gevamatic 60 (AgFa-Gevaert)
automatic developer.
2.13 RNA Analysis
2.13.1 RNA Extraction Using Guanidinium Hydrochloride
RNA was extracted from yeast cells using a
variation of the method of Cox (1968) was used. Yeast
cultures were grown to late logarithmic phase (optical
density at 600nm = 0.6) then pelleted by centrifugation
at 3,000 rpm for 10 min. Spheroplasts were then prepared
as described in Section 2.16.2, pelleted and following
resuspension in 10ml of 8M guanidinium hydrochloride,
disrupted using a hand-held homogeniser. Cell debris was
removed by centrifugation at 7,000 rpm and the
supernatant transferred to a sterile tube. 100% ethanol
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(0.5 volumes) was then added prior to precipitate the RNA
(45 min incubation at -20°C). The precipitate was
collected by centrifugation at 10,000 rpm for 15 min.
The pellet was resuspended in 5ml of 6M guanidinium
hydrochloride and 0.5 volumes of cold 100% ethanol prior
to a further incubation at -20°C for 45 min. The
precipitate was pelleted as before and the 6M guanidinium
hydrochloride treatment repeated. The resultant pellet
was resuspended in sterile DEPC-treated diw (2ml) and
1/10 volume 2M sodium acetate (pH5.5) added along with
2.5 volumes cold 100% ethanol. Samples were incubated at
-20°C overnight. RNA was pelleted by centrifugation at
10,000 rpm for 15 min and resuspended in 1ml of sterile
DEPC-treated diw. The RNA concentration was determined
by measuring the optical density at 260nm (for RNA OD at
260nm = 1 = 40pg/ml) and stored at -70°C.
2.13.2 Gel Electrophoresis of RNA
RNA was size fractionated through formaldehyde
denaturing gels by a modification of Derman et al (1981)
according to Meehan et al (1984). Samples were suspended
in 50% formamide, 6% formaldehyde and lOmM sodium
phosphate, pH6.5 and samples were heated to 50°C for 15 -
30 min prior to loading. Bromophenol blue/orange G-dye
was then added in the presence of 10% Ficoll and the
samples were separated at 30V for 16-30 hr in lOmM
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sodium phosphate buffer pH6.5. Gels were then soaked in
lOxSSC prior to transfer to nitro-cellulose. Transfer
was carried out overnight in lOxSSC according to
Southern (1975). Filters were baked in vacuo at 80"C for
1 - 2 hr to bind the RNA.
2.14 Microbial Transformation With Plasmid DNA
2.14.1 Bacterial Transformation Using Calcium Chloride
Competent E.coli cells were prepared using the
calcium chloride method as described by Maniatis et al
(1982). The strain of interest was grown overnight in L-
broth then diluted (1/100 v/v) into fresh media (50ml).
The culture was grown at 37°C until the absorbance at
550nm = 0.6 then chilled on ice for 20 min. Cells were
collected by centrifugation and resuspended in 50mM CaCl2
(10ml). After a further 20 min incubation on ice, cells
were sedimented and again resuspended in 50mM CaCl2 (5ml).
Cells were stored at 4"C and used within 4 days after
preparation.
Transformation was carried out as follows
DNA (lOng - lpg) was added to 200jil of competent cells
and left on ice for 30 min and then heat-shocked at 42'C
for 90 sees. L-broth (500jj1) was then added and the
culture placed at 37 *C for 60 min to allow the expression
of the selectable marker. This culture (200jj1) was then
plated onto L-agar plates containing the appropriate
antibiotic and incubated overnight at 37°C.
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2.14.2 Yeast Transformation Using Lithium Acetate
Competent S.cerevisiae were prepared using lithium
acetate as described by Itoh et al (1983). The strain of
interest was grown overnight in YPDA to stationary phase
then diluted (1/100 v/v) into YPDA (50ml). The culture
was grown until the optical density at 600nm reached 0.4
then harvested by centrifugation. The pellet was washed
in 10ml TE and sedimented again. After resuspending the
pellet in 5ml of TE, lithium acetate (Sigma) was then
added to a final concentration of 0.1M and the cells
incubated at 30°C for 60 min with gentle shaking. DNA
(10pg) was then added to 200ul aliquots of cells and the
mixture incubated at 30°C for a further 30 min. PEG-4000
(Sigma) was added to a final concentration of 35% (v/v)
and the mixture incubated for 60 min at 30°C. The cells
were then heat-shocked at 42'C for 5 min. Cells were
pelleted and resuspended in sterile diw (1ml). Following
further sedimentation the cells were resuspended in lOOul
sterile diw and then plated onto yeast minimal agar
plates with the appropriate selection.
2.15 Screening of Bacterial Colonies for Recombinant
Vectors
The method of Grunstein & Hogness (1975) was used to
bind DNA from plasmid-containing bacterial colonies to
nitro-cellulose. An array of colonies were streaked onto
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duplicate nitro-cellulose sheets (Schleicher & Schuell)
placed onto L-agar plates containing ampicillin
(50jig/ml) . Filters were marked for orientation and the
plates incubated at 37°C overnight. The masterplate was
then stored at 4°C. Filters to be probed were placed
colony side up for 3 min on a sheet of Whatman 3mm
chromatography paper soaked in 10% SDS. Filters were
then transferred to Whatman paper soaked in denaturing
solution (0.5M NaCl, 1.5M NaOH) for 5 min then to paper
soaked in neutralising solution (0.5M Tris-HCl, pH7.5,
1.5M NaCl) for a further 5 min. Filters were then soaked
in 2xSSC for at least 5 min, air-dried at room
temperature and baked in vacuo at 80#C for 90 rain to bind
the DNA to the nitro-cellulose.
Filters were then hybridised to radiolabelled DNA
probes and positive colonies obtained from the master
plate. Plasmid preparations were then carried out on
these colonies.
2.16 Preparation of Yeast Subcellular Fractions
2.16.1 French Press Method
Late logarithmic phase yeast cultures (0.5 - 21)
grown in synthetic SD medium supplemented with
casamino acids (1%) were harvested by centrifugation at
4°C (all subsequent steps were also carried out at 4°C).
Cells were resuspended in microsome buffer (10ml) (0.1M
10/
potassium phosphate pH7.4, lOmM EDTA, 0.25mM PMSF, 20%
glycerol) if microsomes were required. If cytosols were
required cells were suspended in KC1 phosphate buffer
(0.1M potassium phosphate, pH7.7, O.lmM EDTA, 165mM KCl)
Cell suspensions were then passed through a French Press
and the cell debris removed by centrifugation at 8,000
rpm for 10 min. The supernatant was then respun for 20
min at 8,000 rpm to remove the mitochondrial fraction.
The supernatant was then transferred to 6.5ml
polycarbonate tubes (Sorvall) centrifuged at 45,000 rpm
for 90 min in a Sorvall TFT45.6 rotor to separate the
cytosolic (supernatant) and microsomal (pellet)
fractions. Microsomal fractions were resuspended in
microsome buffer using a hand-held teflon/glass
homogeniser (avoiding cavitation). Cytosolic and
microsomal fractions were aliquoted in 1ml volumes
and either used directly for further biochemical analysis
or stored at -40°C until required.
2.16.2 Lyticase Spheroplast Preparation
Late logarithmic yeast cultures (11) were
harvested at 4°C (5,000 rpm, 10 min) then resuspended in
20 ml of reagent 1 (0.1M potassium phosphate, pH7.2, 0.1M
EDTA, 0.1M 2-mercaptoethanol) and incubated for 30 min at
room temperature. Cells were collected and washed twice
in ice-cold diw and twice in reagent 2 (0.1M potassium
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phosphate, pH7.2). The wet cell weight was determined
and the cells resuspended in 50ml of reagent 3 (0.1M
potassium phosphate, pH7.2, lOraM EDTA, 0.9M sorbitol
(Sigma) containing 2.5mg lyticase (Sigma) per gram wet
weight of cells. This solution was incubated at 37°C for
60 min in a 1 litre conical flask with gentle shaking
(100 rpm). The cells were then pelleted (1,000 rpm, 10
min) at 4°C and the supernatant carefully discarded. The
spheroplasts (and undigested cells) were then resuspended
in 10ml of ice-cold microsome buffer and disrupted in a
hand-held teflon/glass homogeniser. Microsomal and
cytosolic fractions were then prepared as in Section
2.16.1.
2.16.3 Sonication Method
Late logarithmic or stationary phase yeast
cultures (50 - 100ml) were harvested by centrifugation
(3,000 rpm, 5 min). Cells were resuspended in 2ml of KCL
phosphate or microsome buffer and subjected to six 15
second sonications using a Soniprep 150 sonicator (MSE)
at full power. Each cell suspension was held on ice for
2 min between steps. Cell debris was then removed by
centrifugation (3,000 rpm, 10 min) and the supernatant




The protein content of yeast samples was
determined using the method of Lowry et al (1951) using
Bovine serum albumin (BSA, Sigma) as a standard. The
reagents used were as follows:-
1. 70mM sodium carbonate:4OmM NaOH
2. 4OmM copper sulphate
3. 71mM sodium potassium tartrate
4. folin Coicalteau reagent (diluted 1:2 with diw)
4. 0.1M NaOH
6. Freshly prepared alkaline copper solution (49ml
reagent 1, 0.5ml reagent 2, 0.5ml reagent 3).
Samples were diluted to a volume of 1ml with 0.1M
NaOH to give a protein concentration within the standard
range (0-200pg). Reagent 6 (5ml), was then added and
after a 10 min incubation at room temperature 500jj1 of
reagent 4 added. The solution was incubated for a
further 30 min at room temperature and the absorbance at
600nm was determined using a Schimadzu U.V. 160
spectrophotometer. The protein concentration was
calculated from a standard curve using BSA
(0;25,80;100;120;150;200pg/ml). The absorbance of the
standards was determined in duplicate and that of the
samples in triplicate.
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In some cases the protein concentration was very
low, for example, when 50ml yeast cultures were used. In
these cases a micro Lowry was used where all the sample
and reagent volumes were decreased by a factor of 5.
2.17.2 Measurement of Cytochrome P-450 Haemoprotein
This was carried out according to the method of
Omura & Sato (1964). Yeast cultures (50ml) were grown in
synthetic SD medium supplemented with 1% casamino acids.
Cells were harvested in late logarithmic phase (Optical
density at 600nm = 0.7), washed once in ice-cold diw and
resuspended in 2ml of 0.1M potassium phosphate, pH7.4.
Cell suspension (1ml) was added to both sample and
reference cuvettes and a few milligrams of sodium
dithionite added to each to reduce the cytochrome P-450.
Carbon monoxide was then bubbled through the sample
curvette and the reduced carbon monoxide difference
spectra recorded at room temperature between 500 and
400nm using a Shimadzu MPS-2000 scanning
spectrophotometer. Cytochrome P-450 haemoprotein
concentration was determined using an extinction
coefficient (450 - 490nm) of 91mM_1 cm-1.
2.17.3 Cytochrome c Reductase Assay
lml of cytochrome c (Sigma) (1.5 mg/ml) was
dissolved in 0.1M potassium phosphate buffer, pH7.4 and
55
heated to 37°C in a spectrophotometer cuvette. Yeast
cellular fractions (lOpl) were added to the cytochrome c
solution. The absorbance of each sample was then
measured at 550nm against a reference cuvette (containing
only cytochrome c solution) on a Shimadzu MPS-2000
scanning spectrophotometer to obtain a base-line. NADPH
was then added to the sample cuvette (final concentration
of 160pg/ml). The subsequent reduction of cytochrome c
was then measured at 550nm for at least 2 min. This was
repeated at least three times for each sample.
2.17.4 Cytochrome P-450 Mediated Metabolism of
7-Benzvloxvresorufin
The metabolism of benzyloxyresorufin to resorufin
was measured flurometrically using a modified version of
that described by Wolf et al (1986). Yeast microsomal
fraction (5 - 20mg protein) was added to 1ml of l.OjiM 7-
benzyloxyresorufin in 0.1M Tris-HCl, pH7.4. The sample
was equilibrated at 37#C then 5)il of NADPH (8mg/ml)
added. The change in fluorescence (at excitation 530nm
and emission 585nm) was then measured for at least 3 min
before adding 5pl of resorufin standard (lOpM). At least
three determinations were made for each sample.
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2-17.5 Glutathione S-transferase Activity Towards 1-
Chloro-2.4-dintrobenzene (CDNB)
The activity towards CDNB was determined by the
method of Habig et al (1974) by measuring the loss of
spectral absorption at 340nm at 37"C. Assay buffer was
prepared by dissolving 41mg of CDNB (Sigma) in 4ml of
100% ethanol and adding this to 196ml of 0.1M potassium
phosphate buffer, pH6.5 warmed to 55°C. Assays were
carried out in 1cm quartz cuvettes using a Shimadzu MPS
2000 scanning spectrophotometer, 20mM GSH (50ul) was
added to the sample cuvette and the background (non-
enzymic) rate of GSH conjugation measured at 340nm.
For each assay 5 - 50pl of yeast soluble fraction (lmg
protein) was added to the sample cuvette and the
enzymatic rate of GSH conjugation measured. Samples were
tested in duplicate.
2.17.6 Glutathione Peroxidase (GPX) Measurements
2.17.6A Total GPX Activity Using Cumene Hydroperoxide
Total GPX activity was measured using the method
of Paglia & Valentin (1967) at 37°C using Cumene
hydroperoxide (CHP) as substrate. Assay buffer (lOOmM
Tris-HCl, pH7.2, 3mM EDTA, ImM sodium azide (Sigma),
1.2mM CHP, 0.5mM NADPH,1 unit glutathione reductase
(Sigma)) in a final volume of 1ml was used for each assay.
Cytosolic samples (5 - lOmg protein) were then added and
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the rate of NADPH oxidation monitored at 340nm on a
Shimadzu MPS 2000 scanning spectrophotometer.
2.17.6B Selenium Dependent GPX Activity
This assay was carried out as for total GPX
activity using hydrogen peroxide (0.25mm) (BDH) instead
of the 1.2mM CHP in the assay buffer.
2.17.6C Non-Selenium Dependent GPX Activity
The non-selenium GPX activity was calculated by
subtracting the value for the selenium-dependent GPX
activity from the total GPX activity (Masukawa et al.
1983). This activity gives an estimate of the
contribution of the alpha class GST to the CHP activity
measured.
2.17.7 Measurement of Glutathione (GSH) Levels Using
Ortho-pthaldehvde (OPT)
The method used to estimate yeast cellular GSH
levels was that of Hissin & Hilf (1976) . Yeast soluble
fractions (50pl) were mixed 1:1 with 10% trichloroacetic
acid to precipitate protein and, by acidifying the
sample, prevent GSH auto-oxidation. Duplicate aliquots
of each sample were added to 1.8ml of GSH assay buffer
(0.1M sodium phosphate buffer, pH8.0, 5mM EDTA). Freshly
prepared OPT (lmg/ml) (Sigma) in methanol was then added
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and the mixture incubated at room temperature in the dark
(15 min). The fluorescence of the GSH-OPT conjugate was
determined using a Perkin-Elmer fluorescence
spectrophomoter (model LS-3, excitation 350nm and
emission 420nm). GSH levels were calculated from a
standard curve obtained using GSH standards ranging
between 0.05 - 5uM.
2.18 SDS-Polvacrvlamide Gel Electrophoresis(SDS-paqe)
SDS-page was carried out using the method of Laemmli
(1970). Glass plates (12 x 14cm) and spacers were washed
with 100% ethanol then diw and dried thoroughly then
assembled into a gel sandwich in the protean I gel
apparatus (Biorad). Either 12% or 9% polyacrylamide
separating gels were used depending on whether GST(12%)
or cytochrome P-450(9%) samples were analysed. These
were prepared as follows
polyacrylamide
concentration acrylamide SGB diw 1% APS TEMED
(ml) (ml) (ml) (ml) (PD
9% ll.l 9.25 14 2 20
12% 14.8 9.25 11.0 2 20
where SGB is separating gel buffer (1.5M Tris, 0.5% SDS,
pH8.0)
1% APS = ammonium persulphate
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TEMED (Sigma) = N, N, N1, N-^-tetramethylethylenediamine
The acrylamide buffer and diw then the 1% APS and
TEMED added. The gel was poured to a height of 12cm then
carefully overlaid with diw and allowed 45 min to set.
Prior to preparing the stacking gel the diw overlay was
removed and a 15 or 20 track comb (washed with 100%
ethanol and diw) inserted. The 4.5% polyacrylamide
stacking gel was prepared using 1.5ml of 30% acrylamide,
2.5ml stacking gel buffer (0.5M Tris-HCl, 0.5% SDS,
pH6.8) 5.7ml diw, 0.3ml 1% APS and 10>ll TEMED. After
mixing, this solution was poured onto the separating gel
and left for 45min to set. The comb was then removed and
the wells washed with electrode buffer (0.052M Tris,
0.053M glycine, 0.1% SDS, pH8.3). The gel was then
coupled to the upper reservoir of the Protean apparatus
and placed in the lower reservoir to which had been added
1 litre of electrode buffer.
The electrodes in the upper reservoir were then
submerged using the electrode buffer. Samples (25-100>ig)
were diluted 1:1 with boiling mix (10% stacking gel
buffer, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol,
0.005% bromophenol blue) and heated to 100°C for 5 min.
Samples (25-100ug) were loaded using a Hamilton syringe
(Hamilton Bonaduz). The gel was run at a current of
20mA/gel while the dye front was in the stacking gel and
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at 30mA/gel through the separating gel. Electrophoresis
was continued until the dye front was within 1cm of the
bottom of the gel.
2.19 Western Blot Analysis
Western blots were carried out according to the
method of Towbin et al (1979) as modified by Lewis et al
(1988) . Following SDS-page the stacking gel was removed
and the separating gel cut along the dye front. The gel
was then marked for orientation (usually by cutting the
top right hand corner) and loaded into a transblot
cassette (Biorad) according to the manufacturers
instructions. The cassette was then placed in a
transblot tank (Biorad) containing transblot buffer (20mM
disodium orthophosphate, 20% methanol) with the nitro¬
cellulose adjacent to the anode. Protein transfer was
then carried out overnight at 250mA. The cassette was
then opened and the nitro-cellulose cut using the gel as
a template and marked for orientation. The nitro¬
cellulose was washed for two 10 min periods in TBST
(50mM Tris-HCl pH7.9, 0.15M NaCl, 0.05% Tween 20 (Sigma))
then blocked for 60 min in 3% Marvel (Cadburys). Two 10
min washes were then carried out prior to a 60 min
incubation with antibodies raised against either the
P450IIB1 and P450IIC1 proteins or the alpha or pi class
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GST subunits. All antisera were diluted 1:500 in TBST.
Following three 10 min washes in TBST the nitro-cellulose
was incubated for 60 min with 1:1000 diluted donkey
antirabbit antibody conjugated to horseradish peroxidase
(Scottish Antibody Product Unit) in TBST. Following a
further three 10 min washes in TBST the protein bands
were visualised using:
a) Peroxidase staining with 4-chloro-l-naphthol (Sigma)
as substrate. Nitro-cellulose filters were placed in
200ml of TBS (50mM Tris-HCl, pH7.9, 0.5M NaCl) and 4-
chloro-l-naphthol (120mg) dissolved in 40ml of methanol.
To this hydrogen peroxide (30%, 80pl) was then added.
When bands were visible the solution was discarded and
replaced by diw.
The filters were then labelled with 125i protein A
as below.
b) 125j protein A labelling. Filters were placed in
50ml of TBST containing 0.19MBq125I protein A (Amersham)
for 45 min. Non-hybridised 125I protein A was removed by
washing the nitro-cellulose in TBST. Filters were
then dried between 3mm Whatman paper. The nitro¬
cellulose was then transferred to fresh Whatman, covered
in Saran wrap, and subjected to autoradiography.
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2.20 L-Canavanine Mutation Assay
2.20.1 Isolation of CAN1 Colonies
This was carried out using a modified version of
Lemontt (1977) where CAN1 colonies were selected from
KY118 containing p56/3a (P450IIB1 expressing) or p56 par
(control). This was achieved by replica plating colonies
grown on supplemented synthetic SD agar [in the absence
of L- tryptophan (Sigma) ] onto agar containing 3 0pg/ml L-
canavanine (BDH). Those colonies that showed no growth
when exposed to the L-canavanine were designated CANl,
i.e. had a functional arginine permease and were selected
for use in subsequent mutation assays.
2.20.2 Use of CANl Strains In Mutation Assay
Single CANl colonies of strain 56/3a or 56 par
were inoculated into supplemented synthetic SD medium
containing 1% casamino acids and grown into late
logarithmic phase. Cultures were then counted using a
haemocytometer (Neubauer) and 4 x 107 cells transferred
to a 30ml sterile Universal tube (sterilin). Cells were
pelleted at 4°C then resuspended in 1.96ml of fresh
medium. They were subsequently treated with the desired
chemical at a variety of concentrations. Chemicals were
dissolved in 40jil DMSO (BDH) . Control cultures contained
only 40/il DMSO. Cultures were treated for 2 hr at 37 °C
in an orbital shaker. The temperature was lowered to
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30"C for a further 16 hr to allow the expression of the
canavanine resistance phenotype (canl). Cultures were
counted and 1x10' cells were plated onto supplemented
minimal agar plates containing 40jig/ml L-canavanine.
Cultures diluted to give 200 cells were also plated onto
YPDA agar plates to determine cell survival. Plates were
incubated at 28°C for 3 days to determine survival and 6
days to determine canavanine resistance. Plates were
scored and mutations/106 survivors calculated. RvsuXAiS
r\orrv\aL=£<2-cL e>u*\<A_ hvodtcdUcm
^ 0"tt£_cL- vv<S j t 5W\I I v/Of*S
2.20.3 Nitrous Acid Mutation Assay Wltyou-nA ( I \iors
Nitrous acid (0.2g/ml) was prepared and added to
log phase yeast cells (2 x 107/ml) carrying either p56/3a
or p56 par to give a concentration of 1 or 2 mg/ml
nitrous acid. Each culture was kept at pH4.5 using the
appropriate pH buffer tablets (BDH). The reaction was
carried out at 30°C in an orbital shaker for 15 min. The
exposure was terminated by increasing the pH to 7.0.
Cells were then diluted 10,000 fold and lOOjil aliquots
plated onto selective (L-canavanine containing) plates




2.21 Yeast Cytotoxicity Assays
Overnight cultures of yeast strains carrying the
appropriate plasmid were inoculated into fresh
supplemented synthetic SD medium at a concentration of 2
x 105 cells/ml. After an overnight incubation at 28°C in
an orbital shaker (200 rpm) culture densities were
measured using a haemocytometer. Cells (4 x 107) were
removed to a sterile Universal tube, pelleted at 4°C,
and then resuspended in 1.96ml of PBS (oxoid). Test
chemical was then added in 40>il of the appropriate
solvent. Cells were incubated for 2 hr at 37°C with
vigorous aeration, diluted 10,000 fold and then lOOjil
aliquots plated in triplicate onto YPDA agar plates.
Plates were incubated at 28°C for 3 days then scored.
For each culture tested the CDNB activity at the
time of drug addition was determined.
2.22 Cytotoxicity Assay After Depletion of Yeast Cellular
GSH Levels
GSH levels in the yeast strains were depleted using
the Y-glutamyl cysteinyl synthetase inhibitor,
buthionine-S,R-sulphoximine (BSO) (Sigma). BSO was
prepared in diw which was filter sterilised then added
to overnight cultures at a final concentration of lOmM.
The GSH levels were estimated either in the presence or
absence of BSO using the OPT assay (Section 2.17.7) then








Current concerns over environmental issues
exemplifies the need for rapid methods to assess the
health risk when humans are exposed to drugs and
chemicals. The DNA damage resulting from exposure to
environmental mutagens (both natural and man-made) is
likely to be a major cause of cancer (Doll, 1977). This
exposure occurs from natural chemicals in the diet as
well as from accidental or deliberate exposure to
synthetic chemicals or complex mixtures such as cigarette
smoke. Chemical-induced mutation in germ cells can
result in genetic defects which may appear in future
generations. At the somatic cell level cancerous cells
may result from modifications in the cell processes that
would normally control cell proliferation.
The available data supports the hypothesis that
environmental factors play a major role in cancer, but
how is exposure to be correlated with cancer incidence?
For example, in Japan there is a very low incidence of
breast and colon cancer but a high level of stomach
cancer. In the USA the reverse is found to be true.
However, Japanese who emigrate to the USA will, within a
generation or two, show high levels of breast and colon
cancer while having the low stomach cancer incidence of
native americans (Ames, 1979). So how are the factors
involved in this cancer incidence to be unravelled?
67 4
One way of linking xenobiotic exposure with cancer
is to use epidemiology. Unfortunately humans typically
have a 20 - 30 year latency period between the initial
xenobiotic exposure and cancer appearance. For example,
men first smoked cigarettes in great numbers around 1900,
but the resultant increase in lung cancer did not become
apparent until 1925 - 1930 (Ames, 1979). Thus human
epidemiology cannot be used as a front-line method in the
determination of individual carcinogens because of the
long latency period involved.
Animal cancer tests are another method for screening
potential carcinogens, however, these studies again have
severe limitations. There are over 50,000 synthetic
chemicals in widespread use and this number is increasing
at the rate of 1000 new compounds per year (Lowe & Omenn,
1986) . Only a small percentage of these chemicals were
actually screened for their potential carcinogenicity or
mutagenicity prior to introduction. Also only 150
chemicals per year (in 1979) were actually screened using
animal tests. So questions arise as to the ability of
animal tests to keep pace with the development of new
chemicals. The tests themselves are also prohibitively
expensive (> $1 million, in 1986), take too long (2-4
years) to allow drug and chemical companies to test and
remove unsatisfactory chemicals while still in
development (Lowe & Omenn, 1986). The sensitivity of
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animal cancer tests is also questioned. If an
environmental carcinogen was to affect only 1% of 100
million people then this would result in one million
cases of cancer. But to detect a chemical causing cancer
in 1% of test animals would require 10,000 animals which
is obviously unfeasible ii . This limitation is overcome,
somewhat, by exposing animals to their maximum tolerated
doses. This increases the tumour incidence and reduces
the problems associated with population size but does
this reflect the risk linked with human exposure?
Short-term tests (STT) have thus been introduced to
screen potentially mutagenic chemicals. These have been
developed from initial experiments designed to study the
mechanisms of DNA damage induced by chemical treatment.
Their role has increased due to reports that rodent
carcinogens are mutagenic in STT (Ames et al. 1973). These
tests have advantages because they are quick and cheap
compared to epidemiological or animal studies.
Originally sensitivities (percentage carcinogens
identified as mutagens) and specificities
(percentage non-carcinogens identified as non-mutagens)
of greater than 90% were reported (Purchase et al. 1976).
In 1984 the National Toxicology Program (NTP)
initiated a study to assess the four most commonly used in
vitro STT. These were the Ames test using S.tvnhimurium,
chromosome aberration and sister chromatid exchange in Chinese
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hamster ovary cells and the mouse lymphoma L5178Y cell
mutagenesis assay (Tennant et al. 1987). It was found that
testing 73 chemicals using standard protocols for each assay
gave only 60% concordance between carcinogenicity and
mutagenicity (as compared to the claims of >90%). Thus no
single in vitro STT adequately predicts the diverse mechanisms
involved in carcinogenesis. Furthermore there was shown to be
no advantage to be gained in using a battery of STT (Tennant
et al. 1987).
The problem is that the present STT have the
significant limitation in that they mostly rely on the
exogenous application of drug metabolising enzymes.
These enzymes in the form of mammalian subcellular
fractions convert the test chemical to its toxic or
mutagenic products (Lu & West, 1986; Wolf, 1986; de
Montellano, 1986). The subcellular fractions used
invariably contain mammalian cytochrome P-450 (P-450).
P-450 metabolism, though generally associated with the
detoxification and excretion of lipophilic compounds, can
also generate chemically reactive nucleophilic products.
It is as a consequence of such reactions that a vast
range of chemicals are mutagenic and carcinogenic (de
Montellano, 1986). The commonly used STT are limited by
poor correlation between mutagenic activity and
carcinogenicity in the extrapolation of this data to man
(Ashby, 1986; Tennant et al. 1987).
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S.cerevisiae has been evaluated in the screening of
compounds for mutagenicity (Callen & Philpot, 1978,
Venitt & Parry, 1988). However, as previously mentioned
endogenous yeast P-450's have narrow specificities being
principally involved in ergosterol biosynthesis (the 140c
demethylase system) this being the major yeast membrane
sterol (Yoshida & Aoyama, 1984). While their level is
limited by the physiological state of fermentation
(Wiseman & King, 1982). This restricts the use of this
test system although, as in the Ames test, hepatic S9
fractions have been used to increase the sensitivity
(Larimer et al. 1978). This also has the limitation in
that the active metabolite is formed outside the cell and
is required to pass through the cell wall and cytoplasm
before any DNA interaction can occur. The expression of
mammalian P-450 cDNA's in S.cerevisiae thus represents an
attractive approach for the development of a new system.
S.cerevisiae represents a suitable organism
especially because high level protein production can be
achieved and it is readily manipulated by standard
molecular biological techniques.
The first successful expression of a mammalian P-450
cDNA was carried out in yeast using a multicopy yeast
expression vector (pAAH5) with the constitutive alcohol
dehydrogenase promoter, ADH1 (Oeda et al. 1985). Other
expression systems have since been developed including
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the monkey kidney COS cell expression system (Zuber et
al. 1987). This transient system was used to express the
bovine 17 ct -hydroxylase cDNA. The protein levels that
have been achieved, however, were extremely low. The
vaccinia virus vector system has been used to express
high levels of P-450 protein (Faletto et al. 1988) but
this again is a transient system as the virus lyses the
host cell. Recently cell lines have been developed which
stably express P450IIB1 in V79 cells (Doehmer et al. 1988)
which when exposed to the promutagen aflatoxin B^"showed
a four-fold increase in mutation rate, (Doehmer et al.
1988).
However, by far the most expression studies using P-
450 have been carried out in S.cerevisiae. Oeda et al
(1985) successfully expressed the rat P450IA1 cDNA in
yeast to a level of 0.8% total yeast cellular protein.
It was found that 50% of this protein contained heme and
was both spectrally and enzymatically active (Oeda et al.
1985). This latter finding was important since it proved
that a mammalian P-450 could couple efficiently with the
endogenous yeast NADPH-dependant cytochrome P-450
reductase (reductase). As a consequence of these studies
many P-450's have been expressed in yeast with a wide
variety of protein levels achieved from very low to
extremely high (Gonzalez, 1988). Other experiments have
been carried out that show that although mammalian
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P-450's will function with a yeast reductase the
enzymatic activity is greater (around two-fold) if the
mammalian reductase is expressed in the same cell
(Murakami et al. 1986). This is of importance if
5.cerevisiae is to be used as a host for P-450's either
for structure/function studies or to develop the organism
as an STT.
Other work has shown that a hybrid protein produced
in yeast by fusing amino acid residue 57 of the rat P-450
reductase to the carboxy terminus of rat P450IA1 will
give a protein that is catalytically self-sufficient
(reductase independent). This hybrid has four times the
activity of the rat P450IA1 protein expressed with only
the yeast reductase in the cell (Murakami et al. 1987).
Finally, P-450 expression in yeast facilitates site-
directed mutagenesis (SDM) studies to study the role of
specific amino acid residues around the heme binding
cysteine in determining the spectral properties, and
catalytic activity of the enzyme (Shimizu et al. 1988).
Such studies have also been used to identify amino acid
residues determining substrate specificity (Sakaki et al.
1987). Expression in yeast has also been used to examine
the effect on catalytic activity of the point mutations
found in a mouse P450IA1 cDNA isolated from a C37
hepatoma cell line (Kimura et al. 1987).
To date, however, there have been no studies in
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which the rat P450IIB1 protein has been expressed in
yeast. The suitability of a yeast strain expressing a
mammalian P-450 as a mutation test organism has also not
been examined. It was to this end that the rat P450IIB1
protein was expressed in the S.cerevisiae strain KY118
and its mutation rate determined on exposure to a range
of chemicals. It was hoped to show the potential of a
battery of yeast strains expressing mammalian activation
systems. These could be used as STT to routinely screen
new chemicals for mutagenic activity.
The rat enzyme studied, P450IIB1, is one of the two
major phenobarbital (PB) inducible P-450's, the other
being P450IIB2. These two proteins are immunochemically
indistinguishable (Atchinson & Adesnik, 1986). At the
amino acid level there are only 14 substitutions in 491
residues giving a 97% homology between the two proteins
(Atchinson & Adesnik, 1986). They also have similar
substrate specificities. However, the purified P450IIB1
protein is usually found to be the more active. It is
five times more active in benzphetamine (Guegerich et
al. 1982) or testosterone metabolism (Waxman et al.
1983). When benzo(a)pyrene or 7,12 dimethyl
benz(a)anthracene are used as substrates P450IIB1 is seen
to be 2-3-fold more active (Wilson et al. 1984).
However, most interesting is the metabolism of certain
resorufin analogues, for example pentoxyresorufin, where
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there is a 100-fold greater rate of metabolism by
P450IIB1 (Wolf et_al, 1988).
There are other members of the rat P450IIB family
which are at best marginally inducible by PB (Gonzalez,
1988) . The data acquired to date suggests the presence
of six genes in the rat (Gonzalez, 1988). There is
thought to be considerable nucleotide similarity but
whether all six are expressed is as yet unknown (Adesnik
& Atchinson, 1986; Gonzalez, 1988). Members of the
P450IIB subfamily have been isolated from several other
species such as rabbit, man and mouse. Again there are
thought to be multiple genes in each species.
Studies have shown that the mechanism of P-450
induction by PB requires both de novo RNA and protein
synthesis (Adesnik & Atchinson, 1986). Enhanced levels
of P450IIB2 mRNA could be detected within 3 hr of PB
treatment which peaked at 16 hr then declined. The peak
mRNA level was 25-100-fold higher than the level
measured in untreated animals and accounted for
approximately 1% total liver poly A+ mRNA (Adesnik et al.
1981). It was concluded that as protein levels increase
concurrently with mRNA that PB regulation of P450IIB1 and
P450IIB2 synthesis is primarily at the level of
transcription (Adesnik & Atchison, 1986). Other
chemicals are known to induce P450IIB1 these include
barbiturates, mephenytoin, trans-stilbene oxide, xylene,
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SKF-525A, chlordane, Kepone, isopropanol (weakly), 1,1-
di(p-chlorophenyl)-2,2-dichloroethylene,
allylisopropylacetamide and polyhalogenated biphenyls.
Table 3.1 lists the catalytic activities which have been
examined for P450IIB1 and for which significant activity
has been measured. This table emphasises the broad
substrate specificity of this enzyme.
RESULTS
3.2 Subcloninq of P450IIB1 into pUC-9
The isolation and subcloning of the P450IIB1 cDNA
used in these experiments has previously been described
in detail (Doehmer et al. 1988; Monier et al. 1988). The
full-length cDNA was assembled from portions of two
overlapping P450IIB1 partial cDNA clones and a portion of
a genomic clone for P450IIB2 providing the 5' coding
sequence (the P450IIB2 sequence is identical to P450IIB1
over this region). The resultant full-length cDNA was
sub-cloned into the expression vector pSP64 to give the
plasmid, pSP-450. This was used by Adesnik and co-workers
for in vitro transcription/translation experiments to
study the N-terminal amino acid sequences of the protein
involved in the cotranslational insertion of the protein
into the endoplasmic reticulum (Monier et al. 1988).
Since the ultimate goal was the expression of the
P450IIB1 cDNA from the yeast expression plasmid, pMA56,





























Cyclopropylaminc and cyclopropyl ether oxidation
Dichlorinated biDhenvl oxidation
Table 3.1 Cataytic Activities of the Rat P450IIB1 Protein.
The table details the catalytic activity of the rat P450IIB1 protein (P-450pb-b) towards
a variety of structurally diverse xenobiotics. Activity is expressed as nmol product



















lodobenzene I-oxygenation (iodosoben/ene dependent)
4-lpomeanol (covalent binding to protein)
Iproniazid oxidation
Isopropylhydrazine oxidation
Isosafrole heme adduct formation
Lasiocarpine oxidation
Laurie acid (11- and 12-hydroxyIation)
N-Methyl-4-aminoazobenzene N-demethylation



























Trichloroethylene oxidation to chloral
Epoxidation
Vinyl chloride






cDNA had to be compatible with the unique EcoRI
restriction site in the expression vector. A strategy
had to be devised that would result in the P450IIB1 cDNA
having flanking EcoRI restriction sites. The restriction
map of psP-450 (Figure 3.01) shows an EcoRI site in the
multiple cloning site of the SP64 vector while the cDNA
has a unique Ncol site spanning the translational
initiation codon. The cloning strategy adopted is shown
diagramatically in Figure 3.02. An Ncol restriction
digest linearised the spP-450 plasmid while the Klenow
fragment of E.coli DNA polymerase I was used to create
blunt-ends. Radiolabelled 32P-dATP allowed the Klenow
reaction to be followed (Figure 3.03). 32P-dATP labelled
EcoRI linkers, d(GGAATTCC), were then blunt-end ligated
to the plasmid using T4 DNA ligase. Autoradiography
again allowed this reaction to be followed (Figure 3.04).
An EcoRI restriction digest produced a cDNA with EcoRI
restriction sites flanking the coding sequence. This
cDNA was separated from the contaminating sp64 vector
using preparative agarose gel electrophoresis, excised
from the gel and isolated by centrifugation through a
spin-X column. The cDNA was then ligated to EcoRI
digested pUC-9 and transformed into E.coli strain JM101.
Potential pUC-9/P450IIBl bearing colonies were selected
using the blue/white test with X-gal. TELT DNA mini
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Fig.3.01 Restriction Map of spP-450.
The full-length P450IIB1 cDNA can be released from the sp64 vector using an Ncol / EcoRI
restriction digest The Ncol restriction site overlaps the translational initiation codon and the


















Fig.3.02 Strategy for the cloning of P450IIB1 cDNA into the Yeast
Expression Vector pMA56.
The Ncol restriction site overlapping the translational initiation codon of the cDNA
was used along with Klenow enzyme and EcoRI synthetic linkers to produce EcoRI
restriction sites flanking the P450IIB1 cDNA. The cloning of the P450IIB1 cDNA to
produce spP-450 has been detailed elsewhere (Monier et al. 1988). Reactions were as
detailed in materials and methods.
Fig.3.03.Klenow Reaction to Remove the Cohesive Ends from
spP-450.
The Klenow reaction (section 2.10.3) using 32p.dA.TP was used to radiolabel the
spP-450 plasmid. Preparative agarose gel electrophoresis and autoradiography was
used to follow the success of the reaction.
Lane No.—► 12 3 4
I—spP-450*
Fig.3.04. PAGE to follow EcoRI Linker Ligations.
An 8% polyacylamide gel was used to separate the 32P-labelled EcoRI linkers and
determine the efficiency of ligation. Unligated linkers were loaded in lane 1; linkers
self-ligated in lane 2 and linkers ligated to spP-450 in lanes 3 and 4. A ladder effect
from monomers upwards is a sign of success in the reaction. This is only observed
where T4 DNA ligase has been added to the reaction (lanes 2-4).
after EcoRI digestion, the plasmids were subjected to
preparative agarose gel electrophoresis. The results are
shown in Figure 3.05. As can be seen, only the plasmid
in lane 2 appears to have a band that comigrates with the
P450IIB1 cDNA released by an EcoRI/Ncol double digest of
pSP64 (lane 14). To determine if this band is in fact
P450IIB1 a Southern transfer was performed and the
nitro-cellulose filter probed with 32P labelled
P-450IIB1. The result is shown in Figure 3.06. Only two
tracks give a positive signal for P450IIB1 the control in
lane 14 and the EcoRI digested PUC-9/P450IIB1 plasmid DNA
in lane 2. This unequivocally demonstrated that the
pUC-9 plasmid in lane 2 has the P450IIB1 insert. This
plasmid was designated pUC/PB3a and used in all further
studies to sub-clone the P450IIB1 cDNA into the yeast
expression vector.
3.3 Removal of Terminal Phosphates of PMA56
The pMA56 yeast expression vector (from J.D. Beggs,
Dept. Molecular Biology, University of Edinburgh) is shown
in Figure 2.01. This plasmid is a 2ji based shuttle vector
that can be propagated in both E.coli and S.cerevisiae.
The possession of a pBR322 origin of replication and
a p-lactamase gene allows replication and selection in
E.coli. For replication in yeast pMA56 has the 2p. origin
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Fig.3.05. Restriction Digestion of Possible pUC/PB3a Clones.
EcoRI restricted pUC/PB3a DNA (l|Jg) isolated from various E.coli JM101
transformants was loaded in lanes 2-13. Hind III digested Phage lambda DNA (l|ig)
was loaded in lane 1 and EcoRI/Ncol digested spP-450 DNA loaded in lanel4 as a
size marker for the P450IIB1 cDNA. After preparative agarose gel electrophoresis
only the DNA loaded in lane 2 gave a band comigrating with the P450IIB1 (PB3a)
cDNA released from the spP-450 vector (lane 14).
 
Fig.3.06. Southern Analysis of EcoRI Digested pUC/PB3a Clones.
32P-labelled P450HB1 cDNA isolated from the spP-450 vector was used to
probe the agarose gel in fig.3.05 after the DNA had been transferred to
nitrocellulose. Again only the DNA in lane 2 along with the control in lane 14


















of replication (Beggs et al. 1976) and TRP1 gene to allow
the complementation of the trol host mutation giving a
positive selection for the plasmid. The vector has the
strong constitutive alcohol dehydrogenase promoter, ADC1
(Hitzeman, 1981; Ammerer, 1983).
In order to decrease the number of self-ligated
vectors bacterial alkaline phosphatase was used on EcoRI
digested DNA to remove the terminal phosphate groups of
the vector. This prevents the vector from religating in
the absence of a cDNA insert. To test the success of the
phosphatase reaction the vector was ligated to itself or
to EcoRI digested pUC-18. The products were then
subjected to agarose gel electrophoresis. This is shown
in Figure 3.07. The plasmid produced from this
successful reaction was designated p56-RIBAP and used for
subsequent ligation to the P450IIB1 cDNA subcloned into
pUC-9.
3.4 Subcloninq of P450IIB1 into PMA56
The P450IIB1 cDNA was isolated from pUC-9 via an
EcoRI restriction digest, agarose gel electrophoresis and
centrifugation through a spin-X column. The cDNA was
then ligated to p56-RIBAP and transformed into the E.coli
strain DH1. The colonies produced were subjected to the
colony screening assay of Grunstein & Hogness (1975) with
32P-labelled P450IIB1 cDNA as a probe. The result of
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Fig.3.07. Bacterial Alkaline Phosphatase (BAP) Treatment of
EcoRI Digested pMA56.
The 5'- phosphate groups of EcoRI digested pMA56 were removed using
BAP to prevent self-ligation and increase subcloning efficiency (section 2.9.2).
EcoRI digested pUC-18 was used in conjunction with preparative agarose gel
electrophoresis to test the plasmid produced (p56-RI BAP). Lanesl-3 contain
p56-RI BAP, undigested pMA56 and EcoRI digested pMA56 (p56-RI)
respectively. Lanes 4 and 6 contain p56-RI BAP ligated to pUC-18 and lane 5
contains p56-RI ligated to pUC-18. Lanes 7 and 9 contain self-ligated p56-RI BAP
and EcoRI digested pUC-18 respectively. Lane 8 contains unligated EcoRI digested
pUC-18. The 0X174 Hae III DNA size Marker was loaded in lane 10. The p56-RI
BAP vector gives a much cleaner ligation to pUC-18 when compared to p56-RI
(lanes 4 and 6 vs. lane 5). This result shows that the BAP tratment has reduced the
efficiency of self-ligation without hampering the ligation of insert DNA.
which is seen in Figure 3.08. This gave six possible
recombinant plasmids. DNA was prepared from each and
subjected to EcoRI digestion to determine if the P450IIB1
cDNA was present. At the same time a BamHI digest to
determine the orientation of the cDNA within the vector
was carried out. These digests are shown in Figures
3.09.1 and 3.09.2. The plasmid shown in lane 2 in Figure
3.09.1 and lane 3 in Figure 3.09.2 was used for all
further expression studies since it possessed both the
P450IIB1 cDNA and the correct, 2.0Kb, fragment from the
BamHI digestion diagnostic of the orientation required
for protein expression. This plasmid was designated
p56/3a. The parental, pMA56 vector, was designated p56
par.
3.5 Cytochrome P-450 Estimation in Various S.cerevisiae
Strains
The object of the study undertaken was to express a
mammalian P-450 in yeast and to examine the potential of
the protein to activate promutagens. A strain that had a
low endogenous P-450 level was required since it was
desirable to have as low a background activation rate as
possible, i.e. metabolism catalysed by endogenous yeast
P-450 needed to be minimal. The strain also had to be
trpl to allow for the selection of the p56/3a vector.
The strain had also to produce reductase to allow the
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Fig.3.08. Colony Hybridisation Analysis on Transformed
coli DH1 Cells.
The colony hybridisation method of Grunstein & Hogness (1975) (section 2.15)
was used to determine which of the transformed E. coli DH1 colonies contained the
p56/3a vector. Using 32P- labelled P450IIB1 cDNA as a probe followed by
autoradiography this gave six possible p56/3a carrying colonies (marked by
arrow).
Fig.3.09. Restricion Enzyme Analysis on Possible p56/3a
Constructs.
Plasmid DNA was isolated from the six possible p56/3a carrying DH1
colonies identified in fig.3.08 as described in section 2.4.2. This DNA
was subjected to restriction analysis and agarose gel electrophoresis
to determine if the P450IIB1 cDNA (PB3a) was present (fig.3.09.1) and the
orientation of the insert (fig.3.09.2). The EcoRI restriction digest
identified four plasmids carrying the P450IIB1 cDNA (lanes 2,3,4
and 6 respectively in fig.3.09.1). The BamHI digest identified the
diagnostic 2.0Kb fragment required for expression in lanes 3,4 and
8 in fig.3.09.2. In both fig.3.09.1and 3.09.2 Hind III restricted
phage lambda DNA was used as a DNA size marker (lane 1).
Fig.3.09.1
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mammalian P-450 to function. The P-450 levels of various
trpl strains were determined from their CO binding
spectra. Strains were cultured to late logarithmic
phase. The strains assayed were 1/ RH971; 2/ 1-103-50;
3/ 1.16B; 4/ ENYWA-1A; 5/ UTL-7A; 6/ YS18; 7/ KY118.
Strains 1-6 were a generous gift from A. Hinnen of the
Ciba-Geigy Biocentre, Basle, Switzerland and KY118 a gift
from J.D. Beggs. The CO-binding spectra of each strain
are shown in Figures 3.10A through 3.10G. The strains 1-
103-50; 1.16B; ENYWA-1A; UTL-7A and YS18 all show
significant Soret peaks at 450nm whereas strains RH971
and KY118 show no such peak. The levels of P-450 were
then calculated using an extinction coefficient (450-490)
of 91mJT1cm-1 and the results shown in Table 3.2 The
strains RH971 and KY118 have very low levels of P-450
(7.32 pmol/OD). This capacity to produce P-450 (although
at low levels) also suggests the ability to produce yeast
reductase which would give an active mammalian P-450.
From this it was decided to use the KY118 strain as the
recipient for the p56/3a vector.
3.6 P450IIB1 mRNA Expression
The lithium acetate method of Itoh et al (1983) was
used to transform the S.cerevisiae strain KY118 either
with p56/3a or p56 par. The resultant colonies were then





Fig.3.10 Cytochrome P-450 Levels in Various S.cerevisiae
Strains.
Carbon monoxide binding spectra were carried out on whole yeast cells according to the
method of Omura & Sato (1964) (section 2.17.2). Various S.cerevisiae strains were
examined all of which had the trpl mutation. The strains used were RH971 (A);
1-103-50 (B); 1.16B (C); ENYWA-1A (D); UTL-7A (E); YS18 (F); KY118 (G). The
soret maximum at 450nm is marked with an arrow in each case. An extinction
coefficient (450-490nm) of 91mM:1 cm-1 was used to determine the level of P-450 in
each strain (table 3.2).






















Table 3.2 Cytochrome P-450 Levels in various S.cerevisiae
Strains.
The P-450 spectra in Fig.3.10 were used to determine the level of P-450 in each of
the trpl mutant strains. An extinction coefficient (450-490nm) of 91mM"1cm-1 was
used. P-450 levels were calculated as (Aborbance at 450nm/0.091) x 1000/ ODgoo.
harvested in late logarithmic phase. RNA was extracted
from both strains and subjected to electrophoresis
through a formaldehyde denaturing gel. RNA was then
transferred to nitro-cellulose and probed with
32P-labelled P-450IIB1 cDNA. This Northern blot is shown
in Figure 3.11. The KY118 strain carrying p56/3a shows a
cross-reacting band to the 32P-labelled P450IIB1 cDNA but
no such band is observed in the track which the 56 par
strain was loaded. The smearing effect seen in the
P450IIB1 RNA band produced from the p56/3a vector is
probably due to the absence of a transcription
termination sequence in pMA56. This was removed from the
vector pAAR6, along with an ARS1 sequence, to produce
pMA56 (Parent et al, 1985)
3.7 P450IIB1 Protein Expression
3.7.1 Level of P450IIB1 Protein Expression
The p56/3a and p56 par carrying strains were again
inoculated into supplemented synthetic SD medium and
allowed to grow into stationary phase before being
harvested. Cells were homogenised and 50ug of protein
from each was subjected to Western blotting. Polyclonal
antibodies raised against rat P450IIB1 or P450IIC
proteins were used as probes along with 125I-labelled
protein A. The anti P450IIC antisera was used as a
negative control since it would not be expected to
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Fig.3.11. Expression of P450IIB1 mRNA in S. cerevisiae
Strain KY118 transformed With p56/3a or p56par.
Total RNA was isolated from KYI 18 containing either the p56/3a
(lane 1) or p56par(lane 2) vectors. In lanes 3-5: 4, 10, and 20(ig
of PB-induced Wistar rat RNA was loaded. Samples were analysed as
in section 2.13.
react with the P450IIB1 protein as they are only 50%
similar at the protein level.
Only the p56/3a transformed strain contained a
protein band that reacted with the anti P450IIB1 antibody
(Figure 3.12). The protein observed had the same
mobility as the protein standard isolated from rat liver.
No cross-reacting bands were observed in the p56 par
transformed strain or the p56/3a strain probed with the
antibody to P450IIC (Figure 3.12). Thus the P450IIB1
antibody was specific for the protein produced from
the p56/3a vector and does not cross-react with endogenous
yeast proteins. Densitometric scanning of the band
intensity and comparison with P450IIB1 protein standards
indicated that between 0.1 - 0.2% of total yeast protein
was P450IIB1.
3.7.2 Subcellular Localisation of P450IIB1 Protein
Subcellular fractions were prepared from the yeast
strains carrying the p56/3a and p56 par vectors using the
French press method detailed in Section 2.15.1. These
fraction were subjected to SDS-page then Western
blotting using P450IIB1 antisera and 125I-labelled
protein A. This is shown in Figure 3.13. In the rat
liver the P450IIB1 protein is localised in the
endoplasmic reticulum (equivalent to the microsomes track
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Fig.3.12. Expression of P450IIB1 Protein in S.cerevisiae.
SDS-page followed by Western blot analysis (section 2.19) was carried out
on whole cell extracts of p56/3a or p56par transformed KYI 18. Antibodies
raised against the rat P450IIB1 or P450IIC proteins were used to identify the
P450IIB1 protein and test the specificity of the recognition respectively.
Only the p56/3a transformed strain produces a protein that cross-reacts with
the P450IIB1 antibody (the lower molecular weight bands are due to the
degradation of the P450IIB1 protein). When the
P450IIC antibody is used no such band is observed thus the P450IIB1
antibody is specific for the P450IIB1 protein. The p56par transformed strain
shows no cross-reacting band with eiter antibody. 50pg of protein was loaded
per track.
encoded by the amino terminal 20 amino acid residues of
the protein (Monier et al, 1988). The question thus
posed was whether this signal sequence would function
similarly in S.cerevisiae to localise the protein to the
endoplasmic reticulum or would the P-450 protein be found
free in the cytosol. From the Western blot (Figure 3.13)
it is obvious that there is only a faint cross-reacting
band in the track containing cytosol showing that the
P450IIB1 protein is not free within the cytoplasm.
Whereas there is a highly reactive band found in the
track loaded with the microsomal fraction. Thus the
P450IIB1 protein produced from p56/3a is localised to the
yeast endoplasmic reticulum implying that the insertion-
halt-transfer sequence is functional within S.cerevisiae.
A large quantity of P450IIB1 protein, around 1/5 - 1/10
of that in the microsomal fraction was found in the cell
debris. This may demonstrate a limitation in the use of
the French press to disrupt yeast cells. This may be due
to the endoplasmic reticulum being attached to the cell
membrane which is sedimented during the first clearing
spin.
3.8 Determination of P-450 Reductase Levels in Strain
Carrying p56/3a
As previously discussed (Section 1.1) cytochrome P-
450's receive electrons from P-450 reductase. The yeast
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Fig.3.13. Subcellular Localisation of P450IIB1 Protein in
g, cerevisiag.
SDS-page followed by Western blot analysis of control yeast cultures and yeast
transformed with the vector containing P450IIB1 cDNA (p56/3a) was carried out
subcellular fractions using an antibody raised against the purified P450IIB1
protein. It can be seen that the 52kD protein associated with P450IIB1 is
predominantly localised in the microsomal fraction. Western blots were
carried out as described in section 2.19. with 25|0.g of protein loaded in each
track.
enzyme has been shown to have the capacity to couple to a
mammalian P-450 enzyme (Oeda et al. 1985). On this basis
it was necessary to establish the level of reductase
present in the KY118 strain. The simplest determination
of the reductase level in yeast is to use the cytochrome
c assay. This reaction is not specific for P-450
reductase but detects all cellular reductases. Various
subcellular fractions of the 56/3a strain were assayed
for reductase activity and compared to control and PB-
induced rat liver microsomes (Table 3.3). The level of
reductase is highest within the microsomal fraction
suggesting this is P-450 reductase. The level found in
the yeast microsomal fraction is approximately equal to
that found in control rat liver microsomes and 50% of
that in PB-induced microsomes. The level of reductase
activity associated with the yeast microsomal fraction
should give P450IIB1 activity.
3.9 Optimisation of P450IIB1 Protein Expression
It has been shown previously (Wiseman et al. 1985)
that the level of yeast P-450 can be affected by the
concentration of glucose present in the growth medium.
Levels of < 2.5% glucose gave rise to 'low glucose
behaviour' which reduces the level of P-450 obtained. In
glucose concentrations of >5% there is late accumulation
of P-450 to a higher level ('high glucose' behaviour).
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Control Rat Liver Microsomes 168.0
PB-Induced Rat Liver Microsomes 260.3
Table 3.3 Reductase Level in S.cerevisiae Subcellular Fractions.
The P-450 reductase assay (section 2.17.3) was used to estimate the level of
endogenous yeast reductase in the subcellular fractions of the P450HB1 expressing
strain. Reductase activity is expressed in units /mg of protein, using an extinction
coefficient of 18.7 mM-fcnr1. For comparison the reductase level found when the assay
was carried out using control and PB-induced rat liver microsomes is included.
To find the glucose concentration that gave the maximum
production of P450IIB1 protein and minimal endogenous P-
450 levels the 56/3a and 56 par strains were grown in
supplemented synthetic SD medium containing 1% casamino
acids and a range of glucose concentrations (1,2,5, 20%).
CO spectra were determined from late logarithmic cultures
to estimate P-450 content (Figures 3.14 A-D, Figure
3.15 A-D and Table 3.4). The glucose concentration at
which the P450IIB1 level was optimal and the endogenous
P-450 level minimum was 2%. Higher concentrations of
glucose had no effect in inducing endogenous P-450 levels
but decreased the level of P450IIB1 by 50%. It is unclear
why there should be a variation in P450IIB1 at differing
glucose concentrations is unknown but for all further
experiments a glucose concentration of 2% was used.
3.10 Functional Assay of P450IIB1 Protein
The requirement of P-450 for reductase made it
necessary to determine if the P450IIB1 protein measured
by CO binding (Section 3.9) was functional, i.e. could
couple to the yeast reductase to produce a functional
monooxygenase system.
There are many reactions that can be used as a
measure of P450IIB1 activity, for example, the
0-deethylation of 7-ethoxycoumarin or benzphetamine N-




Fig.3.14 Effect of Changes in Glucose Concentration on KY118
Cytochrome P-450 Levels.
The carbon monoxide binding spectra of whole wild type KYI 18 cells grown in
different glucose concentrations was determined according to the method of Omura &
Sato (1964) (section 2.17.2). The glucose concentrations used were 1% (A); 2% (B);
5% (C); 20% (D). P-450 levels were calculated using an extinction coefficient




Fig.3.15 Effect of Changes in Glucose Concentration on P450IIB1
Protein Levels.
The carbon monoxide binding spectra of whole P450IIB1 expressing KYI 18 cells
grown in different glucose concentrations was determined according to the method of
Omura & Sato (1964) (section 2.17.2). The glucose concentrations used were 1% (A);
2% (B); 5% (C); 20% (D). P-450 levels were calculated using an extinction coefficient
























Table 3.4 Cytochrome P-450 Levels in the P450IIB1 ExpressingStrain
When Grown in Different Glucose Concentrations.
The P-450 spectra in Fig.3.14 were used to determine the level of P-450 when the strain
expressing the P450IIB1 protein (56/3a) was grown in medium with glucose
concentrations of 1,2,5 or 20%. An extinction coefficient (450-490nm) of 91mM"1cm-1
was used. P-450 levels were calculated as (Absorbance at 450nm/0.091) xlOOO/ODgoo.
used was the O-dealkylation of benzyloxyresorufin to
resorufin (Burke & Mayer, 1974). Resorufin is a
fluorescent product that can be measured
spectrophotometrically such that the rate of resorufin
appearance is a direct determinant of P450IIB1 activity.
Yeast microsomal fractions were prepared from both
the 56/3a and 56 par strains. The O-dealkylation of
benzyloxyresorufin was then determined using
approximately 50jjg of microsomal protein. The assays
were carried out a minimum of five times and a
representative trace obtained from both strains is shown
in Figure 3.16. Metabolism was only detected in the
56/3a strain with the level of O-dealkylation of
substrate being 0.16 nmol/min/mg microsomal protein.
3.11 Mutation Assays
3.11.1 Mutation By Nitrous Acid Exposure
One guestion that had to be answered before
comparing the effect of P-450 expression on mutation
frequency was whether the presence of P450IIB1 protein
affected the mutation rate of the strain independent of
its function as a monooxygenase. To answer this nitrous
acid was used as a mutagen. Nitrous acid is a direct
acting mutagen requiring no metabolic activation for its
effect. The result is shown in Figure 3.17. There
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Fig.3.16. Functional Assay on P450IIB1 Protein Expressed
in S.cerevisiae.
The O-dealkylation of benzyloxyresorufin was carried out according to the
method of Burke & Mayer (1974) as modified by Wolf et al (1986). The lower line
indicates the activity of the p56par microsomes and the upper that of p56/3a. Only the
microsomes of the P450IIB1 expressing strain (p56/3a) have significant activity.
strains with the 56/3a strain having a slightly lower
mutation frequency. Thus the presence of a foreign
protein does not increase the background mutation
frequency. It would thus be possible to compare the
mutation rates of both the P450IIB1 producing strain and
the control strain (56 par) when exposed to a variety of
chemicals requiring metabolic activation.
3.11.2 The Use of L-canavanine in Mutation Assays
Kitagawa & Tomiyama (1929) and Kitagawa & Yamada
(1932) during studies on urea formation in mammalian
liver employed both chemical and enzymatic procedures to
study urea levels. The enzymatic procedure using jack
bean seed urease gave consistently greater urea values.
This led to the discovery of a basic amino acid named
canavanine after its isolation from the jack bean,
canavalia ensiformis. The occurrence of L-canavanine is
limited to the Lotoideae. a major subfamily of the
leguminosae (Rosenthal, 1977) where large quantities are
stored in seeds, e.g. up to 5% of dry weight in the jack
bean seed.
L-canavanine is a structural analogue of L-arginine.
The difference being the replacement of the terminal CH2
group in L-arginine with oxygen. On this basis, L-
canavanine can substitute for or antagonize virtually
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Fig.3.17. Mutation Rate Induced by Nitrous Acid Exposure
in Strains p56par and p56/3a.
The direct acting mutagen nitrous acid was used to test the background
mutation rates in the two yeast strains (section 2.22). There appeared to be
no significant increse in the mutation rate of the P450IIB1 expressing strain
(p56/3a) compared to the control strain (p56par). Thus the presence of a
foreign protein does not alter the mutation rate of the KYI 18 yeast strain.
(YUa^^U)^ f 'itrvSu/v^ors
the preferred substrate. Thus L-canavanine can be
activated by arginyl transfer RNA synthetase (Mitra &
Mehler, 1967). Once L-canavanine has been linked to the
%
tRNA it can be inserted, in place of L-arginine, into
proteins as they are synthesised. Since L-canavanine is
chemically much less basic than L-arginine under
physiological conditions it is less positively charged
than L-arginine (Rosenthal, 1977). This charge
difference affects the amino acid interactions
determining protein folding thus producing aberrant
canavanyl proteins. Evidence (Rosenthal et al. 1987)
suggests that proteins structurally altered by the
incorporation of L-canavanine are functionally impaired.
Grenson et al (1966) demonstrated that S.cerevisiae
actively transports the amino acid L-arginine into the
cell using a specific permease and that this uptake can
be competitively inhibited by L-canavanine. Furthermore
resistance to L-canavanine was shown to be associated
with the loss of this arginine permease function. These
observations coupled to work carried out by Whelan et al
(1979) shows that CAN1 locus codes for the primary
structure of the arginine permease.
Whelan et al (1979) also demonstrated the potential
of the CAN1 locus in the study of mutation due to the
ease of selection for both forward and reverse mutations.
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The S.cerevisiae strain KY118 does not have a suitable
genetic marker for use in mutation studies. However, the
diploid S.cerevisiae series of D4-D7 developed by
Zimmerman (1973) for mutational studies do not have the
required trpl genotype to allow the positive selection of
p56/3a. It was thus decided to use the development of
resistance to L-canavanine as a measure of mutation
frequency. The selection for the loss of the arginine
permease function means there should be no problem with
the type of mutation induced. Any mutation that causes a
non-functional arginine permease should be detected.
Compounds belonging to the major classes of chemical
carcinogens were tested using the L-canavanine mutation
assay as detailed in Section 2.19.2. These were
benzo(a)pyrene (a polycyclic aromatic hydrocarbon),
sterigmatocystin (a mycotoxin), cyclophosphamide (a
nitrogen mustard), 2-anthramine (an aromatic amine), 2-
acetylaminofluorene and P-naphthylamine (arylamines).
This work was a collaborative project with Ms. Sian
Ellard (School of Biological Sciences, University College
of Swansea). Each chemical was tested a minimum of three
times.
3.11.3 Cyclophosphamide
Cyclophosphamide (CPA) is a widely used
chemotherapeutic agent that requires hepatic
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bioactivation by P-450 to cause both it's
antitumourogenic and mutagenic effects (Brown et al.
1986). CPA is activated to 4-hydroxy CPA which undergoes
ring opening to aldophosphamide mustard which
spontaneously decomposes to form acrolein and, what is
thought to be the biologically active metabolite,
phosphoramide mustard. Since P450IIB1 has been
implicated in CPA metabolism (Sladek, 1972; Dearfield et
al, 1986), this compound was chosen as a representative
of the anticancer drug that requires metabolic activation
to exert anti-tumour effects.
A representative dose-response curve obtained when
the 56/3a and 56 par strains were exposed to
cyclophosphamide is shown in Figure 3.18. Only in the
strain expressing the P450IIB1 protein is there a dose-
related increase in mutation frequency. This increase
was up to 8-fold at 1600 jig/ml CPA relative to that
obtained when only DMSO was added to the culture. No
such increase in mutation rate was observed in the KY118
strain containing p56 par.
Sladek (1972) has studied CPA metabolism in rats
administered with known stimulaters and depressors of
rat hepatic P-450. The treatment of both males and
females with PB increased the rate of CPA metabolism
by 7- and 23- fold respectively. Since P450IIB1 is one
of the two major PB- inducible proteins in the rat
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Fig.3.18. Exposure of S.cerevisiae Strains to Cyclophosphamide
(CPA).
The mutation rate of each strain on exposure to CPA was determined by selection for
resistance to L-canavanine (section 2.20.2). The strain producing the P450IIB1 protein
(56/3a —♦— ) gives a dose related increase in mutation rate (upto 8-fold at 1600(ig/ml
CPA) while the control strain (—(3—) containing the 56par vector gives no such
increase. Mutation rate was calculated as mutations/106 survivors. This experiment was
repeated three times with similar results (maximum mutation rates of 4-; 4-; and 6-fold
respectively).
(Adesnik & Atchison, 1986) this suggested a role in CPA
metabolism. Dearfield and coworkers have more direct
evidence for the role of P450IIB1 using HepG2 cells
(Dearfield et al. 1986). These cells were only capable
of metabolising CPA when a PB-inducible mRNA was
detected using Northern analysis. The probe used, pR17,
was prepared from enriched P-450 mRNA from PB-induced
rats (Adesnik et al. 1981).
The work discussed above gives strong
circumstantial support to the role of P450IIB1 in CPA
metabolism, however, the results presented here
demonstrate uneguivocally that P450IIB1 is involved in
CPA metabolism. Also, CPA is not a mutagen in strain
KY118 unless P450IIB1 is present. CPA has been shown to
be mutagenic in S.cerevisiae (Kelly & Parry, 1983) ,
however, in these experiments endogenous P-450 levels
were maximised whereas here endogenous P-450 have been
kept to a minimum to decrease background mutation rates.
This probably accounts for the lack of induced mutation
when the 56 par strain was exposed to CPA.
3.11.4 Stericfmatocvstin
Sterigmatocystin (STC) is a carcinogenic mycotoxin
produced as a secondary metabolite by Aspergillus.
Penicillium and Bipolaris species (Schroeder & Kelton,
1975). In rats, STC has been shown to induce
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hepatocellular carcinomas after oral or intraperitoneal
administration as well as squamous cell carcinomas
after repeated skin applications (Essigmann et al.
1979). STC requires metabolic activation by P-450
and because of it's structural similarity to
aflatoxin B-]_ (AFB^) is of interest as a model compound
for cancer induction. STC is 10-100 times less potent
as a hepatocarcinogen in rats then AFB^ (Dickens et al.
1966).
Figure 3.19 shows a representative curve obtained
when the 56/3a and 56 par strains were exposed to STC.
As with CPA only the P450IIB1 expressing strain showed a
dose related increase in mutation rate on STC exposure.
However, the increase was not as pronounced (four-fold
relative to the DMSO only control). Again, the
56 par strain showed no equivalent dose-dependent
increase in mutation rate.
Work carried out by Essigmann et al (1979) has
shown that the active biological intermediate of STC
metabolism by P-450 is STC-1,2-oxide. This epoxide binds
( 7
DNA to give the adduct (N -guanyl -1-
hydroxysterigmatocystin). It is proposed that this
adduct may account for the toxic effects such as
inhibited mitosis and stimulated DNA repair. In these
experiments Essigmann used PB-induced rat liver
microsomes to activate STC. Again, this suggested a role
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Fig.3.19 Exposure of S.cerevisiae Strains to Sterigmatocystin
(STC).
The mutation rate on exposure to STC was determined as in Fig.3.18. The P450IIB1
producing strain ( —♦— ) gives an increase in mutation rate of up to 4-fold (at
160|ig/ml).The control strain (56par —Q—) shows no such increase on STC exposure.
This experiment was repeated three times with the same result.
in STC activation for P450IIB1 as the major active PB
form in the rat liver. The results (Figure 3.19) support
this with a 4-fold increase in mutation frequency
occurring at lOOpg/ml. This P450IIB1 is involved in STC
bioactivation which implicates this protein in the
formation of hepatocarcinomas associated with rats
administered with STC.
3.11.5 Benzofa)pyrene
Benzo(a)pyrene (B(a)P) is a polycyclic aromatic
hydrocarbon whose metabolic activation by P-450 and
expoxidehydrolases gives a dihydrodiol epoxide causing
DNA modification (Conney, 1982). 3-Methylcholanthrene
(MC)-inducible P-450s are thought to be the major
metabolisers of B(a)P while the PB-inducible P-450s are
thought not to play an activation role. This is borne
out by the result shown in Figure 3.20 where neither the
P450IIB1 expressing strain nor the 56 par, control,
strain shows any dose related increase in mutation
frequency on B(a)P exposure.
Previous work using purified rat liver P-450s
(Wilson et_al, 1984) has shown that the P450c (P450IA1),
the major MC-inducible P-450, has approximately 30 times
the activity towards B(a)P than P450IIB1 in a
reconstituted system. Thus the expression of P450IIB1 in

















Fig.3.20. Exposure of S.cerevisiae Strains to Benzo(a)pyrene
(B(a)P).
The mutation rate on exposure to B(a)P was determined as in fig.3.18. Neither the
P450IIB1 producing strain (—♦—) nor the control strain (—Q—) show any dose related
increase in mutation rate when exposed to B(a)P. This experiment was repeated twice
with the same result.
The testing of B(a)P in the Ames test (Robertson
et al. 1983) has shown that only P-448 (equivalent to
P450IA1) will metabolise B(a)P and its 7-8 dihydrodiol
derivative to mutagenic products. Again, testing
P450-PB (equivalent to P450IIB1) did not result in an
increase in the number of trp+ revertants. Again this is
in agreement with that presented here where P450IIB1 did
not cause an increase in mutation rate by the
bioactivation of B(a)P.
3.11.6 2-Acetvlaminofluorene and p-naphthylamine
These chemicals are both arylamines.
^-naphthylamine (fi-NA) exposure has been related to an
increase in bladder cancer amongst humans. 2-
acetylaminofluorene (2-AAF) was originally proposed as an
insecticide before its carcinogenic potential was
realised. Arylamines are metabolised by a number of
cellular enzymes. They can be acetylated by cytosolic
acetyltransferases and then deacetylated by microsomal
deacetylases (Hein, 1988).
Anylamines can undergo both N- and C- oxidations
to hydroxyarylamines by monooxygenases such as cytochrome
P-450 or flavin containing monooxygenases (Kudlubar &
Hammons, 1987). The N-hydroxylation is the reaction
that produces the active metabolite involved in
mutation (Johnson et al. 1980).
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A typical mutation experiment for 2-AAF and B-NA
is shown in Figure 3.21A and 3.2IB. As with B(a)P there
was no measurable difference between the 56 par strain
and the 56/3a strain for 2-AAF. However, B-NA did show
an increase in mutation frequency but this was not
dependent on metabolic activation by P450IIB1. The
result with 2-AAF is in agreement with the work of Johnson
et al (1980) using purified rabbit liver microsomes where
the N-hydroxylation of 2-AAF was carried out by forms 4
and 6 (equivalent to rat P450IA2 and P450IA1
respectively) while the P450IIB1 equivalent, form 2,
exhibited no catalytic activity with 2-AAF as substrate.
However, work using uninduced rat liver microsomes
and antibodies specific to the major proteins of MC- or
PB-induced rat livers has shown that a PB-P-450 specific
antibody can decrease the mutagenicity of 2-AAF by 30% in
an Ames test (Kawajiri et al. 1983). This suggested a
role for P450IIB1 in the bioactivation of 2-AAF in
uninduced rats. Thus it was hoped that P450IIB1
expression in yeast could definitely answer whether
P450IIB1 had a role in 2-AAF activation. The results
(Figure 3.21A) support the work suggesting no role for
P450IIB1 in the N-hydroxylation (activation) of 2-AAF
(Johnson et al. 1980; McManus et al. 1984) rather than
that of Kawajiri et al (1983) which suggests it does.
B-NA has also been shown to undergo N-oxidation by
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Fig.3.21. Exposure of S.cerevisiae Strains to Arylamines.
The P450IIB1 expressing strain (—♦—) and the control strain (56par —a— ) were
exposed to either 2-acetylaminofluorene (2-AAF)(Fig.3.21.A) or P-naphthylamine
(P-NA) (Fig.3.21.B) as in fig.3.18. In the case of 2-AAF neither strain gives a dose
related increase in mutation rate. For P-NA an incresase in mutation rate is seen (up to
lOOpg/ml) in both strains indicating that the increase is P450IIB1 independant. The
decrease in mutation rate at concentrations above 100p.g/ml is due to toxic levels of
P-NA being reached. These experiments were repeated twice with the same results.
while the P450IIB1 protein was found to have no activity
towards ^J-NA for the N-hydroxylation (activation)
reaction although it was found to have 1-hydroxylation (a
C-hydroxylation) activity. In this set of experiments fi-
NA did show a dose-related increase in mutation
frequency. However, this was independent of metabolic
activation by P450IIB1 since this increase was seen in
both the control and P450IIB1 expressing strains. The
reason for this apparent non-requirement of bioactivation
by P-450 is unknown. Some other monooxygenase within the
yeast cell, for example a flavin containing monooxygenase,
may activate the )B-NA.
3.11.7 2-Anthramine
2-Anthramine (2-AN) is an aromatic amine which is
an amino derivative of anthracene. As with 2-AAF and p-
NA the activation reaction is an N-hydroxylation. Since
the reaction in other aromatic arylamines is carried out
preferentially by the MC-inducible P-450 forms would this
be true for 2-AN or would P450IIB1 play a role?
There was no detectable difference between the two
strains in the activation of this compound as seen from
Figure 3.22. This is in agreement with recently
published work using the Ames test to study 2-AN
activation and the effect of specific antibodies to





.3.22. Exposure of S.cerevisiae Strains to 2-Anthramine
(2-AN).
The P450IIB1 expressing (-♦—) and the control (—0—) strains were exposed to
concentrations of 2-AN up to 40|ig/ml as in fig.3.18. The increase in mutation rate
observed at lOpg/ml for the strain expressing the P450IIB1 protein was not
reproducible when this experiment was repeated.
1989). This work showed that an antibody specific to
P450IIB1 (recognising P450IIB2 but no other PB-inducible
P-450) did not inhibit trp+ reversion using aroclor 1254
microsomes as an activation system. The trp+ reversion
could be inhibited by an antibody specific to P450IA1.
This implies a role for P450IA1 in the bioactivation of
2-AN but negates a role for P450IIB1. The work here,
although it cannot suggest a role for P450IA1 in 2-AN
activation, certainly disproves any role for P450IIB1.
3.12 Discussion
It has been proposed (Bridges, 1974) that a rational
approach to mutagenicity testing should involve a three-
tier strategy. This concept has been updated (Ashby,
1986) such that the first-tier of testing would use in
vitro assays to define genotoxins, suggesting that these
assays should be the Ames test and the in vitro
chromosomal assay according to Scott et al (1983).
If a chemical is found to be genotoxic in these assays
then the next two stages should be conducted in vivo (if
negative all testing should cease and the chemical
assigned to be of low genotoxic hazard) . The micro
nucleus test should be employed for the second tier and
if negative then the third tier should be a liver
genotoxicity test probably using the unscheduled DNA
synthesis (UDS) test. If a negative result is obtained
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in both these tests then current evidence suggests that
this genotoxin will neither be carcinogenic nor mutagenic
to the germ cells of mammals (Ashby, 1986).
However, the best in vitro STT may not be the two
described by Ashby (1986) as the requirement for
exogenous activation factors limits the efficiency of the
assay. Also the NTP program (Tennant et al. 1987) has
shown that the concordance of these tests is only
approximately 60%. This may be because most human
carcinogens require metabolic activation via the P-450
monooxygenase system. Thus it can be imagined that
particularly short-lived but highly reactive metabolic
species formed outside the cell by these reactions will
probably not be able to traverse the various cellular
compartments to be in a position to react with DNA and so
elicit a detectable response. This would label a
chemical as of low genotoxic hazard according to Ashby
(1986). Thus an intracellular activation system would be
of potential usefulness in an STT.
The results presented here exhibit the potential of
genetically engineered S.cerevisiae strains to produce
such an STT. Previous work to evaluate the usefulness of
S.cerevisiae has shown that although there is potential,
there is a problem with narrow specificity and
physiological limitations in the endogenous P-450 system.
Although protocols have been developed to increase the
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levels of yeast P-450 (Kelly & Parry, 1983) and studies
have shown that promutagens of relevance to human hazard
can be activated (Callen & Philpot, 1978; Parry & Parry,
1988), there is some debate over whether the active
species formed are actually those produced in man.
However, the use of well defined and easily manipulated
yeast expression vectors, as described here, to produce
high levels of proteins involved in the bioactivation of
promutagens (0.2% of total cellular protein in this
case) could be of obvious merit. Not only would the
problem of non-detection of highly reactive though
unstable intermediates be overcome but the use of a
battery of such strains would determine the particular
isoenzyme(s) involved in the activation. This is
relevant since recent work has shown that there is
polymorphic expression of certain P-450 isoenzymes within
the population which may have an effect on the
predisposition of individuals to cancers with
environmental components (Wolf, 1986; Gonzalez et_al,
1988).
In this study the major rat PB-inducible P-450,
P450IIB1 has been expressed in the S.cerevisiae strain
KY118 to produce functionally active protein. The
potential of this system to activate promutagens has been
evaluated using six chemicals known to be bioactivated.
In two cases, cyclophosphamide and sterigmatocystin,
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where PB-inducible P-450s have been implicated in the
bioactivation reactions the presence of the P450IIB1
protein was shown to increase the mutation frequency in a
dose-dependent manner relative to control. In three
other cases, 2-acetylaminofluorene, 2-anthramine and
benzo(a)pyrene, where P-450s other than the PB-inducible
family have been implicated no dose-dependent increase in
mutation frequency could be detected. In one case, f}-
napthylamine, a dose-dependent increase in mutation
frequency was found independent of the presence of
P450IIB1 protein. Other monooxygenases such as the
flavin containing monooxygenase were probably responsible
for this result (Johnson et al. 1980). The last case
shows the requirement for adequately controlled STT
experiments since without a control mutation rate curve
an erroneous conclusion regarding P450IIB1 activation of
p-napthylamine could have been drawn.
Purchase (1982) has proposed that all predicative
STT for chemical carcinogenicity should be thoroughly
validated using established carcinogens and non-
carcinogens. Three stages are proposed:-
1) the developing test is subjected to limited
validation (using as few as 10 chemicals); 2) a test can
be considered developed when adequate validation studies
(at least 100 chemicals) have been completed to enable
performance criteria to be ascertained; 3) an
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established test where large scale validation in several
laboratories has occurred. Performance criteria are most
commonly based on sensitivity, specificity and
predicative value as defined by Cooper et al (1979) such
that sensitivity (or true positive fraction) equals the
number of carcinogens positive in a test divided by the
total number of carcinogens.
Specificity (or true negative fraction) equals the
number of non-carcinogens negative in a test divided by
the total number of non-carcinogens. Predicative value
equals the number of positive results from carcinogens
divided by the total number of positive results.
However, the chemicals studied here all are known
carcinogens and as such these equations need to be
redefined to give an accurate representation of this
system thus:
sensitivity equals the number of positive results divided
by the number of chemicals activated by PB-inducible P-
450 (2;2= 1.0)
specificity equals the number of negative results divided
by the total number of chemicals not activated by PB-
inducible P-450 (3 7 4 = 0.75)
Predicative value equals the number of positive
results from chemicals activated by PB-inducible P-450
divided by the total number of positive results equals
two divided by three* which equals 0.67.
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* the p-naphthylamine result has been included as a
positive result although the increase in mutation
frequency was similar in both the control and P450IIB1
expressing strain.
Although the number of chemicals tested was small
(six) the predicative value of 0.67 compares favourably
to that of the commonly used STT (Tennat et al. 1987).
Thus the test described here would seem to have some
potential.
However, there are a few flaws that require action
before the test could be widely adopted. These flaws are
mostly associated with the S.cerevisiae strain used. The
mutation rate was determined by the development of
resistance to L-canavanine which is due to the loss of
arginine permease function (Grenson et al. 1966). This
is a general genetic endpoint which will measure any DNA
lesion producing a mutation at the CAN1 locus. This has
the disadvantage that no information can be obtained on
the type of genetic damage a chemical is actually
producing. Thus a possible improvement to this test
would be the development of strains with genetic markers
with specific defects to enable the type of genetic
damage a chemical induces (point mutations, small or
large deletions etc.) to be determined. Other
improvements of the yeast strain could involve the
isolation of mutants that are hypersensitive to genetic
103
damage. For example, by mutating the error-free DNA
repair systems in favour of error-prone (SOS-like)
pathways. This would increase the sensitivity of the
strains to the action of the activated promutagen under
test. One could also envisage the mutation of other
cellular processes within the cell for example the use of
GSH deficient mutants. The thiol compound GSH is known
to play a fundamental role in the protection of cells
from electrophilic species for example bioactivated
cyclophosphamide (Hayes & Wolf, 1988). GSH deficient
strains should be more susceptible to genetic damage due
to a reduced detoxication capacity. Recent work by Balzi
et al (1987) has identified a protein from the PDR1 locus
in S.cerevisiae associated with regulation of drug
transport. Over expression of this protein is seen to
produce hypersensitive cells very susceptible to
cytotoxic insult. Thus these type of mutants could also
be incorporated into the basic test system detailed here
to increase intracellular chemical concentration. This
would enable P-450 mediated activation to occur as
efficiently as possible.
It has been reported (Ohkawa et al. 1989) that
another limitation in mammalian P-450 expression in
S.cerevisiae is due to limited production of the
endogenous yeast P-450 reductase within the cell. The
expression of the rat P-450 reductase in S.cerevisiae has
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shown that the protein is highly unstable and thus cannot
be used to increase cellular P-450 reductase levels
(Ohkawa et al. 1989). Thus a potential method of
increasing the activity of a mammalian P-450 in yeast
would be to over express the endogenous yeast reductase.
The cDNA has been cloned (Ohkawa et al. 1989) and so
could be over expressed from a yeast expression plasmid,
perhaps via stable integration into the yeast genome
using a Yip (Yeast Integrating Plasmid). Alternatively
the selection of mutants with increased reductase
expression using classical genetics could achieve a
similar end.
The potential of the STT described here can, of
course, only be developed if a battery of P-450 can be
expressed in S.cerevisiae and so act as activation
systems for potential promutagens. The work presented
here clearly shows that a single P-450 cannot be
responsible for the activation of all promutagens even
though each P-450 possesses a broad substrate specificity
(Nebert & Gonzalez, 1985). Also the P-450 expressed
should ideally be from humans, since it is often
difficult to determine orthologous and homologous
proteins between species, and would better demonstrate
human risk.
A similar system to that described here has, in
fact, been developed using mammalian cells instead of
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S.cerevisiae (Doehmer et al. 1988) where the rat P450IIB1
protein has been expressed in V79 cells. An increase in
aflatoxin (AFB^) induced mutation associated with
P450IIB1 metabolism has been observed. It could be
argued that the use of mammalian cells better reflects
human risk as cellular processes relate better to those
found in the whole animal. However, yeast has the
advantage that it is easier to propagate and manipulate.
The use of molecular biological techniques to produce
exogenous P-450 expressing strains is easier in yeast
than in mammalian cells. Also the use of classical
genetics to develop strains of yeast which have increased
sensitivity to genetic damage or have particular genetic
lesions is only possible in S.cerevisiae and not in
mammalian cell lines. But whether the undoubted
potential of the yeast expression system described here
is developed into a widely used STT remains to be seen.
The over expression of mammalian P-450's within
S.cerevisiae is a flexible system that can be used for
purposes other than as a short-term test system. For
example, it could be used to generate large quantities of
active metabolites such as the AFB^-8,9-epoxide or the
sterigmatocystin-1,2-oxide which are thought to be the
biologically active metabolites of aflatoxin B^ and
sterigmatocystin respectively. The fact that large
quantities of protein can be produced from the expression
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vectors propagated in S.cerevisiae (up to 1% total
protein from the ADC1 promoter) means that the large
quantities of protein required for X-ray crystallography
or studies on substrate specificity r can be produced from
such an expression system. This would reduce the need
for complicated isolation protocols required to produce
P-450 isoenzymes free from other contaminating P-450.
Procedures which take a great deal of time and care when
isolating P-450 from mammalian tissue.
Perhaps the most useful application of this
expression system is to couple P-450 expression in yeast
with site directed mutagenesis (SDM). Here amino acid
residues thought to be critical to the function of the
protein can be examined and the effect on their
substitution on P-450 mediated reactions studied.
Furthermore residues thought to be important in the
substrate specificity of the protein can also be
investigated using the same techniques. These types of
study are now starting to be used to answer P-450
structure/function questions (Kimura et al. 1987; Sakaki
et al. 1987; Shimizu et al. 1988; Imai et al. 1988;
Lindberg & Negishi, 1989).
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CHAPTER 4
THE EXPRESSION OF HUMAN GLUTATHIONE B-TRANBFERASE8 IN S.CEREVISIAE
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4.1 Resistance to Antineoplastic Therapy
Chemotheraphy is an effective treatment for a number
of cancers especially when used in conjunction with
ionising radiation or surgery. However, in many cases
relapses occur because a subset of the tumour cells
become resistant to the treatment regimen employed.
Frequently resistance to several drugs develops
concurrently causing a very serious problem for the
patient. Studies in vitro have shown that many genetic
changes can be produced by anticancer drug treatment.
Some drugs induce point mutations, others chromosome
abnormalities or DNA strand breaks, some gene
amplification and still others DNA hypomethylation (Warr
& Atkinson, 1988). These types of genetic change are
partially dependant on the nature of the drug used (Warr
& Atkinson, 1988). For example, DNA strand breaks are
associated with intercalating agents and drugs such as
(.
adriamycin which generate reactive free radicals.
Examples of these types of genetic change will be briefly
discussed.
4.2 Point Mutations and Drug Resistance
The simplest form of mutation is a base substitution
leading to an amino acid change. Evidence that base
substitutions or amino acid changes play a role in drug
resistance is mainly from work in cell culture (and other
109
organisms) rather than human tumours. For example, in
one study a cDNA for dihydrofolate reductase (DHFR) (the
target enzyme for methotrexate) was cloned from a highly
methotrexate (MTX) resistant cell line (mouse 3T6)
(Simonson & Levinson, 1983). The DNA sequence of the
cDNA showed a single base substitution which resulted in
an arginine - leucine change at amino acid 22. X-ray
crystallography work showed that arginine-22 is a
critical residue in the target site for MTX (Simonson &
Levinson, 1983). Cells transfected with the mutant DHFR
cDNA were highly resistant (Simonson & Levinson, 1983).
Thus a simple base change in the correct position within
a target protein can result in drug resistance.
4.3 Chromosome Abnormalities and Drug Resistance
Resistance to purine analogues such as
6-mercaptopurine or 6-thioguanine has been shown to
involve gross chromosome changes. The target for these
compounds is the enzyme, hypoxanthine guanine
phosphoribosyl transferase (HGPRT). In one study Fuscoe
et al (1983) found that 17 UV-induced purine analogue
resistant hamster cell lines contained point mutations
within the HGPRT gene. However, another two mutations
involved deletions of large sections of the gene (Fuscoe
et al. 1983). This finding is important because it
emphasises that resistance can be caused by a loss of
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gene function, a mechanism which is often overlooked.
The most commonly discussed mechanism of resistance being
an increase in the levels of a specific protein (or
proteins) or mutations which reduce drug sensitivity.
Harris & Collier (1981) have shown that resistance
to purine analogues can also be associated with abnormal
chromosome numbers suggesting a gene dosage effect in
resistance. However, work by Fox & Radacic (1982) has
shown that chromosome numbers can return to normal after
selective pressure is removed but resistance can remain.
One answer to this apparent dichotomy is that a gene
duplication has occurred that is undetectable by
cytological procedures but is still capable of producing
the required gene dosage effects. Low levels of gene
amplification such as this has been found in resistance
to other drugs such as MTX and 5-fluorouracil (Warr &
Atkinson, 1988). The amplification of the DHFR gene
during the development of MTX-resistance has been
particularly well studied. MTX binds to the DHFR protein
with 1000 times higher affinity than the endogenous
substrate, dihydrofolate. Toxicity due to MTX can be
overcome by overproduction of DHFR. Cell lines have been
isolated where DHFR contributes up to 20% of the total
soluble protein (Alt et al. 1978). Biochemical tests
suggest that the DHFR protein produced in the resistant
lines is identical to that of their sensitive
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progenitors. The increased levels of DHFR protein were
shown to be associated with an increase in DHFR gene copy
number (Alt et al. 1978). Thus gene amplification can
play a role in the development of drug resistance.
4.4 Role of DNA Hvpomethvlation in Drug Resistance
Mammalian DNA is methylated such that
5-methylcytosine is produced at the sequence CpG. The
pattern of methylation is normally clonally inherited and
evidence suggests that this can affect gene expression
since DNA hypomethylation is thought to be related to
gene activation (Bird, 1984). It is interesting that the
DNA of benign and malignant human colonic neoplasms have
been shown to be hypomethylated (Goelz et al. 1985).
Whether this relates hypomethylation to drug resistance
in tumours is unclear but is a potential mechanism for
the over-expression of drug resistance proteins.
4.5 Multiple Drug Resistance
The previous sections demonstrate that genetic
changes can result in multiple drug resistance. The
phenotypes of this phenomenon also include alterations in
membrane permeability, DNA repair, DNA topoisomerase II
and drug detoxification. The roles of each of these will
be briefly examined with emphasis on the role of the
glutathione S-transferases as drug detoxification
proteins in drug resistance.
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4.5.1 Changes in Membrane Permeability and Drug
Resistance
The development of resistance to certain
antineoplastic drugs in mammalian cell lines or in human
tumours frequently leads to the onset of resistance to
other structurally and functionally dissimilar drugs.
This phenomenon has been termed multidrug resistance
(mdr). The mdr phenotype has been correlated with
changes in the plasma membrane function and structure
and associated with a reduced net drug accumulation
within the target cell (Gerlach et al. 1986). The mdr
phenotype which is associated with a membrane bound drug
efflux protein named p-glycoprotein or P-170 can be
reversed by the calcium channel blocker verapamil.
Verapamil interacts directly with the protein to cause
its effect (Gerlach et al. 1986). High levels of P-170
have been detected in some drug resistant human cancers
(Bell et al. 1985). Gros et al (1986a) have shown that
if a p-glycoprotein cDNA is expressed in mammalian cells
they acquire this mdr phenotype. This strongly supports
a causal role for this protein in drug resistance
mechanism. The sequence of the p-glycoprotein cDNA has
yielded much information about its structure ard function
(Gros et al. 1986b). The protein contains approximately
1,300 amino acid residues and consists of two very
similar halves which appear to have arisen as a tandem
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duplication (Gros et al. 1986b). Each half of the
protein contains a consensus sequence for an ATP binding
site which supports the role of the protein as an ATP-
dependent drug efflux pump. P-glycoprotein has close
homology with a number of bacterial membrane transport
proteins (Gros et al. 1986b). The homology is greatest
with the E.coli hemolysin transport protein where, over
the common region, 60% of the amino acids in the mouse
p-glycoprotein are either identical or are conservative
substitutions. This degree of homology is one of the
greatest ever detected between proteins from pro- and
eukaryotes (Warr & Atkinson, 1988). This strong
evolutionary conservation indicates that these sequence
motifs play a fundamental role in the cell.
It is, however, important to note that each
multidrug resistant cell line appears to display a
different pattern of cross-resistance and the degree of
intracellular drug accumulation does not always correlate
with the degree of resistance (Cowan et al. 1986).
Changes in other enzymes have also been found in such
drug resistant cell lines thus p-glycoprotein is not the
sole cause of resistance to anticancer drugs.
4.5.2 Changes in DNA Repair Capacity and Drug Resistance
An increase cellular DNA repair may result in
multiple drug resistance by its capacity to reduce DNA
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damage. This could limit the usefulness of many
antineoplastic drugs especially alkylating agents.
However, as with most enzymes potentially involved in mdr
the precise relationship between altered DNA repair
capacity and acquired drug resistance is complicated by
the multiple changes occuring within a cell on exposure
to a DNA damaging agent. For example, the cellular
methylation level may be affected on drug exposure with a
subsequent alteration in gene expression.
Correlations have been shown to exist between DNA
repair capacity and drug tolerance although this is
mainly from work carried out on the 06-methyltransferase
system in E.coli. This enzyme is the product of the ada
gene and has been shown to have the ability to repair 06-
methylguanine and other similar lesions (although less
efficiently) (Sekiguchi & Nakabeppu, 1987). A similar
DNA methyltransferase with high activity towards 06-
methylguanine is also present in mammalian cells. If
this activity is absent (e.g. in CHO cell lines) the cell
exhibits hypersensitivity towards alkylating agents such
as MNNG. This indicates an important role for this
enzyme in the protection of cells from the damge
associated with exposure to alkylating agents.
In mammalian cells the repair of O-alkylpyrimidines
is less well understood that that of O-alkylpurines.
Although these adducts are repaired the proteins which
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appear to be analagous to the E.coli O-alkylpyrimidine
methyltransferases do not act on these lesions. This
repair pathway must be different to that in E.coli (Brent
et al. 1988). Thus techniques are required to further
characterise these pathways that do not require the use
of E.coli as a model system.
There are other DNA repair processes in mammalian
cells that may be involved in drug resistance. These
involve excision repair, a process involving the excision
of DNA on both sides of an adduct followed by gap removal
via the action of DNA polymerases. However, no overall
correlation has emerged between the level of excision
repair and susceptibility to DNA damage (Fox & Roberts,
1987). Thus more than DNA repair capacity alone may be
involved. DNA repair capacity has been shown to be
affected by a number of factors. These include the
chromatin structure around the DNA lesion with expressing
genes preferentially repaired as compared to the genome
as a whole . The intracellular level of dNTPs can also
affect DNA repair capacity (Fox & Roberts, 1987).
A decreased level of DNA repair also has the
potential to produce an mdr phenotype. It has been
proposed that the inhibition of DNA replication (by DNA
damage) can lead to the reinitiation of replication at a
previously unused origin behind the stalled replication
fork (Shimke et al. 1986). This could lead to the
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amplification of DNA segments whose polypeptide products
can confer resistance to chemotherapeutic regimens.
The above suggests that alterations in cellular DNA
repair capacity can produce an mdr phenotype. However,
the evidence accumulated to date is not conclusive.
There are reports that sequences from mammalian genomes
have been transfected into hypersensitive mammalian cell
lines to produce normal levels of DNA repair (Harris &
Hickson, 1989). However, these transfected cell lines are
not actually more resistant than the normal wild-type
cell line. Thus the study of DNA repair has so far not
led to definite answers as to its role in acquired drug
resistance.
4.5.3 DNA Topoisomerase II (topll) and Drug Resistance
DNA topoisomerases play an important role within
cells by mediating alterations in chromosome structure.
Based on their mechanism of action they are divided into
two:- type I and type II. Type II enzymes produce
breaks in two DNA strands then pass another DNA duplex
through the break. The DNA breaks are then repaired.
Experiments with yeast temperature dependent topiI
mutants suggest that this is an essential gene required
to unwind daughter chromosomes at the end of mitosis (Di
Nardo et_al, 1984).
TopII has been used as a target for several
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anticancer drugs including VP-16, adriamycin and m-AMSA.
These augment the formation of the 'cleavable complex'
where topll is covalently attached to the 5'termini of
the cleaved double-stranded DNA. The cleavable complex
is in some way stabilised so preventing repair of the
DNA. This results in the observed cytotoxicity of these
topll-active drugs in vivo.
There are four mechanisms by which resistance to
topll-active drugs has been shown to occur. Firstly cell
lines have been produced that are resistant due to the
presence of a mutant topll. For example, VP-16 resistant
CHO cell lines produced by ethyl methanesulphonate
mutagenesis (Glisson et al. 1986). Identical levels of
topll are found in the parental and resistant lines,
however, the resistant population contain a heat labile
topll that does not form enzyme-DNA cleavable complexes
when stimulated by topll-active drugs. Secondly topll
levels vary during the cell cycle such that levels are
decreased in quiescent cells. This decrease in topll
levels can prevent sufficient cleavable-complex being
formed and reduce drug cytotoxicity. Thirdly (and less
well characterised) topll activity can be regulated in
vitro by phosphorylation and poly(ADP)-ribosylation, as
well as other factors (Pommier et al. 1986). Fourthly
confluent L1210 cells which give equivalent drug-induced
DNA damage when compared to logarithimically growing
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cells are significantly more resistant to VP-16 induced
cytotoxicity (Sullivan et al. 1986). It is, however,
unclear why this resistance is observed.
Thus alterations in topll activity has the
potential to produce an mdr-phenotype with cross-
resistance to several widely used chemotherapeutic
agents. It may also represent an attractive target
molecule to differentiate normal and neoplastic cells.
4.6 GST-Mediated Detoxification and Drug Resistance
The role of GST in cellular resistance to antineoplastic
therapy can be divided into two types:-
1) role of GST in intrinsic drug resistance;
2) role of GST in acquired drug resistance.
4.6.1 GST and Intrinsic Drug Resistance
Intrinsinc resistance to cytotoxic drugs is widely
observed in drug therapy. Such resistance is commonly
observed in the treatment of parasitic organisms and
human tumours. Significant GST levels have been found in
human parasites such as nematodes, cestodes and
helminths. For example, Kawalek et al (1984) have
examined the GST levels in the nematode Haemonchus
contortus. The level of GST activity was found to be
approximately 2-fold higher in a cambendazole-resistant
strain when compared to a sensitive control. This may be
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of great significance as nematode resistance is one of
the most pressing problems facing antihelmintic
chemotherapy. This resistance is on the increase with
reports that up to 43% of sheep farms in New South Wales,
Australia have drug-resistant strains of nematode (Webb
et al. 1979). Other studies have shown that the
resistance of mice to Schistosoma infection is due to the
recognition of a GST mu-like nematode GST present on the
surface of the worm (Smith et al. 1986). The importance
of this enzyme in nematode infection and resistance to
chemotherapy is unclear. The cestode Moniezia expansa
has also been shown the potential to become drug-
resistant (Douch & Buchanan, 1978). Thus GST may play a
role in the resistance of human parasites to modern
chemotherapeutic regimens and thus present a major
problem in the fight to eradicate these diseases.
Human tumours have been shown to have high levels
of GST prior to chemotherapy and these are found to be
intrinsically resistant to chemotherapeutic regimens.
For example GST pi has been shown to be expressed at high
levels in cancer of the colon, stomach, pancreas and
uterine cervix (Kodate et al. 1986; Sato et al. 1987).
Immunoblotting has shown GST pi to be overexpressed in
adenocarcinoma of the breast and lung, nodular small cell
lymphoma and mesothelioma (Shea & Henner, 1987). GST pi
has also been shown to be expressed in squamous cell
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carcinoma (Hayes & Wolf, 1988). The over-expression of
GST pi is also seen in cell lines, for example both small
cell and non-small cell carcinoma cell lines (Aswathi et
al, 1988; Wolf et al. 1987). It has been suggested that
GST pi may be a marker for drug resistance (Ketterer,
1988). However, whether high levels of GST expression
represent a significant factor in the failure of
chemotherapy remains unclear.
4.6.2 Role of GST in Acquired Drug Resistance
There are four main models that have been studied
to evaluate the role of GST in acquired drug resistance.
Firstly, the role of GST in the rat hepatocarcinogenesis
model (see Farber, 1984). Secondly, the changes in
GST expression that occur when normal cells are treated
with cytotoxic compounds. Thirdly, changes in GST levels
in cell lines resistant to cytoxic drugs and lastly the
examination of GST in tumours before and after the onset
of resistance to antineoplastic therapy. The changes
which occur in GST subunit expression within these models
are discussed overleaf.
4.6.3 GST Expression in Rat Hepatocarcinoqenesis
The changes that are induced within the rat liver
by feeding a hepatocarcinogen, such as aflatoxin
represent the most studied in vivo model which
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implicates the GST in drug resistance (Hayes & Wolf,
1988). The importance of drug resistance in the
development of preneoplastic foci to liver tumours has
been emphasised by Farber (1984). The initial response in
the rat liver when exposed to a hepatocarcinogen is an
overall increase in alpha and mu class enzymes
(specifically subunits 1 & 3) (Kitahara et al. 1984).
Subsequently, subunits belonging to all three types of
GST become over-expressed in pre-neoplastic foci. These
subunits are 1, 3 and 7 (from the alpha, mu and pi class
GST respectively) (Sato et al. 1984).
Many of these pre-neoplastic foci develop into
nodules rich in GST isoenzymes and eventually into
neoplastic tumours. However, most redifferentiate into
apparently normal hepatocytes (Farber, 1984). Initially
the hepatomas resulting from the nodules have the same
overall expression of subunits 1, 3 and 7 as in the
nodules. As the tumour progresses all but subunit 7
(pi class enzyme) is repressed (Ketterer, 1988). It has
been proposed that subunit 7 can be used as a biochemical
marker for the development of hepatocarcinogenesis.
The role of GST in the progression of pre¬
neoplastic foci to fully fledged primary hepatomas
has not as yet been determined. However, since drug
resistance has been proposed as an important link in
these events (Farber, 1984) the over-expression of GST
122
may give the pre-neoplastic foci a growth and hence
selective advantage over the neighbouring cells. Indeed
these cells have been shown to be drug resistant. The
over-expression of GST in neoplasia may not be an
important part in the process, but may be an indirect
consequence of the changes which occur. For example, the
5'upstream region of the GST pi promoter contains a
phorbol ester responsive element, TRE (Sakai & Muramatsu,
1987) which also appears to be activated by the c-Ha ras
protooncogene (Sakai et al. 1988). Thus the expression
of GST pi may be a consequence of c-Ha ras expression
within the pre-neoplastic foci and nodules (Cowell et al.
1988) .
4.6.4 GST Changes Induced in Normal Cells bv Cvtoxic
Prugg
The bone marrow in male CBA mice has been used as a
model to investigate the response of normal cells to the
cytotoxic effects of cyclophosphamide, 1-p-D-
arabinofuranosylcytosine (araC) and X-irradiation
(Adams et al. 1985). The bone marrow is of interest due
to the toxicity caused in this tissue by the anticancer
drugs used in modern chemotherapy. Indeed the bone
marrow is often the origin of secondary cancers caused
by treatment with chemotherapeutic agents. As mentioned
previously (Section 1.10.4) exposure of an animal to a
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low dose of a cytotoxic agent has the potential to
protect against a normally lethal dose of the same
compound (Millar et al. 1975) . Thus a low dose of
cyclophosphamide was used (75 mg/kg) to 'prime' the bone
marrow. This was found to cause an initial decrease in
GSH levels (Adams et al. 1985). However, 5-7 days post-
treatment the GSH and GST levels were found to be
enhanced (2-3 fold in both cases). Animals given an
otherwise lethal dose of cyclophosphamide (350 mg/kg)
during this period were found to survive (Adams et al.
1985).
Similar effects were seen with araC and X-
irradiation. The increase in GSH and GST induced by the
different compounds may thus represent a general "stress"
response of cells to cytotoxic injury.
4.6.5 Role of GST in Resistance within Human Tumours
In an in vivo study of drug resistance two ovarian
cell lines were derived from the ascites of a patient
before (PEOl) and after (PE04) the development of
clinical drug resistance to cisplatinum, chlorambucil and
5-fluorouracil (Wolf et al. 1987a). The PE04 cell line
was shown to be 3-fold more resistant to cisplatinum and
chlorambucil but not more resistant to 5-fluorouracil
(Wolf et al. 1987a). The glutathione and glutathione-
dependent enzymes of these cell lines have also been
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examined and differences have been observed. It was
found that GSH levels were increased 1.4-fold in PE04 while
Y-glutamyltranspeptidase, an enzyme involved in the
regulation of GSH synthesis (Ahmad et al. 1987), was
elevated 6.3-fold (Lewis et al. 1988a). Overall, an
increase in GST levels of 2.9-fold were measured.
Activity towards both ethacrynic acid and CDNB were
increased (Lewis et al. 1988a). This difference could
not be associated with the expression of a specific GST
subunit as both pi and alpha class enzymes could be
detected at similar levels. The mu subunit was absent
from both. However, this study provided the first
evidence that tumour cells obtained before and after the
onset of drug resistance have differences in GSH and GSH-
dependent enzymes. It is highly supportive of a role for
GST and GSH in acquired drug resistance.
4.6.6 Role of GST in The Resistance of Mammalian Cell
Lines to Cytotoxic Drugs
There are examples of all three classes (alpha, mu
and pi) of cytosolic GST being over-expressed in cell
lines made resistant to cytotoxic drugs. Also, Clapper &
Tew (1989) have reported a role for a 29kD microsomal GST
in acquired resistance to nitrogen mustards in a Walker
256 rat mammary carcinoma cell line. However, as this
chapter deals with the human cytosolic GST these will
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be given greater emphasis.
An MCF-7 human breast cell line has been selected
for resistance to adriamycin (Cowan et al. 1986; Batist
et al. 1986). A 45-fold increase in GST activity was
measured using CDNB as substrate. This was associated
with the appearance of a pi class enzyme, pi. The
resistant cell line, although selected for resistance to
adriamycin, was also shown to be resistant to the vinca
alkaloids (vincristine and vinblastine), VP-16 and
actinomycin D, i.e. a classic mdr phenotype (Cowan et al.
1986). The resistance was greatest towards vinblastine
(375-fold). It should also be noted that an increase in
GST pi expression is not the only biochemical change
associated with the MCF7 Adr1* cell line (Cowan et al.
1986). Other biochemical changes measured include an
overall decrease in intracellular levels of adriamycin
(2-3-fold) associated with an increase in p-glycoprotein
activity (Batist et al. 1986). Also, there is a decrease
in Cytochrome P-450 levels (Phase I - toxification
enzymes), as estimated by arylhydrocarbon hydroxylase
activity, of at least 40-fold (Cowan et al. 1986). Other
phase II enzymes are also increased, the
UDP-glucouronyltransferase enzymes are increased 2-3-fold
with respect to the wild-type MCF-7 cell line (Cowan et
al, 1986). It is interesting that the changes observed
in this cell line mirrored those found in rat
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hyperplastic nodules. In view of the range of
biochemical changes induced by adriamycin exposure it is
difficult to completely assign a role for GST pi in the
acquired resistance observed. It may be that the GST pi
is merely a marker for resistance. The alpha class of
GST enzymes have also been implicated in drug resistance
by the work of Robson et al (1987). A Chinese hamster
ovary (CHO) cell line was produced that was resistant to
chlorambucil (Robson et al. 1986) and designated CHO-
Chlr. The total GST activity in the resistant cell line
was increased 3-fold (as measured by CDNB activity) while
a 2-and 5-fold increase in GST-mediated ethacrynic acid
conjugation and peroxidase activity towards cumene
hydroperoxide were also measured (Robson et al. 1987).
Consistent with these changes were an increase in GST pi
and alpha class enzymes (Robson et al. 1987). No
increase in p-glycoprotein could be detected, however,
GSH levels were increased (2-fold) (Robson et al. 1987).
It is thus entirely possible that the resistance to
chlorambucil may be mediated by the increase in
intracellular thiol concentration rather than the
increase in GST activity. GSH has been implicated in the
detoxification of nitrogen mustards including
chlorambucil (Wolf et al. 1987b).
The mu class of enzymes have been implicated in
*
cellular resistance to 1,3-bis (2-chloroethyl)-1-
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nitrosourea (BCNU) by the recent work of Smith et al
(1989). A 9L rat gliosarcoma cell line has been derived
(9L-2) that is 3-4-fold more resistant than the parental
cell line (Smith et al. 1989). Immunoblotting showed
that the 9L-2 subline, which had an overall decrease in
GST activity, had elevated levels of the mu class
enzymes. The same analysis showed a decrease in pi class
GST levels in 9L-2. In support of this finding the mu
class GST were shown to have the highest activity in the
deactivation of BCNU. A Vmax to Km ratio of 29.2 for 3-4
and 26.1 for 4-4 respectively were measured. The alpha
class enzyme 1-2 had a ratio of only 2.3 while the pi
enzyme, 7-7, also had very low activity towards BCNU as
substrate (Smith et al. 1989). This study provides
strong evidence for the role of the over-expressed GST in
drug resistance. It is one of the few studies to have
shown that the drug used to produce the resistant subline
is in fact a GST substrate. Dulik et al (1986) have
produced the only other study demonstrating that GST are
directly involved in the detoxification of anticancer
drugs. Melphalan was shown to form GSH conjugates in the
presence of GST. Both microsomal and cytosolic GST were
shown to be involved (Dulik et al. 1986; Dulik &
Fenselau, 1987). The rate of conjugate formation was
increased upto 100-fold in the presence of GST (Dulik et
al, 1986).
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Thus, all three classes of GST have been implicated in
the resistance of cell lines to cytotoxic drugs.
However, the evidence for the involvement in the
resistance mechanism is circumstantial. It is also not
clear whether GST over-expression is causal or
coincidental in cell lines resistant to anticancer drugs.
The expression of cDNAs encoding human alpha and pi class
GST in S.cerevisiae. was carried out here to try and
resolve the situation.
RESPLTS
4.7 Subcloninq of Human Aloha Class GST into PMA56
The isolation of the alpha class GST used in
these studies has been reported previously (Lewis et al.
1988b). Initially a large scale plasmid preparation was
carried out on the plasmid designated pUC/B^ An EcoRI
restriction digest followed by preparative agarose gel
electrophoresis was used to show that the plasmid
(pUC/B^) did indeed contain the human alpha class GST.
Following an EcoRI digestion of pUC/B-^ DNA (20pg)
the GST alpha cDNA was isolated by passage through a
spin-X column. The cDNA was then ligated into the
p56-RIBAP vector (see Section 3.3). After
transformation into E.coli DH1 the resultant colonies
were subjected to the colony screening method of
Grunstein and Hogness (1975) using 32P-labelled GST B-^
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cDNA as a probe. This gave six possible colonies
containing recombinant plasmids (Figure 4.01). Plasmid
preparations were carried out on these colonies and
restriction analysis with EcoRI used to determine which
contained the GST cDNA as insert. This is shown in
Figure 4.02. The plasmids designated 56/B-^-l; 56/8-^-3
and 56/B-^-6 were shown to have cDNA inserts. Each of
these were transformed into the S.cerevisiae strain KY118
to determine which produced GST B-^B^ protein.
4.8 Expression of GST B-^B-^ Protein in S.cerevisiae
Strain KY118
A single colony from each transformant was
inoculated into supplemented synthetic SD medium (50 ml)
and grown into stationary phase. Cells were harvested
and cytosolic preparations (Section 2.16.3) subjected to
SDS-page and Western blotting. Antibodies raised against
the purified human alpha class GST (B^^) were used
followed by 125I-labelled protein A to give the result in
Figure 4.03. Both the p56/B1-l and ^56/3^6 plasmids
gave bands which comigrated with the purified human GST
B^B^ standard. The p56/B^-6 containing strain was used




Fig.4.01. Colony Hybridisation Analysis on Transformed E.coli
DH1.
The colony hybridisation method of Grunstein & Hogness(1975)(section 2.15) was
used to determine if the p56/Bi vector was present in the transformed E.coli DH1
colonies. 32p-labelled human alpha class cDNA was used as a probe giving six possible
p56/Bj carrying colonies (marked by arrow). The control is E.coli JM101 transformed
with the pUC/Bi vector.
Lane No.—2 3 4 5
Fig.4.02. Restriction Analysis on Possible p56/Bi Clones.
EcoRI restricted 56/Bi DNA (ljLXg) isolated from E.coli DH1 transformants was loaded
in lanes 2-4 (corresponding to 56/Bi-l, 56/Bi-3 and 56/Bi-6 respectively). EcoRI
digested pUC/Bj DNA (l|ig) was loaded in track 1 and EcoRI restricted pMA56 DNA
in track 5. All three EcoRI digested 56/Bi plasmids were found to have a cDNA insert
co-migrating with that of pUC/Bi.
Fig.4.03. Expression of Human Alpha Class GST in S. cerevisiae.
SDS-page followed by Western blot analysis (section 2.19) was carried out on the
cytosolic fractions (50|ig) of p56/Bi-l, p56/Bj-3 and p56/Bi-6 transformed KYI 18.
Antibodies raised against the human alpha class GST (B]B]) (Stockman et al.1987")
were used to identify the presence of the human GST protein. Purified human alpha
class GST protein (BjBi) was loaded as standard. A band co-migrating with the alpha
class GST standard was found in the p56/Bi-l and p56/Bi-6 transformed strains.
The lower molecular weight bands are due to the degradation of the B1B1 protein.
The cytosolic fractions were prepared as detailed in section 2.16.3.
4.9 Subcloninq of Human Pi Class GST into PMA56
The human pi class cDNA was a generous gift from
Professor M. Muramatsu (Dept. Biochemistry, Tokyo,
Japan). Its isolation has been detailed elsewhere
(Kano et_al, 1987). Briefly the rat GST-P cDNA was used
as a probe to screen a human placenta cDNA library in
Agtll. The cDNA was isolated from purified phage clones
by EcoRI digestion. The cDNA was subcloned into the
EcoRI site of pUC-19. The cDNA has been sequenced and
shown to be full-length (Kano et al. 1987) consisting
of 630bp coding sequence and a 78bp non-coding 3'-region.
The cDNA was isolated as in Section 4.7 and ligated to
p56-RIBAP (Section 3.3). The Grunstein & Hogness colony
screening procedure (1975) was used to screen the
transformed E.coli DH1. This gave a possible 27
recombinants (Figure 4.04). Six colonies were taken for
plasmid preparations. The plasmids obtained designated
56/Ac-l to 56/AC-6 were digested with EcoRI and subjected
to preparative agarose gel electrophoresis (Figure 4.05).
Of the six plasmids only p56/Ac-5 did not
possess a cDNA insert. Each of the plasmids containing
the GST pi cDNA were transformed into S.cerevisiae strain
KY118 as Itoh et al (1983).
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Fig.4.04. Colony Hybridisation Analysis on Transformed E.coli
DH1.
The colony hybridisation method of Grunstein & Hogness(1975) was used to determine
if the p56/Ac vector was present in the transformed E.coli DH1. 32P-labelled pi class
GST cDNA was used as a probe. This gave 27 possible p56/Ac containing colonies
from which six were picked at random (marked by arrow). The control is E.coli JM101
transformed with the pUC/Ac vector.
Lane No.—► 12345678 9
pUC-1 9
pM A56
Fig.4.05. Restriction Analysis on Possible p56/Ac Clones.
EcoRI restricted 56/Ac DNA (lpg) from E.coli DH1 transformants was loaded in lanes
3-8 (corresponding to 56/Ac-l-6 respectively).Hind III digested phage X DNA (l|ig)
was loaded in lane 1. In lanes 2 and 9 was loaded EcoRI digested pUC/Ac and pMA56
DNA respectively. Only the plasmid designated p56/Ac-5 lacks the cDNA insert
co-migrating with that of pUC/Ac.
4.10 Expression of GST Pi Protein in S.cerevisiae Strain
KYI 18
Only the plasmids designated 56/AC-2; 56/AC-3;
56/Ac-4 and 56/AC-6 gave colonies on transformation.
These colonies were inoculated into supplemented
synthetic SD medium (50ml), harvested and cytosolic
preparations subjected to SDS-PAGE and Western blotting
using antibodies raised against purified human GST pi
protein and 125I-labelled protein A (Figure 4.06). Only
the strain containing the 56/AC-4 plasmid produced a
protein band comigrating with purified pi GST standard.
This strain was used in subsequent experiments.
4.11 Subcellular Localisation of GST Proteins
Subcellular fractions were prepared from the yeast
strains transformed with the p56/B^-6; p56/Ac-4 and
p56/Ac-3 (as control) vectors using the method detailed
in Section 2.16.1. These fractions were subjected to
SDS-page and Western blotting using anti-GST pi and
anti-GST alpha antisera (Figure 4.07). As expected the
GST proteins were localised in the cytosolic fraction
with little or no protein being present in the microsomal
(endoplasmic reticulum) fraction. Densitometric analysis
and comparison with GST B-j^ or GST pi standards
indicated that both the GST pi and GST proteins were
produced at 0.5% of total yeast protein.
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Std. 56/AC-2 56/AC-3 56/AC-4 56/AC-6 Std.
Fig.4.06. Expression of Human Pi Class GST in S. cerevisiae.
SDS-page followed by Western blot analysis was carried out on the cytosolic
fractions(50]ig) of p56/Ac-2, p56/Ac-3, p56/Ac-4, and p56/Ac-6 transformed KYI 18.
The standard corresponds to purified human pi class GST protein. Only the p56/Ac-4
transformed strain produces a band which co-migrates with the standard. The cytosolic


































anti GST pi • _ _• — 56/AC-4
Fig.4.07. Subcellular Localisation of Human GST Proteins in
S.cerevisiae.
Protein samples (25pg) from various yeast subcellular fractions were seperated by
SDS-page followed by Western blot analysis using antibodies to GST pi and GST
BiBi. Subcellular fractions were prepared as described in section 2.16.1. Cell debris
= 10,000g pellet; S9 = N15,000g supernatant; microsomes = 246,000g pellet;
cytosol=246,000g supernatant. Standards were either purified human GST alpha (BiBj)
or pi protein. No cross reacting bands were observed in the cytosol of the yeast
containing the pi class GST cDNA inserted into the pMA56 vector in the reverse
orientation (control).
4.12 Functional Activity of Expressed GST Proteins
The activity of the expressed human GST proteins was
initially determined using the general GST substrate
l-chloro-2,4-dinitrobenzene (CDNB). Yeast strains
expressing either the human alpha or pi class GST have
high activity in the conjugation of CDNB. The activity
of the pure alpha class GST towards this substrate is in
the order of 64 umol/min/mg protein with pi being
105 umol/min/mg protein (Mannervik & Danielson, 1988) .
The activities determined using CDNB are shown in Figure
4.08. The control strain had an activity towards CDNB
as substrate of less than 10 nmol/min/mg cytosolic
protein (10 units). The GST pi producing strain had
activity of up to 1000 units with a normal range between
350-600 units. Maximal activities for the alpha class
GST producing strain were also up to 1000 units.
However, the usual level was between 100-250 units. Thus
both GST were active towards CDNB when expressed in
S.cerevisiae. This activity was usually 10-50-fold
higher than in the control culture the activities being
of a similar level to those found in human liver cytosol.
The large variation in activities measured may be
due to the time in the growth phase where the cells were
harvested. It was interesting that cultures harvested in
stationary or early logarithmic phase had less GST











Fig.4.08. GST Activity Towards l-Ch!oro-2,4-Dinitrobenzene
(CDNB) in Cytosolic Fractions of S.cerevisiae.
The GST activity of the yeast strains 56/Ac-3 (control); 56/Ac-4 (GST pi) and 56/Bi-6
(GST alpha) was measured using the GST-mediated conjugation of CDNB with GSH at
30°C according to^the method of Habig et al (1974) (section 2.17.5). The data
represents the mean + standard deviation for twenty two determinations and is expressed
as nmol/min/mg cytosolic protein.
growth. Whether this is due to increased protein
accumulation during cellular growth or an increased rate
of degradation in stationary phase is unknown. The pi class
GST appeared to be more stable within the stationary yeast
cultures than the alpha class protein. The alpha class
GST appeared to be degraded within the cell as the
cultures became stationary . CDNB activity was also
reduced in stationary phase . it was found that 4 hours after
inoculation into fresh medium GST activity was only
58 units compared to a control value of 11 units while
the GST pi activity was already 300 units.
Cumene hydroperoxide was also used to test for GST
activity. Only the human alpha class GST has peroxidase
activity towards this substrate. The specific activities
of the purified alpha and pi class proteins are 10.6
pmol/min/mg protein and pi = 0.03 jumol/min/mg protein
respectively (Mannervik & Danielson, 1988). As predicted
the control and pi expressing strains had essentially the
same level of peroxidase activity (5 units) whereas the
alpha expressing strain had a level of up to 100 units
(Figure 4.09).
4.13 Measurement of Glutathione (GSH) Levels in The Yeast
Strains
It has been shown that GSH is involved in the

























control GST pi GST alpha
Fig.4.09. GST Activity Towards Cumene Hydroperoxide (CHP)
in Cytosolic Fractions of S.cerevisiae.
The peroxidase activity of the yeast strains 56/Ac-3 (control), 56/Ac-4 (GST pi) and
56/Bi-6 (GST alpha) was estimated using CHP in a coupled reaction by measuring the
rate of NADPH oxidation (section 2.17.6B). The data represents the mean + standard
deviation for six determinations.
electrophilic agents (melphalan, cyclophosphamide,
chlorambucil) and reagents generating reactive oxygen
(adriamycin, daunorubicin, mitomycin C) (Wolf et al.
1987b). Various studies have shown a relationship
between GSH level and tumour cell resistance (Calcutt &
Connors, 1963; Connors, 1966; Lewis et al. 1988a). It
was, therefore, important to establish whether the over-
expression of the GST altered cellular GSH levels
The mean values of GSH were calculated as 24.9+2.9,
23.0+6.9, 25.8+9.7 nmol GSH/mg soluble protein for the
control, GST alpha and GST pi expressing strains
respectively (Figure 4.10). Thus a variation in GSH
could not play a role in the differential sensitivity of
the three strains when exposed to cytotoxic drugs.
Now that it had been clearly established that GST
could be expressed in S.cerevisiae in a functional form
it was of central importance to establish whether these
expressing strains had altered resistance to anticancer
drugs. A description of these experiments and a brief
description of the mechanism of action of the compounds
used is given below.
4.14 Cytotoxicity Assays on Yeast Strains
4.14.1 Effect of GST Expression on Adriamycin Toxicity
Adriamycin is a member of the anthracycline






Fig.4.10. Glutathione (GSH) Levels in S.cerevisiae.
The GSH level of the three yeast strains 56/Ac-3 (c); 56/Bi-6 (a); 56/Ac-4 (n) were
measured according to the method of Hissin & Hilf (1976) (section 2.17.7). The mean
values± standard deviation were 24.9+ 2.9 (c); 23.0± 6.9 (a); 25.0+ 9.7 (jt) as
calculated from six determinations.
late 1960s (Young et al. 1981). These compounds now play
a major role in the effective treatment of acute
leukaemia, non-Hodgkin lymphomas, breast cancer,
Hodgkins disease and sarcomas (Young et al. 1981).
Adriamycin itself is a glycoside antibiotic originally
isolated from the fungus Streotomvces peucetius. The
molecule contains an amino sugar, daunosamine, linked
through a glycoside bond to adriamycinone, a
reg-pigmented napthacenequinone nucleus. The use of
adriamycin in cancer treatment is hampered by the
conventional toxicities associated with anticancer drugs,
haematopoietic suppression, nausea, vomiting as well as
a unique cardiomyopathy toxicity. This affect on cardiac
tissue is thought to be caused either by binding of
adriamycin to the cell membrane of the cardiac cell or by
redox cycling and generation of toxic free radicals (see
later).
The anthracyclines produce a wide range of
biochemical effects that have potentially toxic
consequences. This complexity has made it difficult to
assign a given biochemical action to specific host tissue
toxicity or tumour cell killing. At present there are




Adriamycin binds tightly (intercalates) to DNA which
has several consequences including the blockage of DNA,
RNA and protein synthesis as well as the inhibition of
DNA repair (Painter, 1978). Some of these effects are
due to adriamycin-induced DNA fragmentation, e.g. double
and single-strand breaks. This strand breakage has been
shown to be linked to some degree with the interaction of
adriamycin with DNA topoisomerase II (Tewey et al. 1984).
It is thought that this interaction has two effects, it
prevents the DNA unwinding activity of DNA topoisomerase
II and it stabilises the cleavable complex which leads to
DNA double-strand breaks. Adriamycin can also cleave DNA
via a free radical mechanism (Tewey et al. 1984).
B. Membrane Binding
It has been shown (Tritton & Lee, 1982) that
adriamycin can damage cell membranes. This
observation is based on the finding that adriamycin
linked to large polymeric agarose beads, which prevents
drug uptake, is still cytotoxic.
C. Free Radical Formation
Many studies (Bachur et al. 1982; Meijer et al. 1987;
Cervantes et al. 1988) have evaluated the ability of
adriamycin to catalyse the formation of oxygen radicals.
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Bachur et al (1982) have shown that the nuclei of rat
liver cells can catalyse a single electron reduction
process of adriamycin to give free radicals. The
enzymes involved being NADPH-dependent cytochrome P-450
reductase and xanthine oxidase. These free radicals
react with cellular DNA and as a consequence are
cytotoxic. The adriamycin semiquinone free radical
produced by this bioactivation can, in the presence of
molecular oxygen, produce superoxide anions, hydrogen
peroxide, and hydroxyl radicals. These latter highly
reactive products are the ultimate toxic species which in
addition to reactions with DNA, can attack membrane
lipids to produce lipid hydroperoxides which are
mutagenic. Cervantes et al. (1988), using an ovarian
cell line sensitive, A2780, and resistant
A2780ad, to adriamycin have shown that only hydroxyl
radicals and not superoxide anion or hydrogen peroxide
play a role in the antitumour effects of this compound.
In the studies here adriamycin was initially chosen as a
test compound because it has been reported that an MCF-7
cell line made resistant to this drug over-expressed GST
pi (Batist et al. 1986; Cowan et al. 1986). As other
biochemical changes were also observed in this cell line,
it was important to establish whether the over-expression
of GST pi is directly involved in the resistance
mechanism or merely a casual phenomenon. It was also
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possible that other GST isoenzymes play a role in
protection against adriamycin particularly in view of
their function as peroxidases.
To answer these questions adriamycin toxicity was
determined in the control (56/AC-3), GST pi (56/AC-4) and
GST alpha (56/1^-6) yeast strains. Concentrations of up
to 80 jug/ml adriamycin were used as described in Section
2.21. A typical survival curve obtained is shown in
Figure 4.11. The concentration of drug which kills
50% of cells (LD50) were 5pg/ml, 15 pg/ml and 40 pg/ml
for the control, GST pi and GST expressing cells
respectively. On this basis the GST pi and alpha strains
are 3-and 8-fold more resistant than control. The
differences in sensitivity between the three strains were
found to be most pronounced at the higher drug
concentrations. A dose of 80 jug/ml killed 96.4% of the
control cells but approximately 40% of the cells
expressing GST B-j^ survived, 15% of the cells expressing
GST pi also survived this dose. The increase in
resistance in the GST alpha and pi class GST expressing
strains at this dose were 11.1- and 4.2-fold
respectively. This finding is important since high
levels of cell kill are necessary in order to observe
marked therapeutic benefits in patients receiving
chemotherapy. In view of the narrow therapeutic index of
anticancer drugs, because of cytotoxicity to normal
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Fig.4.11. Sensitivity of S.cerevisiae Strains to Adriamycin.
The three yeast strains (control; GST alpha ;GST pi) were exposed to concentrations of
adriamycin up to 80|ig/ml as detailed in section 2.21. The activity of each strain was
determined as 9.7 units (control); 103.3 units (GST alpha); 597.3 units (GST pi) using
CDNB as substrate. The data are expressed as a percentage ± standard deviation of the
survival obtained in cultures where no adriamycin was added. The survival curve
obtained is representative of the results obtained in three other experiments.
cells, even small (2-fold) changes in drug sensitivity
may make a patient completely refractory to further
treatment, i.e. drug resistant.
The shape of the dose-response curve obtained with
adriamycin was biphasic with an initial rapid decrease in
cell viability followed by a more gradual decline. This
is not unexpected when the multiple cytotoxic effects of
adriamycin are considered (DNA intercalation, membrane
binding, free radical formation). The above data
demonstrate that both GST pi and GST B-j^ can play a role
in the development of resistance to adriamycin. This
cannot be due to GST-induced changes in cellular GSH
levels (4.12). Neither GST nor GST pi have been
shown to catalyse conjugation of adriamycin to
glutathione (Ketterer, 1988). The method of resistance
may not be due to a classical detoxication reaction
involving GSH conjugation. GST have been shown to act as
a drug or carcinogen binding proteins (Ketterer et al.
1967) and such binding and sequestration of adriamycin
may represent the mechanism of resistance. To test
this 14C-labelled adriamycin was mixed with pure mouse
GST pi or GST B^B^ and the mixture subjected to gel
permeation chromatography (Figure 4.12).
However, no radioactivity was found to be associated
with the GST peaks. Thus neither GST pi nor GST B-j^B-^ has
the capacity to bind adriamycin. Alternatively GST
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Fig.4.12 GST-Binding Assay using Adriamycin as Substrate.
In order to establish whether the alpha or pi class GST could bind adriamycin, GST
B]B](150}ig)(a) or mouse GST n (100|ig)(b) were incubated in 200p.l of PBS overnight at
4°C with 14C-labelled adriamycin (lOOnmol, 125000dpm) (Amersham). The mixture was
the applied to a protein PAK Gloss SW (Waters) gel filtration HPLC column. Samples
were eluted using 20mM sodium phosphate buffer, pH6.5. The GST and adriamycin
peaks were monitored at 280nm. Fractions (1ml) of the eluate were collected in
scintillation vials and the radioactivity content determined by liquid scintillation counting.
Peak 1 represents the elution of the GST proteins from the column and peak 2 that of the
radiolabeled adriamycin. The small peak of radioactivity seen just after the GST elution
peak is seen when adriamycin is added to the column in the absence of protein. Thus it
does not represent binding of adriamycin to the GST protein.This work was carried out by
Dr. A. Bartoszek (ICRF Laboratory of Molecular Pharmacology and Drug Metabolism)






























mediated resistance may be via cellular protection
against adriamycin-induced peroxidative attack.
Many of the GST-mediated protection mechanisms
involve glutathione and to further delineate the
mechanism of resistance the cellular GSH levels were
depleted using buthionine sulphoximine (BSO). BSO is an
inhibitor of Y-cysteinyl synthetase a key enzyme in GSH
synthesis. Cultures were treated overnight with BSO and
cytotoxicity assays carried out using adriamycin. The
fluorometric assay of Hissin & Hilf (1976) was used to
determine the level of GSH depletion in each case. The
presence of BSO reduced the levels of GSH by 56%; 60 and
50% for control, GST and GST pi expressing yeast
cells respectively (Figure 4.13). GSH depletion had
unexpected effects on adriamycin toxicity. This
treatment actually reduced rather than enhanced the
toxicity of this compound. This treatment did not appear
to affect the resistance observed in cultures expressing
GST pi but did reverse the resistance mediated by GST
B1B1* Thus GSH appears to be only partially involved in
GST-mediated protection against adriamycin. The above
data suggests that mechanisms other than those involving
GSH may be involved in the protection mechanism.
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Fig.4.13. Effect of Buthionine-S,R-SuIphoximine (BSO)
Treatment on Adriamycin Cytotoxicity.
The yeast strains were treated as detailed in section 2.22 using lOmM BSO. Cells were
exposed to concentrations of adriamycin up to 80pg/ml (section 2.21). These cells
were then compared to cultures which had not been exposed to BSO. In each case the
cellular GSH concentration was determined (section 2.17.7). BSO treatment reduced the
level of GSH by 56, 60 and 50% for control, GST alpha and GST pi respectively
(relative to untreated cultures). Dashed lines indicate cultures exposed to BSO and solid
lines those untreated with BSO. - x — = control; -P and -4— represent cultures
expressing GST alpha (BiBi) and GST pi respectively. This experiment was carried out
in triplicate with less than 10% variation between values and repeated twice with
the same effects observed.
4.14.2 Effect of GST Expression on Chlorambucil Toxicity
Nitrogen mustards, which include the widely used
anticancer drug chlorambucil, are amongst the oldest
antineoplastic agents in clinical use. It is believed
that these compounds like other alkylating anticancer
drugs, act by reacting with DNA to produce either
monoalkylation products or highly cytotoxic cross-links
(Calabresi & Parks, 1980). Chlorambucil reacts
spontaneously to form an electrophilic carbonium ion
which will react with nucleophilic centres such as DNA or
protein in the absence of enzymes (Hemminki & Kallama,
1986). This compound does not, therefore, require
metabolic activation to exert its toxic effects unlike
cyclophosphamide. Thus the chlorambucil-induced cross¬
links in DNA can be either inter- or intra-strand, and
can also involve DNA-protein cross-links. It is thought
that the cytotoxicity of alkylating agents is directly
related with their cross-linking efficiency (Roberts,
1978). In support of this conclusion bifunctional
alkylating agents, such as chlorambucil, are more
cytotoxic than their monofunctional counterparts (McCann
et al. 1971; Connors, 1975). Hemminki & Kallama (1986) in
an in vitro study with three nitrogen mustards of
clinical relevance (cyclophosphamide, melphalan and
chlorambucil) have shown that the major DNA cross-links
formed by the action of these compounds is through the N-
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7 position of guanine. Chlorambucil was chosen in this
study primarily because cell lines made resistant to this
compound have been shown to over-express alpha class GST
isozymes (Robson et al. 1987; Buller et al. 1986).
Robson et al (1987) showed that the total level of GST in
the chlorambucil-resistant line (CHO-Chlr) was elevated
3-fold (as determined with CDNB) with activity against
ethacrynic acid (specific for pi class GST) and cumene
hydroperoxide (specific for alpha class GST) raised 2-
and 5-fold respectively. The alpha class Yc subunit has
also been shown to be elevated in a Walker 256 rat breast
carcinoma cell line resistant to chlorambucil (Buller et
al, 1986; Clapper et al. 1987). Many other changes
have also been measured in the Walker cell-line including
increased DNA repair capacity thus the exposure of the
yeast strains to chlorambucil should answer whether the
alpha and/or pi class human GST are directly involved in
resistance to chlorambucil. A typical cytotoxicity curve
obtained on exposure of the yeast strains to chlorambucil
is shown in Figure 4.14. Calculation of the LD50 values
for each strain were 100; 200 and 450 pg/ml for control,
GST pi and GST expressing strains respectively.
This corresponds to a 2-fold and 4.5-fold increase in
resistance to chlorambucil.
As with adriamycin, it is at the higher levels of
drug that the differences in sensitivity between the
143
Chlorambucil (fxg/ml)
Fig.4.14. Sensitivity of S.cerevisiae Strains to Chlorambucil.
The three yeast strains were exposed to concentrations of chlorambucil up to 600jig/ml
as detailed in section 2.21. In this experiment the activities of each strain (using CDNB
as substrate) were determined as 5.2 units (control); 137.7 units (GST alpha); 407.9
units (GST pi). The data are expressed as a percentage ± standard deviation of the
survival obtained in cultures where no chlorambucil was added. The curve shown is
representative of the results obtained in five other experiments.
control and GST producing strains were most marked. At a
concentration of 500pg/ml 97% of the control cells were
killed. However, 15% of the cells containing the pi
class enzyme and 27% of the GST expressing strain
survived, i.e. a 5-fold and 9-fold reduction in
sensitivity in relation to the control.
Although chlorambucil has not been shown to be a
substrate for the alpha or pi class GST it is known that
chlorambucil will react with GSH (Wolf et al. 1987).
Since it is expected that GST will increase the rate of
this reaction it is feasible that chlorambucil is a
substrate for this enzyme system. Further evidence for
this comes from the work of Dulik et al (1986) who have
shown that melphalan (an aromatic nitrogen mustard like
chlorambucil) will form GSH-conjugates in the presence of
GST (both cytosolic and microsomal forms). To determine
if GSH was involved in the observed resistance in the
yeast cells BSO was again used to deplete the cellular
levels of this cofactor. This treatment reduced content
by 82.9, 66.5 and 73.3% in control, GST pi and GST alpha
(B^B-^) expressing cells respectively (Figure 4.15). In
cultures which had not been exposed to BSO the GST B-j^
and GST pi expressing strains were significantly more
resistant than the control strain. BSO-treatment
significantly sensitised all the cultures to the toxic
effects of chlorambucil. In addition exposure to BSO
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Fig.4.15 Effect of Buthionine-S,R-Sulphoximine (BSO) Treatment
on Chlorambucil Cytotoxicity.
Cell cultures were trated as detailed in section 2.22 using lOmM BSO. Cells were then
exposed to chlorambucil (section 2.21) at concentrations up to 600pg/ml. These were
then compared to cultures which had not been exposed to BSO. In each case the cellular
GSH concentration was determined (section 2.17.7). BSO treatment reduced the GSH
level by 83,73 and 67% for control, GST alpha and GST pi respectively (relative to
untreated cultures). Dashed lines indicate cultures exposed to BSO. Solid lines those
untreated with BSO. —x— = control;—B— and —♦— represent cultures expressing
GST alpha (BiBi) and GST pi respectively. This experiment was carried out in
triplicate with less than 10% variation between values and repeated twice with
the same effects observed.
completely abolished the difference in sensitivity
between the three strains. The fact that resistance to
chlorambucil can be reversed by depletion of cellular GSH
indicates that glutathione is important in the mechanism
of toxicity of this compound. This result does not
provide direct evidence that GST-mediated conjugation is
involved in the resistance observed. Although coupled to
the fact that there is no significant difference in GSH
levels between the three strains is strongly suggestive
that this is, in fact, the case.
4.14.3 Effect of GST Expression On 1.3-Bisf2-chloroethvl)
-1-nitrosourea (BCNU) Toxicity
BCNU is the preferred chemotherapeutic agent for
human brain tumours as it is able to cross the blood-
brain barrier (Evans et al. 1987). However, more than
60% of brain tumours show insensitivity to BCNU and
others acquire resistance during therapy. One major
resistance mechanism is the cellular capacity to repair
06-alkylguanine DNA adducts (Bodell et al. 1984) but
other mechanisms are thought to exist. This may include
an increase in drug inactivation. BCNU has been shown to
be inactivated by a denitrosation reaction that is
catalysed by both the cytochrome P-450 monooxygenase
system (Hill et al. 1975) and the GST (Talcott & Levin,
1983). So are the GST pi and GST B1B1 involved in
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resistance to BCNU? The result of a cytotoxicity assay
using BCNU is shown in Figure 4.16. Neither human GST pi
nor GST B^B^ expression appears to confer resistance to
this compound. This is an agreement with recently
published work of Smith et al (1989) who have shown that
only the rat mu class isoenzymes (3-3 and 4-4) have
significant activity towards BCNU as substrate while the
alpha class enzymes (1-1 and 2-2) and pi class (7-7) had
only weak activity.
4.14.4 Effect of GST Expression on l-Chloro-2.4-
Dinitrobenzene (CDNB) Toxicity
CDNB is used as a general GST substrate. CDNB is
also mutagenic in the gram negative bacterium,
S.typhimurium (Summer & Goggelmann, 1980) where a rapid
reaction is observed between GSH and CDNB. This was
initially thought to be a deactivation reaction for this
compound. More recent studies using a TA100 strain of
S.tvphimurium and a derivative that had only 10% wildtype
levels of GSH (NG-57) has shown that CDNB is actually
more mutagenic in the GSH+ strain (TA100) (Kerklaan et
al, 1985; Kerklaan et al. 1987). Further work from the
same group has shown that CDNB cytotoxicity was increased
in a rat liver cell line (RL-4) when intracellular GSH
levels were increased (two-fold) by treatment with the
monoethyl ester of glutathione (EGSH). There was also a
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Fig.4.16 Sensitivity of S.cerevisiae Strains to
l,3-Bis(2-chIoroethyI)-l-nitrosourea (BCNU).
The three yeast strains were exposed to concentrations of BCNU up to 20fig/ml as
detailed in section 2.21. The activities of each strain (using CDNB as substrate) were
determined as 8.5 units (control); 130.2 units (GST alpha); 420.6 units (GST pi).
This experiment was carried out in triplicate with less than 10% variation between
values.
corresponding decrease in CDNB induced cell-death when
diethylmaleate (DEM) was used to decrease GSH (to 20% of
control levels) (Bruggeman et al. 1988). There is,
therefore, contradictory information on the role of GSH
in protecting against CDNB. A role for the GST in the
protection against CDNB toxicity has not been reported,
however it has been shown that an NCIH322 cell line made
resistant to CDNB (Wareing et al. 1988) expresses alpha
and pi class GST subunits. In order to evaluate a direct
role for the GST in the resistance mechanism the human
GST expressing yeast strains were exposed to CDNB.
Different effects caused by CDNB were observed between
the GST B^]^ and GST pi expressing strains (Figure 4.17).
The GST expressing strain is more resistant and the
GST pi strain less resistant than the control. The LD50
values for the three strains are 30, 55 and 70 jig/ml for
the GST pi, control and GST alpha strains respectively.
Similar to the findings with the anticancer drugs the
differences in sensitivity were most marked at the
highest drug concentrations such that at 80pg/ml CDNB the
survival of the three strains were reduced to 3.2, 15.1
and 34% for the GST pi, control, and GST alpha
respectively. Thus the GST pi strain is approximately 5-
fold more sensitive than the control and over 10-fold
more sensitive than the GST B-j^B-j^ expressing strain. The
GST alpha strain is seen to be 2.3-fold more resistant to
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Fig.4.17 Sensitivity of S.cerevisiae Strains to 1-Chloro-
-2,4-Dinitrobenzene (CDNB).
The three yeast strains were exposed to concentrations of CDNB up to 80(ig/ml as
detailed in section 2.21. The activity of each strain was determined (using CDNB as
substrate) as 5.2 units (control); 137.7 units (GST alpha); 407.9 units (GST pi). The
data are expressed as a percentage ± standard deviation of the survival obtained in
cultures where no CDNB was added. The curve shown is representative of the results
obtained in three experiments.
the cytotoxic effects of CDNB than the control strain.
The difference in sensitivity between the B-lB-l
expressing strain and the control strain is much less
than for either chlorambucil or adriamycin. The reasons
for this is unknown. The mechanism(s) of cellular
toxicity induced by CDNB are unknown and likely to be
complex. It is known for example that FDNB, the fluro-
derivative of CDNB, can inactivate the transport of
glucose into the cell resulting in cell death (Walmsley,
1988). This suggests that some of the cytotoxic effects
of CDNB may occur outside the cell and outwith the range
of detoxification (or toxification) by GST. This may
lead to the observed smaller differences in sensitivity
between the yeast strains. The two GST expressing
strains also have different effects on the sensitivity of
the host cell to CDNB exposure. Over-expression of the
human alpha class GST confers resistance while the pi
class GST does not. Both human enzymes have high
activity towards CDNB as substrate with alpha having
64pmol min-1mg-1 and pi, 105pmol min^mg-1
(for the purified enzymes) (Mannervik, 1985). Thus if
GST conjugation to CDNB was a toxification reaction then
both strains would be expected to be more sensitive than
the control which has very low endogenous activity
towards CDNB. One possible explanation is that the alpha
class enzyme induced resistance is not due to conjugation
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to GSH but to some other mechanism. This mechanism may
be the covalent binding of CDNB to the protein. This
would be a detoxification reaction as it would reduce the
active drug concentration. This has been reported to
occur at a very high rate with purified rat liver GST
isoenzymes where up to 30% of the GST can be found
covalently bound to CDNB after a 5 min incubation
(Jakoby, 1978). In order to evaluate the role of GSH in
CDNB toxicity BSO was used to deplete cellular GSH. If
the mechanism of resistance seen in the alpha expressing
strain is due to covalent binding of CDNB to the GST
protein then the level of resistance would be independant
of cellular GSH. In the case of the pi class GST if the
conjugation of GSH to CDNB is the mechanism of
sensitisation then depletion of GSH should reverse this
effect. This result is shown in Figure 4.18.
The GST B1B1 expressing strain was still
approximately 2-fold more resistant than control after
BSO treatment. However, the depletion of GSH altered the
sensitivity of the GST pi expressing strain such that it
is no longer more sensitive than control CDNB exposure.
Thus GSH appears to play a role in GST pi-induced
sensitivity to CDNB while the GST B-j^ conferred
resistance is GSH independent. This result is consistent
with the alpha class GST enzyme protecting the cell by
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Fig.4.18 Effect of Buthionine-S,R-Sulphoximine (BSO)
Treatment on CDNB Cytotoxicity.
The yeast strains were treated as detailed in section 2.22 using lOmM BSO. Cells were
exposed to concentrations of CDNB up to 80|ig/ml (section 2.21). The cellular GSH
concentrations were determined and the level of GSH depletion calculated by comparison to
untreated cultures . GSH levels were reduced by 70, 72 and 60% for control, GST
alpha and GST pi respectively.The results are expressed as percentage survival ± standard
deviation of the survival obtained in cultures where no CDNB was added. This experiment




4.14.5 Effect of GST Expression on Cumene
Hydroperoxide (CHP) Toxicity
Previous work has shown that the alpha class of
GST have high selenium-independent peroxidase activity
towards the organic hydroperoxide, cumene hydroperoxide
(CHP) (Lawrence & Burk, 1978; Lawrence et al. 1978;
Prohaska, 1980). This activity has been shown to be
distinct from the selenoenzyme (selenium-dependent)
glutathione peroxidase (Lawrence et al. 1976).
This work has been advanced by Wareing et al
(1988) where an NCIH322 cell-line resistant to CDNB is
also cross-resistant to CHP. For this reason the 56/6-^-6
strain expressing the human protein was exposed to
CHP and the sensitivity compared to the control strain
(56/Ac-3). The human pi class expressing strain (56/Ac-
4) was not tested as this enzyme has very low peroxidase
activity towards CHP (Section 4.12). The result shown in
Figure 4.19 indicates that the human alpha class enzyme
(Bq^) can protect cells against the cytotoxic effects of
organic hydroperoxide exposure. The increased level of
resistance compared to the control is seen to be around
2-fold at lOOpM CHP. This is in agreement with the work
of Wareing et al (1988) where a 2.5-fold increase in the
LD50 levels of a CDNB-resistant NCIH322 cell-line has
been observed on exposure to CHP.
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Fig.4.19 Sensitivity of S.cerevisiae Strains to Cumene
Hydroperoxide (CHP).
The yeast strains were exposed to concentrations of CHP up to 100|iM as detailed in
section 2.21. The activity towards CDNB as substrate was determined as 9.7 units for
control and 89.6 units for GST alpha. In this experiment the GST pi expressing strain
(56/Ac-4) was not tested as substrate. The results are expressed as percentage survival
± standard deviation of the survival in cultures where no CHP was added. The curve
shown is representative of those obtained in the three times this experiment was carried
out.
4.14.6 Effect of GST Expression on 1.2-Dibromoethane
CDBE^ Toxicity
Conjugation to glutathione is obviously an
important detoxification reaction for electrophilic
xenobiotics. But despite its primary detoxifying role
GSH-conjugation to certain compounds results in their
transformation into more reactive and hence toxic
derivatives. These can be grouped into three such that
the conjugate:-
1) is itself the reactive species
2) is further metabolised to the reactive species
3) releases reactive species where the conjugation
reaction is reversible.
There are examples of all three types.
The vicinal dihalogenoalkane 1,2-dibromoethane
(DBE) belongs to the first type such that the
S-2-bromoethylglutathione species formed is directly
active. DBE was first produced in 1826 and is now widely
used as a soil fumigant as well as a lead scavenger in
petrol containing tetra-alkyllead and antiknock
preparations. DBE has been shown to cause base pair
substitutions in S.tvphimurium even in the absence of an
exogenous metabolising system (Rannug, 1980). However,
the mutagenicity is considerably increased by the
addition of rat liver cytosol to the incubation mixture
(van Bladeren, 1988). It has been shown that the GSH-DBE
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conjugate causes in vitro unschedule DNA synthesis (UDS)
in F-344 rat pachytene spermatocytes and hepatocytes as
well as in vivo UDS when given i.p. to rats (Working et
al. 1986). If GSH levels were depleted with DEM then
DBE-induced UDS was not observed in vitro (Working et al.
(1986) .
DBE was thus chosen to see if the expression of
human GST's within the yeast cell, would cause an
increase in DBE toxicity. The result is shown in Figure
4.20. Both the alpha and pi class GST expressing strains
are more sensitive to the toxic effects of DBE than the
control strain. The strain expressing GST alpha has a
much steeper fall in survival than the GST pi strain
suggesting that human alpha class enzymes catalyse the
conjugation of GSH to DBE to a greater extent than GST
pi. The GST pi and B-j^ expressing strains were found to
be 2.5- and 3-fold more sensitive than control to the
toxic effects of 800pg/ml DBE.
This result demonstrates that in certain
circumstances (analogous to some cytochrome P-450
oxidation reactions) the GSH conjugates formed by GST




Fig.4.20 Sensitivity of S.cerevisiae Strains to 1,2-Dibromoethane
(DBE).
The yeast strains were exposed to concentrations of DBE up to 1200pg/ml (as detailed in
section 2.21). The activity of each strain was measured using CDNB as substrate and
found to be 8.3 units (control), 119.5 units (GST alpha) and 394.4 units (GST pi). The
results are expressed as a percentage ± standard deviation of the survival obtained in
cultures where no DBE was added. Similar results were obtained when this experiment
was repeated.
4.15 Co-Expression of Human Pi and Alpha Class GST in
S.cerevisiae
The experiments described above (4.14.1) indicated
that the mechanism of action of the pi and alpha class
GST towards adriamycin may be different. This raised the
possibility that when expressed in the same cell they may
significantly increase the resistance towards this
compound (most human cells express both these proteins
simultaneously). Experiments were therefore carried
out to establish whether this was the case. However, it
was first necessary to clone the GST pi cDNA into an
expression vector with a marker other than TRP1. The
isolated pi class GST cDNA was blunt-end ligated into the
PvuII site of the vector pVTlOO-U which has the ADC1
promoter but URA-3 as the selectable marker (Vernet et
al. 1987). After transformation into E.coli DH1 the
colony-screening method of Grunstein & Hogness (1975) was
used with 32P-labelled GST pi cDNA as a probe to
determine possible pVTlOO-U recombinant plasmids (Figure
4.21). Six colonies were picked at random and the
plasmid DNA isolated. EcoRI restriction digests were
then used to determine which plasmids contained the human
pi class cDNA as insert (not shown). This gave five
possible plasmids, designated pVT/Ac-1 to pVT/Ac-5 which
were transformed into the S.cerevisiae strain KY118 using
lithium acetate (Itoh et al. 1983). Colonies from each
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Fig.4.21 Colony Hybridisation Analysis on Transformed E. coli DH1
Cells.
The colony hybridisation method of Grunstein & Hogness (1975) (section 2.15) was used to
determine which of the transformed E.coli DH1 colonies contained the pVT/Ac vector.
32-P-labelled GST pi cDNA was used as a probe and six positive colonies picked at random
(marked by arrows).
transformation were grown in supplemented synthetic SD
medium. Cytosol fractions were prepared and subjected to
SDS-page and Western blotting with the GST antisera
(Figure 4.22). Only the plasmid designated pVT/Ac-4 gave
a cross-reacting band with the human GST pi antibody.
This plasmid was then used to transform the £56/3^-6
strain (expressing the human protein). Western blot
analysis of the resulting strain, designated B-jAc, is
shown in Figure 4.23. Two bands which co-migrated with
both the purified human GST B^B-^ and GST pi standards
were observed. Thus it is possible to express both
proteins from different vectors providing each has its
own unique selectable marker. Simultaneous expression of
two proteins in S.cerevisiae has also been reported by
Murakami et al (1986) who simultaneously expressed
cytochrome P4501A1 and P-450 reductase. However, in
their system both expressed cDNAs were arrayed in tandem
on the same plasmid. In the experiments here the level
of GST expression from the two different vectors seemed
to vary between experiments and in some of the
experiments one of the proteins predominated.
The sensitivity of this strain relative to those
expressing either GST B-^B-^ or GST pi was then
established. The strain expressing both GST
simultaneously had approximately 2-fold higher CDNB
activity (Figure 4.24) (350 units for B^/Ac vs 220 units
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Fig. 4.22 Expression of Human Pi Class GST using pVT 100-U.
SDS-page followed by Western blot analysis was carried out on cytosolic fractions (50pg)
of pVT/Ac-1 to pVT/Ac-4. An antibody raised against the human GST pi was used to
identify the presence of the human GST pi protein. Purified human GST was loaded as
standard. A band co-migrating with the standard is only observed in the pVT/Ac-4
transformed strain. The control is cytosol from the 56/Ac-3 transformed strain. Cytosolic
fractions were prepared as in section 2.16.3.
Fig.4.23 Co-Expression of Human Pi and Alpha Class GST in
S.cerevisiae.
SDS-page followed by Western blot analysis was carried out on cytosolic preparations
(50pg) of p56/Bi; pVT/Ac-4; p56/Ac-3 (control) and pBi/Ac. Antibodies raised against the
purified alpha (BjBi) and pi class GST were used to identify the proteins. The purified
human proteins were loaded as standards. The pBi/Ac strain gives two bands corresponding
to the human GST pi and GST BjBi proteins.The p56/Bj-6 and pVT/Ac-4 transformed
strains only give single cross-reacting bands. No cross-reacting bands are seen in the
control. These samples were prepared from the cultures used to give thec^totoxicity curve
in Fig.4.25. Cytosolic fractions were prepared as in section 2.16.3.
400 n
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.4.24 CDNB activity in Yeast Cultures Expressing Human GST.
GST activity in cultures used for the cytotoxicity assy in fig.4.25 were measured using
CDNB as substrate. C = control culture, a = culture expressing GST BjBi, rc = culture
expressing GST pi and (x/jt = culture expressing both alpha and pi class GST
simultaneously. CDNB activities are given in the text
for the GST pi and 150 units for the GST B-j^ strains) .
The control strain (56/AC-3) had only minimal activity
towards CDNB (10 units).
Strain B-^Ac was significantly more resistant to
adriamycin than either of the single GST expressing
strains (2-fold) (Figure 4.25). Thus the expression of
multiple GST isoenzymes within a cell appears to decrease
the sensitivity of the host cell to cytotoxic insult even
in comparison to cells which over-express only one GST
isoenzyme. The result here suggests that this increase
is additive with approximately 2-fold greater survival
obtained for the double expressing strain as compared to
the single GST producing strains. This may be related to
the overall protein levels as the strain expressing both
the human GST isoenzymes had approximately 2-fold higher
activity towards CDNB (Figure 4.25).
If extrapolated the result above suggests that in
a human tumour the overall levels of both alpha and pi
class GST (and probably also the mu class GST) will be
important in determining tumour response to the
prescribed antineoplastic treatment. That the over-
expression of both isoenzymes confers greater resistance
to adriamycin than the expression of a single GST is
\
interesting in that early studies indicated that pi class
enzymes were predominantly over-expressed in cell-lines
resistant to adriamycin (Batist et al. 1986; Cowan et al.
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Fig.4.25 Adriamycin Cytotoxity on S.cerevisiae Simultaneously
Expressing Human GST BjBj and GST Pi.
The yeast strains (control, GST alpha, GST pi (pVT/Ac-4) and GST alpha/pi(pBi/Ac))were
exposed to concentrations of adriamycin up to 80pg/ml as detailed in section 2.21. The
activity of each strain is shown in Fig.4.24. The data are expressed as a percentage ± standard
deviation of the survival obtained in cultures where no adriamycin was added. The survival
curves obtained were similar when the experiment was repeated.
1986). In cell lines made resistant to alkylating agents
the alpha class GST was shown to predominate (Robson et
al. 1987; Lewis et al. 1988b). However, more recent
studies shown that both the alpha and pi class GST can be
elevated in cell-lines resistant to alkylating agents
(Wareing et al. in preparation). This is also true in
the drug-resistant preneoplastic foci of rat livers
(see Farber, 1984) where the GST of alpha, pi and mu
classes are all over-expressed. Thus in a human tumour
the GST enzyme which is actually over-expressed may be
determined by the presence of the factors necessary for
gene expression.
4.16 Discussion
There are many reports on the elevation of GST in
cell lines made resistant to antineoplastic drugs (Wang &
Tew, 1985; McGowan & Fox, 1986; Batist et al. 1986;
Robson et al. 1987; Smith et al. 1989). However, in most
cases there are a plethora of changes in enzymes other
than GST. In perhaps the best study Cowan et al (1986)
have shown that GST pi is over-expressed 45-fold relative
to the parental cell line in an MCF-7 cell line resistant
to adriamycin. However, further characterisation of the
resistant cell line has shown that the phase I
(toxication) cytochrome P-450 enzymes were decreased (as
estimated by arylhydrocarbon hydroxylase activity).
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There was also shown to be a 2-3-fold decrease in
intracellular drug accumulation associated with an
increase in p-glycoprotein levels. Also phase II
(detoxication) enzymes other than GST were found to be
over-expressed, for example UDP glucouronyl and sulpho
transferases. These changes associated with adriamycin
exposure thus make it difficult to assign a role for the
over-expressed GST pi in the acquired resistance. This
can be said of all cell line models where continuous drug
exposure has been used to generate the resistant line.
In an attempt to simplify this position two human GST
CDNAs have been expressed in S.cerevisiae. These cDNAs
encode GST and GST pi. The enzymes were produced at
high levels which represents a significant advantage over
mammalian models where low levels of expression are
obtained. The levels of GST produced in S.cerevisiae
were comparable to those obtained from rat liver where up
to 10% of the cytosolic protein can be GST (Jakoby,
1978). The proteins were found to be functional
as determined by activity towards CDNB and CHP as
substrates. Another reason for using S.cerevisiae was
because yeast were reported to have no cytosolic GST
activity (Jakoby, 1978) and thus the contribution of
background activities would be expected to be extremely
low. There is a growing body of evidence that indicates
GSH levels are an important factor in determining the
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susceptibility of tumour cells to a wide range of
cytotoxic drugs (Calcutt & Connors, 1963; Arrick &
Nathan, 1984; Hayes & Wolf, 1988). This includes
alkylating agents, such as melphalan and chlorambucil, as
well as quinone containing compounds, such as adriamycin
and daunorubicin. GSH depletion has been shown to
sensitise ovarian carcinoma cells to the toxic effects of
melphalan, cis-platinum and adriamycin (Green et al.
1984; Hamilton et al. 1985). Thus the GSH levels within
the strains used required to be comparable. This was
indeed the case and expression of GST does not appear to
influence GSH levels. The differences in cellular
sensitivity to cytotoxic insult can thus be directly
attributed to the action of GST within the cell.
The main object of the expression of GST in
S.cerevisiae was to determine if this resulted in altered
sensitivity to alkylating agents, adriamycin and
hydroperoxides. The results suggest that under the
correct conditions the expression of GST can confer
resistance to the host cell. The alpha and pi class GST
are shown here to confer up to 11-fold and 4-fold
resistance to adriamycin respectively as well as 9-fold
and 5-fold resistance to chlorambucil. This supports the
work of Batist et al (1986) who showed the over-
expression of GST pi in an MCF-7 cell line was 192-fold
resistant to adriamycin. While the work of Robson et al
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(1987) have shown that the over-expression of an alpha
class GST in a CHO cell line confers resistance to a
number of nitrogen mustards including chlorambucil. Thus
the over-expression of GST appears to modulate cellular
sensitivity to cytotoxic drugs. It should be noted that
neither alpha nor pi class enzymes have been shown to be
active towards adriamycin as substrate. However, it is
suggested that both may have activity towards the lipid
hydroperoxides formed by the action of free radicals
produced by the guinone-semiquinone cascade induced by
adriamycin metabolism (Ketterer, 1988; Tew & Clapper,
1989). Certainly the alpha class GST expressed has been
shown to protect cells from the cytotoxic damage induced
by organic hydroperoxides in the form of CHP (2-fold)
(Wareing et_al, 1988). In experiments here alpha,
class GST expression resulted in a 2-fold resistance
to CHP indicating a similarity between the cell line
model and expression in S.cerevisiae (the pi class enzyme
was not tested as it has no peroxidase activity towards
CHP) .
Only two anticancer drugs have been shown to be
substrates for GST, namely melphalan and BCNU (Dulik et
al, 1986; Smith et al. 1989). Thus an attempt was made
to determine if GST mediated conjugation to GSH was the
mechanism of resistance. To this end cells were treated
with the GSH depletor BSO in an attempt to sensitise the
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cells to the anticancer drugs. In the case of
chlorambucil conjugation to GSH appeared to be the
mechanism of detoxification. It has been proposed (Russo
et al. 1986) that BSO depletion of cellular GSH could be
used as a mechanism to increase tumour susceptibility to
antineoplastic therapy. However, the report by Calvin et
al (1986) that BSO depletion was associated with the
development of cataracts in mice suggests that this is
probably not feasable. However, the modulation of GSH
levels by other means to increase tumour susceptibility
is an avenue of research that should not be ignored.
The role of GSH in adriamycin detoxication was
complicated. GSH depletion reduced GST B-j^B-^ mediated
resistance to adriamycin but not that mediated by GST pi.
GST pi mediated protection was shown not to involve
adriamycin sequestration. Thus the mechanism(s) by which
the GST pi protects the yeast cells remains unclear. It
is interesting to speculate on what other protection
mechanisms there may be operating. The GST may be acting
as stress response proteins interacting with other
cellular components in a similar manner to Hsp70.
Another anticancer drug tested here was BCNU. BCNU
is used as frontline therapy in the treatment of human
brain tumours (Evans et al. 1987). Neither the alpha nor
pi class GST protected against the cytotoxic damage induced
by this compound. This is in agreement with the recently
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published work of Smith et al (1989) where only the rat
mu class GST (3-4 and 4-4) were shown to have
dinitrosation activity towards BCNU. Neither the alpha
(1-2) nor pi (7-7) enzymes exhibited significant
activity. The lack of difference between yeast strains
is an important result as it shows that the resistance to
adriamycin and chlorambucil is a specific event. Thus
the over-expression of a foreign protein does not a
priori confer resistance. For example, one could imagine
that the over-expression of a foreign protein could
provide an increase in nucleophilic centres to which
reactive electrophiles such as anticancer drugs can bind.
This would result in a reduction in DNA damage, damage
which is likely to be the lethal event to a cell. The
fact that cells expressing human alpha or pi class GST
shown no alteration in their sensitivity to BCNU
suggests that the model detailed here is specific to
those compounds which the GST have activity towards.
The potent alkylating agent and general GST
substrate CDNB was also examined in this system. The
main interest in this compound was derived from the work
of Wareing et al (1988) who have shown that an NCIH322
cell line resistant to CDNB has an elevated expression of
the alpha and pi class enzymes. The results here
obtained support the conclusions that this expression
is involved in the resistance mechanism. This small
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increase in resistance is probably due to the cytotoxic
damaged induced by CDNB outwith the cytosol. For
example, the fluro-derivative of CDNB, has been shown to
be an inhibitor of the glucose transport system with
toxic consequences for the cell (Walmsley, 1988).
Obviously any damage outwith the cell cannot be
protected against by over-expression of a GST. This
would limit the protection potential of the GST system
towards this compound.
The over-expression of the pi class GST which has
higher activity towards CDNB than the alpha class enzyme
actually resulted in the yeast strain being more
sensitive than the control. This result supports that of
Van Bladderen and co-workers who have shown that CDNB-GSH
conjugates are actually more mutagenic in S.tvohimurium
than the CDNB molecule itself.
This increase in mutagenicity could be reversed if a
GSH~strain was used (Kerklaan et al. 1985). The
over-expression of GST pi should increase the level of
CDNB-GSH conjugation within the yeast which could be
activated to more toxic species by the action of
nitroreductases. This would result in an increase in
sensitivity towards CDNB when compared to control as
also seen in the cytotoxicity assay. This raises the
question why does the alpha class GST protect the yeast
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cell? The alpha class GST may be acting not as a GSH-
conjugation enzyme but as a suicide protein forming
covalent linkages to the CDNB leading to deactivating.
This would produce an inactive protein but would also
protect cellular targets from CDNB injury. This
possibility was supported by the finding that on GSH
depletion strain expressing GST pi class became as
sensitive as control, possibly due to a decrease in CDNB-
GSH formation, while the GST expressing strain
remained resistant relative to the control.
The work in this chapter has shown that although the
GST family of enzymes are thought of as detoxication
proteins, under certain circumstances they are shown to
be capable of producing toxic species. The model compound
used was DBE which after conjugation to GSH undergoes
activation to form a sulphur half-mustard (Rannung, 1980;
Van Bladderen, 1988). Both the human alpha and pi class
GST increased the sensitivity of their host cells to DBE
induced damage. Thus although in the majority of cases
GST and GSH give cellular protection to electrophile-
induced damage under certain conditions they can increase
drug sensitivity. This fact could be exploited to
produce anticancer drugs which increase tumour
susceptibility over normal cells if GST levels are found
to be increased.
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4•17 Refinement and Potential of GST Expression in
S.cerevisiae
One problem associated with S.cerevisiae as a
recipient organism is that they are relatively
insensitive to chemical toxins. The levels required to
produce acceptable levels of cell kill are approximately
10-fold higher than that required to produce equivalent
cell death in a mammalian cells. In fact, the
S.cerevisiae strain used proved to be completely
refractory to the nitrogen mustard, melphalan. Even at
the limit of solubility (1600pg/ml) 90% of the control
yeast cells were still viable (data not shown). An
obvious way to circumvent this problem is to produce
mutations affecting the cell wall in an attempt to
produce a strain with a greater sensitivity to cytotoxic
insult. Another method could be to pre-treat the cells
with compounds which are non-lethal but increase the
permeability of the yeast to other chemicals. The
nonapeptide of polymyxin B sulphate reported by
Boguslawski (1985) has potential in this respect. The
nonapeptide is thought to puncture the yeast cell wall
and membrane and facilitate the passage of agents into
the cytoplasm, without being toxic. The parental
molecule, polymyxin B sulphate, is an extremely potent
fungicide. The first proposal to produce cell wall
mutants with hyper-sensitivity to cytotoxic insult will
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be pursued further within the laboratory.
Another refinement would be the functional
expression of a human mu class GST. This would provide a
member from each of the three classes of human cytosolic
GST. This is to be pursued using Polymerase chain
reaction (PCR) to produce a full-length mu class cDNA
from mRNA purified from a human liver expressing mu class
GST.
The system described here also has the potential to
be used as a rapid screen for novel antineoplastic agents
which are bioactivated by GST mediated reactions. Or
conversely to determine agents which are deactivated by
GST such that these are not prescribed in cases where
acquired or intrinsic resistance is a problem. An
example of the former is seen in the bioactivation of
azathiopurine and bleomycin by conjugation to GSH
(Arrick & Nathan, 1984). The work presented here
using DBE shows that the yeast GST expression system
can be used to identify compounds whose toxicity is
increased by GST metabolism.
Furthermore, this yeast expression system has the
potential to identify anticancer drug substrates for the
GST enzymes. This type of information is sadly lacking
in the literature. Only a few studies have provided
conclusive evidence for the role of GST in the formation
of GSH-anticancer drug conjugates (Dulik et_al, 1986;
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Smith et al. 1989). The fact that S.cerevisiae can be
grown in large volumes means that large quantities of the
expressed proteins can be produced. The protein can be
purified to homogeneity and the formation of GSH
conjugates examined in the presence or absence of GST.
Alternatively, GSH-conjugate formation could be directly
assayed in vivo within the yeast cell. In both cases GSH
conjugate formation can be assayed either by mass-
spectroscopy or by some other means.
The large quantities of protein that can be produced
from this expression system is being used to purify the
large amounts of the GST (B^^) protein for X-ray
crystallographic studies.
From the above it is obvious that the expression of
GST within S.cerevisiae is an attractive system that can
hopefully answer many fundamental questions regarding
GST. Studies can involve structure (via X-ray
crystallography) determination of GST substrates, as well
as a rapid screening procedure for novel anticancer drugs
or drugs for the treatment of drug-resistant diseases. A
very flexible system indeed.
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SUMMARY
The work presented in this thesis has shown that the
expression of mammalian drug metabolising enzymes in
S.cerevisiae represents a powerful model system to
dissect the complex biochemical pathways arising from
xenobiotic metabolism.
The rat P450IIB1 cDNA has been expressed in a
functional form as a representative of the cytochrome P-
450 monooxygenase super-gene family. The resultant
recombinant strain was then tested to determine its
suitability as a short term test organism for the
screening of potential mutagens. To test all specificity
of the system compounds were chosen where PB-inducible P-
450 metabolism had been implicated in the activation
mechanism (cyclophosphamide and sterigmatocystin). Other
promutagens where PB-inducible P-450 activation was known
not to play a role were also chosen (benzo(a)pyrene and
p-naphthylamine). Finally 2-acetylaminofluorene and
2-anthramine were tested since the activation mechanism
of these compounds was unclear. The results clearly
demonstrate that S.cerevisiae strains expressing various
cytochrome P-450 isoenzymes represent an attractive
alternative to other test systems where exogenous
activation systems are required.
Many studies have implicated the glutathione S-
transferases in drug resistance although this is mainly
through GST over-expression in resistant cell lines.
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However, complex changes have been shown to occur in the
selection for these resistant lines. These changes
include alterations in P-170, DNA repair, DNA
topoisomerase II, cytochrome P-450 and UDP-glucouronyl-
and sulpho-transferases. Thus it is difficult to
delineate the role played by GST over-expression in the
resistant phenotype. The work presented here was an
attempt to simplify the system under examination. Two
human GST CDNAs, encoding GST and GST pi, were
expressed in S.cerevisiae and the cellular response to
various cytotoxic agents examined. The expression of the
alpha and pi class GSTs in S.cerevisiae was shown to
confer resistance to the anticancer drugs adriamycin and
chlorambucil. The co-expression of GST and GST pi
was also shown to increase resistance to adriamycin over
the strains expressing either GST pi or GST B^B^.
In addition the alpha class GST also conferred
resistance to CDNB and CHP while the resistance phenotype
was shown to be compound specific since no increase in
resistance was observed after BCNU exposure (BCNU is
detoxified by mu class enzymes). Thus the work presented
has unequivocally shown that GST can alter cellular
sensitivity to cytotoxic agents and implies that these
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